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ABSTRACT
Some evidence suggests that anticonvulsants may impair memory function 
in epileptics. This study examined the effects of three major 
anticonvulsants, phenytoin, carbamazepine and sodium valproate, on the 
memory function of epileptic patients.
Studies of the effects of anticonvulsants on memory function have been 
fraught with methodological problems. The results from studies of 
non-epileptics have limited applicability to the use of these drugs in clinical 
practice. Studies of epileptics, on the other hand, are often difficult to 
interpret because of methodological weaknesses largely inherent in 
examining clinical populations. In spite of these methodological difficulties, 
the effects of the drugs are of considerable interest. Anticonvulsants are 
used over very long periods, sometimes a whole life-time and on a 
significant proportion of the general population. There is a significant 
possibility that the side-effects of treatment may be worse than the benefits 
for some patients.
This study examined epileptic patients in a clinical setting but attempted to 
improve on the research methodology that has generally been the case in 
the past. Experiment 1 examined previously untreated epileptics before 
and three months after monotherapy with phenytoin, carbamazepine or 
sodium valproate and compared these with untreated non-epileptic 
controls. Experiment 2 compared the memory performance of patients 
treated with phenytoin and then either remaining on phenytoin or switched 
to carbamazepine. Experiment 3 compared the memory performance of 
epileptics treated with carbamazepine and then either remaining on 
carbamazepine or switched to sodium valproate. Experiment 4 examined 
the relationships between dose and blood level of phenytoin, 
carbamazepine or sodium valproate and folate with memory function.
The results of the study indicate that the effects of anticonvulsants on 
memory function are generally mild. Phenytoin was most frequently 
associated with impairment of memory. No evidence was found that 
carbamazepine produced any deterioration in memory performance. 
Experiment 4 indicated that folate levels, which are depleted by phenytoin, 
are more strongly correlated with impaired memory function than blood 
level of anticonvulsant. This observation supports previous findings that 
have implicated folate in the production of memory impairment. 
Nonetheless, the major conclusion of the study is that monotherapy with 
phenytoin, carbamazepine or sodium valproate, within or below the 
therapeutic range, does not seriously impair memory function.
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CHAPTER 1
GENERAL INTRODUCTION
GENERAL INTRODUCTION 2
1.1 THE PROBLEM
Epilepsy is generally treated with drugs. Table 1.1 shows the main 
anticonvulsant drugs in use today. Some of these have been used for more 
than forty years and yet we have a poor understanding of their mechanisms 
of action and their effects on even fundamental aspects of cognition such 
as memory. Clinical experience and some experimental evidence has 
raised the suspicion that these drugs may have adverse effects on 
memory. This study examines possible adverse effects of anticonvulsants 
on the memory function of epileptic patients.
ANTICONVULSANT DRUG YEAR OF INTRODUCTION
Phenobarbitone 1912
Phenytoin 1938
Primidone 1954
Ethosuximide 1960
Carbamazepine 1969
Sodium valproate 1973
Clonazepam 1975
TABLE 1.1 The year of introduction of the major anticonvulsant drugs. 
Adapted from Eadie and Tyrer (1980).
How is it that our understanding of the undesirable side-effects of 
anticonvulsant drugs has been so poor? Since epilepsy has a prevalence 
of between 0.5% and 1.0% of the general population (Beran, 1981) one 
might expect that prolonged treatment of large numbers of patients would 
have lead to a more presice understanding the side-effects of the 
anticonvulsants than is the case.
It has been known for a long time that anticonvulsants have adverse 
physiological side-effects. For example, Hammond (1876, cited in Dreifuss, 
1983) when demonstrating a patient suffering the side-effects of bromide 
administration, stated:
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As you see, he is broken down in appearance, has 
large abscesses in his neck, and is altogether in a 
bad condition. But this is better than to have epilepsy.
However, surprisingly little is known about the psychological effects of the 
drugs. It is becoming increasingly clear that a better understanding of the 
psychological effects of the anticonvulsant drugs is important. Few people 
today would agree with Hammond's rather extreme therapeutic enthusiasm 
even when dealing with more modern drugs. The skilful use of drugs 
entails a careful balance between the potential benefits and hazards of 
long-term drug therapy. As Webster (1981) stated:
Nowhere is the 'total person' approach more 
important than in the management of epilepsy ...
There has until recently been a lack of awareness by 
the practising doctor in recognising the side-effects 
and the potential hazards of long-term therapy with 
the common anti-epileptic drugs. It is slowly 
beginning to be appreciated that many patients have 
suffered as much, if not more, from the treatment than 
the disorder.
Although anticonvulsant drugs may affect cognition, other factors may also 
play a part. Structural abnormalities in the brain and seizure type and 
frequency are undoubtedly important factors associated with the 
occurrence of impaired cognition. Trimble and Thompson (1981) 
reviewing the relationships between memory, drugs and seizures, 
concluded that although the drugs may impair cognition, brain lesions in 
epileptics have been associated with specific cognitive deficits and that 
long-term memory appears to be affected by seizures.
Many attempts have been made to separate out the various factors which 
contribute to intellectual impairment in epilepsy. Lennox (1942) reviewing a 
survey of 1245 epileptics, postulated five main causes for "mental decay" in 
epileptics. These were: heredity; brain injury prior to seizures; 
psychological handicaps; epilepsy; and anticonvulsant medication. Lennox
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estimated that the drugs were responsible for intellectual deterioration in 
about 15% of his cases. Although in subsequent work Lennox lowered this 
estimate to 5% (Lennox and Lennox, 1960) surveys of serum 
anticonvulsant levels in epileptics have indeed demonstrated that many are 
subjected to excessive levels of the medication which produced "apathy, 
somnolence and mental slowing" (Vadja, Walsh and Bladin, 1978).
Before serum anticonvulsant levels were available, doses of the drugs 
were gradually increased until seizures were controlled or frank toxic signs 
appeared. The dose was then reduced slightly (Trimble, 1981). Drugs were 
administered in this way, because it was found that variable doses were 
required for adequate seizure control (Pippenger, 1980).
An important advance in reducing adverse side-effects of anticonvulsants 
was made when Buchtal and Svensmark (1959/1960) introduced the 
concept of a therapeutic range of plasma drug levels. The upper bound of 
the therapeutic range represented the level of the drug at which the 
incidence of overt symptoms of intellectual or physical deterioration was 
low. The lower bound of the range represented a level of the drug below 
which seizure control was unsatisfactory. Subsequent studies (for example, 
Loeser, 1961; Kutt, Winters, Kokenge and McDowell, 1964; Wallis, Kutt and 
McDowell 1968; Kutt, 1971) demonstrated the clinical utility of plasma level 
assays for phenytoin. Further extensions of this work have led to the 
definition of therapeutic ranges for most of the anticonvulsants (Richens, 
1976).
Whilst it is generally accepted that these therapeutic ranges are a useful 
guide in the treatment of epilepsy, Vajda and Aicardi (1983) point out that 
the levels have come to be regarded as absolute, rather than therapeutic 
guidelines. They believe that the definition of such ranges has been based 
on inadequate evidence from studies with small samples of adult subjects, 
often treated by polypharmacy, at drug levels which are often inadequately
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measured and with little regard to a variety of other confounding variables. 
While symptoms of "mental slowing, apathy and somnolence" (Vajda, et al, 
1978) may be readily apparent above the therapeutic ranges, these and 
other side-effects may be present to a less overt degree at levels of the 
drugs that are within or below the therapeutic ranges.
The difficulty in determining whether anticonvulsants impair cognition 
stems from the difficulties of separating the effect of epilepsy and the 
anticonvulsants on cognition. As noted above, epilepsy is associated with 
cognitive impairments. Systematic studies including groups of untreated 
epileptics are frought with ethical considerations (this point will be 
considered further below). Under this constraint, research in this area has 
tended to confound the two.
1.2 EFFECTS OF ANTICONVULSANT DRUGS ON COGNITION
Trimble and Reynolds (1976) reviewing the evidence for an effect of 
anticonvulsant drugs on mental symptoms, commented that there were few 
well-controlled studies which included sufficient numbers of patients 
studied over reasonable periods using a broad spectrum of 
psychological measures and reporting blood levels of the drugs. 
Nonetheless, they concluded that:
Some evidence suggests that subtle mental 
changes may occur even with blood levels of the 
drug that are within or below the currently accepted 
therapeutic ranges....
Subsequent studies (e.g. Marchesi, Ladavas, Sei Pesce, Fua and Guilliani, 
1981; Thompson, Huppert and Trimble 1980a, 1980b, 1981; Thompson 
and Trimble, 1981, 1983; Trimble and Thompson, 1981, 1983) tended to 
confirm this view.
One important aspect of cognition, memory, has recently received special
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attention and a number of important studies by Thompson (1981) indicate 
that phenytoin, carbamazepine and sodium valproate may have an 
adverse effect on memory. However, her studies using epileptic subjects 
have proved difficult to interpret. The purpose of this study is to examine the 
effects of the anticonvulsants, as used in clinical practice, on memory in 
epileptics.
1.3 EFFECTS OF ANTICONVULSANT DRUGS ON MEMORY
Some studies of the effects of the most commonly used anti-epileptic drugs 
- phenobarbitone, phenytoin, carbamazepine and sodium valproate - on 
memory in adults have been carried out. These will now be reviewed.
1.3.1 The Effect of Phenobarbitone on Memory
Phenobarbitone was first introduced in 1912 and rapidly replaced the use 
of bromides as the predominant treatment for epilepsy (Eadie and Tyrer, 
1980). Although phenobarbitone enjoys less popularity today, it is still 
used extensively, especially in France (Reynolds and Shorvon, 1981).
Wapner, Thurston and Holowach (1962) studied the effect of 
phenobarbitone on epileptic children who were having at least three 
seizures a day. They used a six-week pre-test post-test design including 
non-epileptic controls matched for age, sex, IQ and race. Two forms of the 
Stanford-Binet Intelligence Scale were administered and a picture 
vocabulary test and a multiple T stylus maze (Deutsch, 1953) were used as 
measures of learning. There were no significant differences in the pre- and 
post-test performances of the epileptic children. However, since the 
children had significantly fewer seizures, the effects of reduced seizures 
were confounded with the effects of the introduction of phenobarbitone.
Tchicaloff and Gaillard (1970) used the Wechsler Adult Intelligence Scale
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(WAIS), Rey's Profile of Memory Test Performance and Rey's Test of 
Entangled Lines (a measure of perceptuo-motor abilities) to examine the 
relationship between phenobarbitone and psychometric test performance 
in 20 epileptics. Only the correlation between dose of the drug and 
performance on Object Assembly subtest of the WAIS was significant. 
However, seizure fequency and possible underlying brain damage were 
not controlled in this small sample.
Kalska (1976) examined the effects of phenobarbitone used in polytherapy 
with a cross-sectional design on a sample of 100 epileptics. High blood 
levels of the drug were associated with poorer scores on the Wechsler 
Memory Scale (WMS) and the Benton Visual Retention Test (BVRT). A 
similar result was not observed for phenytoin or carbamazepine.
MacLeod, Dekaban and Hunt (1978) also examined the effects of 
phenobarbitone, both alone and in combination with other drugs. They 
compared performance at high therapeutic levels of the drug with 
performance at low therapeutic levels of the drug. Nineteen epileptics were 
tested at low therapeutic levels and then retested one week later after 
increasing the dose. These workers found that access speed to short-term 
memory, as measured by the Sternberg serial scanning task (Sternberg, 
1966) was significantly reduced at higher therapeutic levels than lower 
therapeutic levels. However, access speed to items in long-term memory, 
as measured by the Posner letter matching task, was not affected. They 
concluded that phenobarbitone had a deleterious effect on short-term 
memory but not long-term memory. Nevertheless, since the retest period 
was only one week, the effects observed may have been due to transient 
changes in performance, which may not have been aparent over longer 
periods of study.
Oxley, Richens and Wadsworth (1979) compared the effect of reducing the 
therapeutic level of phenobarbitone in epileptic patients with the
GENERAL INTRODUCTION 8
performance of an epileptic control group in which no change was made to 
their medication. They found that performance on the WMS improved after 
reducing the dose of phenobarbitone, in spite of an increase in fit 
frequency, but that the level of the drug did not correlate significantly with 
performance. The retest interval in this case was six months.
Camfield, Chaplin, Doyle, Shapiro, Cummings and Camfield (1979) 
studied a group of infants who had had a single febrile convulsion, using a 
double-blind placebo controlled procedure. A significant negative 
correlation with performance on some subtests of the Stanford-Binet 
Intelligence Scale was reported. Although the actual scales were not 
identified in the report, the authors labelled the scales as assessing 
memory and concentration. A trend towards greater impairment with longer 
exposure to the drug was also noted.
Marchesi et al (1981) studied the effects of phenobarbitone, phenytoin and 
carbamazepine on performance by 26 previously untreated epileptics on a 
specially designed memory battery. The epileptics were untreated on the 
first test and then retested 'at least' one month later. They found significant 
impairment of memory performance in patients receiving phenobarbitone 
on a variety of different memory tests.
Several studies of the effect of phenobarbitone on non-epileptic subjects 
have also been carried out. Salzman and Shader (1973) using a placebo 
controlled double-blind procedure, compared the effects of methyl- 
phenidate, diazepam and phenobarbitone on the performance of non­
epileptic volunteers over the age of 60 on the WMS. A non-significant 
improvement in memory performance was noted, especially in males. 
Kornetsky (1958) studied the effect of several drugs on non-epileptic 
volunteers 90 minutes after a single dose of the drug. He observed no 
significant drug effects on motor co-ordination, reaction time and learning, 
although the author did question whether the lack of an effect was related
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to the timing of the testing.
A majority of papers report that phenobarbitone has a deleterious effect 
on memory, even on relatively insensitive clinical tests of memory 
(Tchicaloff and Gaillard, 1970; Kalska, 1976; MacLeod et al, 1978; Oxley 
et al, 1979; Camfield et al, 1979; Marchesi et al, 1981; Salzman and 
Shader, 1973). Although the precise nature of the effect of phenobarbitone 
on memory function in epileptic patients remains unclear, some better 
controlled studies (MacLeod et al, 1978; Marchesi et al, 1981) suggest that 
phenobarbitone exerts a deleterious effect on short-term memory 
performance.
1.3.2 The Effect of Phenytoin on Memory
The use of phenytoin, introduced in 1938 (Eadie and Tyrer, 1980) was 
initially associated with many case reports of improvement in cognitive 
functioning in epileptics (Trimble and Reynolds, 1976). However, this 
improvement in functioning may have been due to the withdrawal or 
reduction of phenobarbitone as much as the introduction of phenytoin. 
Nonetheless, phenytoin has proved to be an extremely effective anti­
epileptic agent (Shorvon, Chadwick, Galbraith and Reynolds, 1978) and is 
now one of the most commonly used medications in the world today. In 
Australia in 1981, phenytoin accounted for 42% of all prescriptions for 
anticonvulsants filled under the National Health Scheme (but excluding 
those provided from hospital pharmacies).
Millichamp, Egan, Hartz and Sturgis (1969) administered a battery of 
psychological tests to 22 children before and after one month of treatment 
with phenytoin. Patients were included in the study if there were obvious 
learning and behaviour difficulties. One test, a test of auditory perception 
and recall, showed an improvement on retest. However, the possible 
influences of practice and placebo effects on this performance were not
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properly controlled.
Rosen (1968) reported a study of 20 patients who were tested before 
and after being switched to either phenobarbitone or mysoline after 
treatment with phenytoin. He stated that:
Comparison of detailed psychological test batteries 
revealed a remarkable improvement in test results 
on the Wechsler Adult Intelligence Scale, Bender- 
Gestalt and other tests of intellectual and 
perceptual performance.
However, the precise extent of the this "remarkable improvement" was not 
documented in the report.
Tchicaloff and Gaillard (1970) reported a significant inverse relationship 
between dose of phenytoin and performance on the Arithmetic and Digit 
Span subtests of the WAIS. The authors suggested that the drug impaired 
performance by affecting attention and concentration. This result 
contradicts earlier-reports of patients becoming noticeably brighter and 
more alert following the introduction of phenytoin therapy, (e.g. Kimball 
and Horan, 1939; McCarton and Carson, 1939; Haward, 1968, 1970, 
1973).
Dodrill (1975a) compared the performance of epileptics with low and high 
therapeutic levels of phenytoin on performance on the WAIS and the 
Halstead-Reitan Neuropsychological Battery. He found that high levels of 
the drug were associated with a greater degree of impairment on a majority 
of measures. However, performance on the Tactual Performance Test 
(TPT) was not impaired.
Dodrill and Troupin (1977) used a double-blind cross-over trial procedure 
with phenytoin and carbamazepine. The test measures were the WAIS 
and the Halstead-Reitan Neuropsychological Battery, as in the previous
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study. They found that performance on carbamazepine was superior on 
some measures but that there was no difference on the TPT.
Nolte, Wetzel, Bregman and Brintzenger (1980) studied eight epileptic 
children before and six months after treatment was initiated. A further eight 
children were tested prior to ceasing treatment and six months after 
treatment had ceased. Although the results were not significant, possibly 
due to the small sample sizes, Nolte et al (1980) did find that performance 
on the HAWIK Intelligence Test and measures of concentration, memory 
and perceptuo-motor skills were impaired after six months of treatment with 
phenytoin and that performance was improved after withdrawal of the drug.
Marches'! et al (1981) studied the effects of phenytoin on the performance 
of epileptic patients on a specially designed memory battery. The 
epileptics were untreated on the first test occasion and then followed up at 
least one month later. They reported significant impairment of memory 
performance in patients receiving phenytoin on a variety of different 
memory tests.
Thompson et al (1981) studied non-epileptic volunteers using a 
double-blind cross-over trials placebo controlled procedure. Subjects were 
assessed before and following two treatment periods of two weeks. A 
variety of tests using verbal and non-verbal material were used. These 
workers found highly significant impairment by phenytoin of memory 
function for both verbal and non-verbal material as well as adverse effects 
on mood, concentration and psychomotor performance.
Trimble and Thompson (1983) studied a group of nine patients treated with 
phenytoin alone who were tested at a three month interval with either high 
or low levels of the drug. They found that high levels of the drug were 
associated with impaired performance on measures of concentration, 
decision-making speed, retention of new information and motor speed.
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However, the results were interpreted using an unprotected t test.
The better controlled of the studies reviewed above indicate that 
phenytoin has a deleterious effect on memory performance in epileptic 
patients (Marchesi et al, 1981; Thompson et al, 1981; Trimble and 
Thompson, 1983). Nonetheless, a significant proportion of papers report 
little or no effect or even an improvement in memory (Millichamp et al, 
1969; Rosen 1968; Dodrill 1975a; Dodrill and Troupin 1977; Nolte et al, 
1980). The possibility must be considered that some of the inconsistencies 
in the results reported may reflect the beneficial effect of withdrawal of 
other medication or a dose-dependent relationship between memory 
performance and blood level of phenytoin. Nonetheless, Trimble (1981) 
summarising a review of the effects of anticonvulsant drugs on cognitive 
abilities and behaviour concluded that:
...some drugs - particularly phenytoin  -  are 
associated with a progressive decline in intellectual 
abilities which is often insidious and unrecognised.
1.3.3 The Effect of Carbamazepine on Memory
Although only available for the last fifteen years, carbamazepine has 
proved to be an extremely effective anticonvulsant, comparable in efficacy 
with phenytoin (Bird, Griffin, Mikalaszewska and Galbraith, 1966; 
Simonsen, Olesen, Kupl, Lund and Wendelobe, 1975). In addition, 
carbamazepine is believed to have a number of beneficial psychotropic 
effects. Dalby (1975) reviewing the literature, concluded that 
carbamazepine improved attention, concentration and perseverence. 
However, it is unclear whether this was a consequence of improved seizure 
control, effects of the drug on mood, withdrawal of other medication, 
placebo effects, or a genuine effect of the drug on cognition.
Martin, Movarrekhi and Gisiger (1965) studied twenty epileptic children for
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six months before the addition of carbamazepine to their drug regimens 
and for a further six months. They found that 34.4% of the children 
improved overall on tests of cognitive function, including memory, 
visuo-spatial and motor abilities, whereas 13.3% were more impaired and 
the remaining 52.3% showed no change.The authors concluded that 
carbamazepine had a beneficial effect. However, no control was made for 
practice or placebo effects nor was the possibility of drug interactions taken 
into account.
Leder (1970) using a double-blind procedure, studied the effect of 
adding carbamazepine or placebo to the drug regimens of 50 epileptics. 
Patients were assessed after three months of placebo or carbamazepine 
using tests of memory, concentration and psychomotor ability. Patients 
also completed rating scales for mood. There was a general trend towards 
improvement on carbamazepine for scores on the test of attention. 
Improvements in mood were also noted. The authors described their 
patients as becoming 'more adapatable and quicker in their actions, 
thought and speech' on the drug.
Dodrill and Troupin (1977) used double-blind cross-over trials to compare 
the effect of monotherapy of phenytoin with the effect of monotherapy of 
carbamazepine on performance on the WAIS and the Halstead-Reitan 
Neuropsychological Test battery. No effects were found on the TPT but 
performance changes were observed on the Stroop Color-Word Test, the 
Wonderlich Personel Battery and tests of apraxia and aphasia. Overall 
performance on carbamazepine was superior to performance on phenytoin 
and the authors felt that the former drug had a 'specific action on the 
intellectual and attentional elements of the tests'.
Siirtola and Siirtola (1979) compared the performance of twelve previously 
untreated epileptics before and after treament with carbamazepine alone 
on performance on the WAIS, BVRT and a paired associates word learning
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test as well as a mood rating scale. In spite of improved seizure control, no 
change in cognitive performance or mood was observed after three months 
of treatment with carbamazepine.
Marchesi et al (1981) compared the performance of 26 previously 
untreated epileptics who were treated with monotherapy of either 
carbamazepine, phenytoin or phenobarbitone. Patients were re-assessed 
after at least one month of drug taking. The tests were designed to assess 
vigilance, attention, psychomotor performance, and short- and long-term 
memory for verbal and non-verbal material. Carbamazepine was found to 
have no effect on vigilance, attention, sensory performances or memory 
function although some motor and adaptive performances appeared to 
improve. However, only six patients were assessed on carbamazepine 
and the results must be interpreted carefully.
Thompson et al (1980b) examined the effect of switching epileptic patients 
on polytherapy to carbamazepine, either alone or in combination with other 
drugs. These patients were compared with patients in which the number of 
drugs was reduced, or in which no change was made to their 
polytherapeutic treatment. Patients who were switched to carbamazepine, 
or who had the number of drugs reduced, showed a significant 
improvement in performance on a variety of different memory tasks. The 
results of this experiment are difficult to interpret because it is unclear 
whether the change in performance was brought about by the introduction 
of carbamazepine or the withdrawal of other medication.
Trimble and Thompson (1983) also studied a group of eight epileptics 
treated with carbamazepine alone. Their subjects were tested on both high 
and low levels of the drug. For several measures, performance was better 
at the lower level although these effects were not significant.
Most of the studies on epileptics examined above were unable to
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demonstrate clearly an effect of carbamazepine on memory, or cognitive 
function in general. However, some studies of the effects of the drug on 
non-epileptic populations have also been carried out. While studies of 
non-epileptic populations avoid some of the methodological problems 
caused by changes in seizure frequency and interactions with other drugs, 
almost all of these studies have used clinical populations, most often 
'minimally brain damaged' children or children with behavioral problems 
(Thompson, 1981). Consequently, these studies are difficult to interpret, 
and will not be discussed further.
Little work has been carried out on non-clinicial populations. Thompson 
et al (1980a) studied the effect of carbamazepine and phenytoin using a 
double-blind cross-over trials procedure with placebo control on normal 
healthy volunteers. Subjects were tested before and after each of two 
treatment periods of two weeks each. They found that carbamazepine, 
unlike phenytoin, did not affect memory performance.
Although the reports on the effects of carbamazepine are difficult to 
interpret for methodological reasons, there is a remarkable lack of any 
evidence that carbamazepine has a deleterious effect on memory at normal 
therapeutic levels (Martin et al 1965; Leder 1968; Dodrill and Troupin, 
1977; Siirtola and Siirtola, 1979; Marchesi et al, 1981; Thompson et al, 
1980a; Thompson and Trimble, 1982; Trimble and Thompson, 1983). It is 
equally true that the evidence for an improvement in performance 
attributable to carbamazepine is, at best, slender.
1.3.4 The Effect of Sodium Valproate on Memory
As sodium valproate is a relatively new drug, little work has been carried 
out on its effect on cognition, including its specific effect on memory. Early 
reports, like those on the effect of carbamazepine and phenytoin, have 
suggested that sodium valproate may have a beneficial effect on
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cognition (Volzke and Doose, 1973; Jeavons and Clark, 1974; Harding, 
Herrick and Jeavons, 1978). However, there have been no properly 
controlled studies of the effect of sodium valproate on memory function in 
epileptic patients.
Thompson and Trimble (1981) studied the effect of sodium valproate 
on performance on a specially designed memory battery using a 
double-blind, cross-over trials, placebo-controlled procedure on 
non-epileptic volunteers. Assessments were carried out before and 
following two treatment periods of two weeks each. This study was carried 
out in a parallel manner to the procedure used to study the effects of 
phenytoin and carbamazepine on normal volunteers. No significant 
differences were found on any of the measures of memory although 
subjects took longer on a decision-making task when receiving the active 
drug.
Trimble and Thompson (1983) also studied a group of seven epileptics 
treated with sodium valproate alone. Subjects were tested at a three month 
interval at either high or low levels of the drugs. They found impairments at 
high levels of the drug on measures of concentration, decision-making 
speed and retention of new information. However, the results were 
interpreted using an unprotected t test.
Few conclusions can be drawn about the possible effects of sodium 
valproate on memory owing to the paucity of studies and the enormous 
variations between existing studies in the test measures used and the 
populations studied. The wide range of blood levels over which this drug 
can be used, its relatively short half-life and its clinical efficacy, ensure that 
this drug is an important alternative anticonvulsant medication. It is, 
therefore, important that further attempts should be made to examine the 
effect of this drug on cognitive function.
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1.3.5 Summary of the Effects of Drugs on Memory
The evidence for an effect of these four anticonvulsants on memory 
function in epileptic patients, when the drugs are used within the 
therapeutic range, is generally methodologically poor. In spite of over 
seventy years since the introduction of phenobarbitone, little is known 
about its effect on memory (except that it probably has an adverse 
effect). Almost nothing is known about the specific nature of its effect on 
memory. Phenytoin also appears to have a deleterious effect on memory, 
but, again, the nature of the deficit remains uncertain, in spite of its 
extensive use. There are some grounds for cautious optimism that 
carbamazepine does not have an adverse effect on memory. Sodium 
valproate is clearly too new a drug to have been properly evaluated.
The evidence for an effect of the common anti-epileptic drugs on memory 
function is, at best, difficult to interpret owing to methodological problems. 
Untreated epileptics with similar clinical histories should be matched to 
treated epileptics, but this has not been done for practical and ethical 
reasons. Non-epileptic controls cannot be treated for prolonged periods 
to allow reasonable comparison with long-term therapy in epilepsy. Many 
studies have failed to report blood levels of the drugs. Early studies have 
failed to classify different types of epilepsy and classification schemes have 
changed. In addition, some studies have confounded the cognitive effects 
of the drugs with the effects of polytherapy or changes in seizure frequency. 
These methodological problems and others will be discussed in greater 
detail in the next chapter.
1.4 POSSIBLE PHYSIOLOGICAL MECHANISMS UNDERLYING 
MEMORY IMPAIRMENT
Despite our general lack of knowledge about the nature of memory 
impairments produced by the drugs, there are several physiological
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mechanisms which could be responsible for these effects. Several 
established or suspected neurotransmitters, such as acetylcholine, 
dopamine, noradreline, seretonin, gama-amino-butyric acid (GABA) and 
folic acid, are known to be affected by the use of anticonvulsants (Tyrer and 
Eadie, 1980). Most work has been carried out on the role of folic acid 
metabolism, seretonin and GABA. All theories of the physiological 
mechanisms underlying the impairment of memory by the drugs are 
speculative. Because the evidence for the effect of folic acid is most 
substantial, and because it is relevant to the findings of this study, only the 
effects of folate will be reviewed here.
1.4.1 Folic Acid, Anticonvulsants and Cognition
Folic acid is a vitamin which is distributed throughout the brain and is 
believed to have an important role in neuronal metabolism (Botez and 
Reynolds, 1979). Flerbert (1962) described a folate deficient diet as 
causing increasing 'forgetfulness' which became apparent during the 
fourth month. Many studies have shown that the administration of 
anticonvulsants can lead to a reduction of folate in the serum and the CSF 
(Reynolds, Gallagher, Mattson, Bowes and Johnson, 1972). Reynolds 
(1976) reported that treatment of epileptics with phenytoin, phenobarbitone 
or primidone resulted in reductions in serum, red blood cell and CSF folate 
levels in 27-91% of cases. Chanarin (1979) reviewing the effects of the 
anticonvulsants on cognition, concluded that phenobarbitone and 
phenytoin were the two common epileptic drugs most often linked with 
reductions in folate levels in epileptic patients. Such observations have led 
several investigators to link cognitive impairments attributed to 
anticonvulsants with folate depletion by those same drugs (Reynolds, 1979; 
Trimble, 1979).
The exact mechanism of the reduction of folate by anti-convulsants is 
unknown. Chanarin (1979) reviewing the effects of anticonvulsant drugs on
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folate, comments that the anticonvulsants may reduce folate level through 
direct action on folate co-enzymes, through indirect action or by acting on 
pathways unrelated to folate. Some evidence suggests that phenytoin 
inhibits the uptake of dietary folates (Hoffbrand and Nichelles, 1968; 
Rosenberg, Streif, Godwin and Castle, 1968) but Fehling, Jagerstad, 
Lindstrand and Westesson (1973) comparing normal people with those on 
anticonvulsant therapy, found that at least two polyglutamic acids were 
equally well absorbed in the two groups. Other evidence suggests that 
hepatic enzyme induction by anticonvulsants may cause a reduction in 
serum folate level (Maxwell et al, 1972). Chanarin (1979) also suggests 
that anticonvulsants may interfere at a stage beyond the action of folates - 
the incorporation of thymidone into DNA.
Reports on the cognitive performance of folate deficient patients have been 
conflicting. Some studies have reported a greater incidence of cognitive 
impairments amongst such patients (Reynolds, Preece and Chanarin, 
1969; Snaith, Mehta and Raby, 1970; Trimble, Corbett and Donaldson, 
1980). Other, better controlled studies have failed to confirm this finding 
(Bowe, Cornish and Dawson, 1971; Gibberd, Nicholls and Wright, 1981; 
Grant and Stores, 1970).
1.4.2 Summary of the Effects of Folate on Memory
There is some evidence to suggest that folic acid in the brain may be 
depleted by some anticonvulsants. This reduction in folate may result in 
impaired cognition, perhaps, even memory.
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1.5 CONCLUSION
Epilepsy is a disorder with a prevalence of between 0.5% and 1% of the 
general population (Beran, 1981). The treatment is almost exclusively by 
drug therapy and involves drug taking for many years, sometimes even a 
whole lifetime. It is possible that a proportion of the epileptic population 
may be suffering from cognitive disabilities produced by the medication for 
the treatment of their epilepsy. The implications for children and those 
individuals relying on their intellect for employment are not difficult to 
appreciate.
Over forty years ago, Lennox (1942) remarked that:
...the careful study of [anticonvulsant] effect on 
intellectual processes of normal and epileptic 
persons is long overdue.
It was still possible to comment in 1981 that:
The paucity of research is regrettable considering the 
potential reversibility of drug induced impairments of 
functioning in contrast with some of the more 
intractable causes... (Thompson 1981).
Bearing in mind that anticonvulsants are neuro-active agents, the state of 
knowledge with respect to their cognitive effects, particularly on epileptics, 
is clearly inadequate. This study was designed to contribute to this 
understanding. It examined the effects of the three most commonly used 
anticonvulsants in Australia, phenytoin, carbamazepine and sodium 
valproate, on the memory function of epileptic patients.
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1.6 SUMMARY OF MAIN POINTS
(1) There are only a few satisfactory studies of the effects of 
anticonvulsant drugs on the memory of epileptics. That is few studies have:
(i) used sufficient subjects;
(ii) reported blood levels of the drugs;
(iii) studied the drugs when prescribed in monotherapy;
(iv) compared a variety of different drugs; and
(v) used specially designed memory test batteries.
(2) Nonetheless, there is some evidence to suggest that memory 
function is impaired at blood levels of the drugs that are within or below the 
currently accepted therapeutic ranges.
(3) If anticonvulsants impair cognition this would have a number of 
important implications for epileptics.
CHAPTER 2
METHODOLOGICAL PROBLEMS IN THE STUDY OF THE 
EFFECTS OF ANTICONVULSANTS ON MEMORY
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2.1 THE  E F F E C T  OF E X P E R I M E N T A L  D E SI G N  ON  
C O N C L U S I O N S
In order to study the effects of the drugs on memory function, the epilepsy 
and drug factors must be manipulated independently. The influence of 
each must be studied in isolation, as well as in combination, before their 
independent effects, as well as their interactions, can be determined.
The drug and epilepsy 'factors' are complex sets of variables. Drug-related 
variables include: type of drug; dose of medication (including no 
medication); frequency of dose; and drug interactions if used 
polytherapeutically. The epilepsy-related variables include: seizure type; 
seizure frequency (including no seizures); age at onset; and duration of 
illness.
While recognising their complexity, it is useful to consider drug-epilepsy 
studies in terms of a simple schematic form, presented in Figure 2.1. 
Epileptics both on and off drugs are compared to non-epileptics both on 
and off drugs. A study, including these groups, could be executed using 
either an independent groups design (in which different subjects fill each of 
the cells) or a mixed repeated-measures design (in which a group of 
epileptics is studied on and off the drug and a group of non-epileptics is 
studied on and off the drug).
Drug
No Drug
Epilepsy No Epilepsy
A B
C D
FIGURE 2.1 Idealised two factor design for studying epilepsy/drug effects.
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No study of the effects of anticonvulsants on memory function has obtained 
subjects for all four groups. Indeed, there are fundamental methodological 
problems with this type of applied research which strongly make it unlikely 
that such a study will ever be executed. It is extremely difficult to obtain 
suitable subjects for Groups B and C. In the case of Group B, very few 
epileptics remain untreated and those who are have few seizures or refuse 
drug treatment. It is difficult to match these epileptics with treated epileptics. 
In order to obtain untreated epileptics with similar clinical histories to 
treated epileptics, medication would need to be withdrawn. Such an 
experiment has never been executed because the withdrawal of drug 
treatment is likely to have a profound effect on seizure frequency.
Non-epileptic subjects cannot be given drugs for prolonged periods. 
Anticonvulsant therapy for epilepsy is normally continued for a period of 
years. The effects of the drugs after prolonged use may well be quite 
different from short-term effects. However, non-epileptic subjects 
administered anticonvulsants have usually only been studied over periods 
of a few weeks (e.g. Thompson et al, 1981). Therefore, Group C has been 
inadequately studied.
The independent groups design has frequently been used to study the 
effects of medication on epileptics (Table 2.1). This design compares 
performance on a variety of tasks. This approach is generally easier to 
execute and avoids many of the pitfalls of longitudinal designs, such as the 
confounding of temporal effects with the effects of drugs or epilepsy. 
However, all independent groups designs have relatively low statistical 
power. They require larger sample sizes in order to achieve a given degree 
of statistical power than are required in mixed repeated-measures designs 
where subjects can act as their own control. This consideration is 
compounded by the fact that individual variance on most psychological 
tests is high and large sample sizes are required before drug effects are
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likely to be statistically significant, particularly if the effects are relatively 
subtle.
INDEPENDENT GROUPS DESIGNS GROUPS DRUGS STUDIED
Tchicaloff and Gaillard (1970) A,D phenobarbitone
phenytoin
Dodrill (1975a) A phenytoin
Kalska (1976) A phenobarbitone
Kornetsky (1958) C phenobarbitone
MIXED REPEATED-MEASURES 
DESIGNS
GROUPS DRUGS STUDIED
Wapner et al, (1962) A,D phenobarbitone
MacLeod et al, (1978) A phenobarbitone
Oxley et al, (1979) A phenobarbitone
Camfield et al, (1979) A,B phenobarbitone
Marches'! et al, (1981) A,B phenobarbiotne
phenytoin
carbamazepine
Salzman and Shader (1973) C,D phenobarbitone
Millichamp et al, (1969) C,D phenytoin
Rosen (1968) A phenytoin
mysoline
phenobarbitone
Dodrill and Troupin (1977) A phenytoin
carbamazepine
Nolte et al, (1980) A,B phenytoin
Thompson et al, (1981) C,D phenytoin
Thompson et al, (1983) A phenytoin
Martin et al, (1965) A carbamazepine
Leder (1970) A carbamazepine
Siirtola and Siirtola (1979) A,B carbamazepine
Thompson and Trimble (1982) A carbamazepine
Trimble and Thompson (1983) A carbamazepine
Thompson et al (1980a) C,D phenytoin
carbamazepine
Thompson and Trimble (1981) C,D sod. valproate
Trimble and Thompson (1983) A sod. valproate
TABLE 2.1 Studies of the effects of anticonvulsants on memory function
classified on the basis of either an independent 
repeated-measures design.
groups design or a mixed
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In addition to comparisons between drug and no drug groups, independent 
groups designs also offer the option of correlation analysis relating 
medication level to performance as a means of studying drug effects. This 
correlational approach can potentially provide a wealth of information, not 
only about simple effects, but also about dose dependent relationships, 
without requiring large numbers of control groups. In such studies, where 
performance levels at zero dose levels may be absent, they can, 
nevertheless, be estimated, in principle, from the obtained 
dose-performance curve. However, the validity of such extrapolation may 
be questionable as experimental levels tend to lie within the therapeutic 
ranges and there is a paucity of data at sub-therapeutic levels. In addition, 
correlational designs require even larger sample sizes than designs 
involving comparisons between groups. In particular, effects which may be 
present at particular stages of treatment can be distorted by correlation 
analysis unless the sample is sufficiently large to be able to study the effect 
of the length of treatment and various other disease related factors as 
independent variables.
The mixed repeated-measures design, in which subjects are studied over a 
few weeks (for example, studies by Thompson et al 1981) to many months 
(for example, six months in the case of Oxley, 1979) and which uses 
subjects as their own controls, has also been used when studying the 
effects of the anticonvulsants on memory (see Table 2.1). This design is 
more sensitive than the independent group design. It can be used to study 
changes in performance overtime and compare performance when treated 
with pre-test performance not on treatment. However, such subjects cannot 
be studied for long without confounding the effects of the drugs with the 
ongoing effects of epilepsy. In spite of these drawbacks, the majority of 
studies in this field have employed this design (see Table 2.1).
Some studies have examined the effects of systematic changes in 
medication. Thompson et al (1980a) and Thompson and Trimble (1981)
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employed a double blind, placebo-controlled cross-over trials procedure on 
non-epileptic volunteers while Dodrill and Troupin (1977) examined the 
effect of changing medication in a non-placebo-controlled cross-over trials 
design on epileptic volunteers. This method provides important 
comparative information about the drugs and avoids many methodological 
difficulties by studying the effects of switching drugs in medicated 
epileptics. (Conceptually, this may be seen as a variant on the scheme 
presented in Figure 2.1, in that in groups switched between Drug 1 and 
Drug 2, the Drug 2 condition is a "non-Drug 1" condition and vice versa). 
The primary disadvantage is that if there are no effects of the drug changes, 
it is unclear whether the drugs are having an equal effect or no effect at all.
One important mixed repeated-measures design is the study of newly 
diagnosed epileptics before and after the initiation of drug therapy. This 
approach has the advantage of attempting to assess the effects of 
epilepsy in the absence of drugs. Provided the test-retest period is not 
long, the effects of seizures are likely to be negligable. The principal 
disadvantage with this approach is that shortening the length of the test 
retest interval prevents the study of long-term drug effects.
In practice, it is difficult to experimentally manipulate the drug and epilepsy 
factors independently. Cross-sectional group designs, longitudinal designs 
and correlational designs each have their own advantages and 
disadvantages. Since no single approach is flawless, studies should seek 
to employ multiple research methodologies in attempting to disassociate 
the effects of anticonvulsants from the effects of epilepsy.
2.2 THE EFFECT OF SUBJECT SELECTION ON THE
EXPERIMENTAL RESULTS
The nature of epilepsy often makes the interpretation of the results of 
studies of the cognitive effects of the drugs difficult. Hughlings Jackson 
(1897) described a seizure as "a disorderly and excessive discharge of
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neurones This definition, in spite of its age, remains as valid today as it 
was when it was made. The extent of the region of disorderly discharge, 
the frequency of occurrence of the discharge and the location or focus of 
the discharge within the brain, are entirely variable. Epileptic neural 
discharges may be generalised or focal or begin focally and become 
generalised. They may be very frequent, occuring almost continously, or 
every few years, or only at certain times in the life of an individual. Focal 
epileptic activity may arise almost anywhere in the brain, although the 
temporal lobes appear to be most susceptible. Epilepsy may vary widely 
in its severity (usually measured by seizure frequency but also to some 
degree by the nature of the seizure), its nature (that is the type of seizures 
and their cognitive effects) and the course of the epilepsy. What all of these 
variations have in common is this "excessive, disorderly discharge of 
neurones" even though the actual behavioural manifestations of the 
seizure may be quite different in degree, nature (see Table 2.2) and course 
from one individual to another.
Although the evidence is not altogether consistent, there is general 
agreement that certain types of epilepsy are frequently associated with 
more or less specific cognitive dysfunction. Deficits have been reported in 
memory, attention, perceptuo-motor abilities and cognitive speed. These 
will now be commented on briefly.
There is good evidence associating memory deficits with temporal lobe 
epilepsy. Most reports have been concerned with patients with intractable 
seizures requiring surgical intervention and these have been reviewed by 
Milner (1974) and Iverson (1977). However, similar results have been 
found with children and adults not requiring surgical intervention (e.g. 
Glowinski, 1973; Fedio and Mirsky, 1969; Quadfasel and Pruyser 
1955).Reports of attentional deficits among epileptics have been common 
(e.g. Holdsworth and Whitmore, 1977; Stores, Hart and Piran, 1978) but the 
evidence is not altogether consistent. A number of studies have reported an 
association between generalised epilepsy and deficits in attention (Mirsky,
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1960; Fedio and Mirsky, 1968, Kimura, 1964). However, other workers 
(Glowinski, 1973; Remschmidt, 1973) found no such association. 
Perceptuo-motor disturbances (including mental slowing) have been 
frequently observed (e.g. Gastaut, 1964; McKinley, 1980). Morgan and 
Groh (1980) reported that visual impairments, at least, may occur more 
frequently in children with partial seizures.
The relationship between severity of epilepsy and intellectual deterioration 
is not perfectly understood. There have been a number of longitudinal 
studies conducted which have all produced dissimilar results (Reviewed by 
Thompson, 1981). Nonetheless, it is possible to conclude that although 
progressive intellectual deterioration is severe for some epileptics, it may 
not occur at all for the vast majority of epileptics. In a recent review of the 
relationship between seizures and cognitive dysfunction byt Trimble and 
Thompson (1981) it is suggested that generalised seizures may produce 
impairments of long term memory. Further unpublished evidence from 
Dodrill (1981, pers. comm.) indicates that the experience of 50 or more 
generalised seizures and/or status epilepticus correlates with a 
significantly reduced IQ. Presumably repeated or prolonged experience of 
hypoxia during the seizure (which does not occur in all seizure types) may 
eventually lead to a measureable deterioration of intellectual function.
Given the heterogeneous nature of the epileptic population, it is essential 
that any study of the cognitive effects of epilepsy and anticonvulsants 
should specify its subject population precisely. Severe epileptics are more 
likely to have a greater degree of cognitive dysfunction. Consequently, 
studies using severe epileptics may fail to measure relatively subtle 
alterations in cognitive function occurring in association with changes in 
medication. In addition, studies of certain groups such as temporal lobe 
epileptics, may fail to observe changes in memory performance due to the 
effects of the drugs because they are masked by the severe existing 
memory dysfunction which is common in epileptics of this sort (Herman and 
Whitman, 1984).
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1 GENERALISED SEIZURES
a) absence seizures (petit mal)
b) myoclonic jerks
c) akinetic seizures
d) clonic seizures
e) tonic seizures
f) tonic-clonic seizures (grand mal)
2 PARTIAL SEIZURES
a) with elementary symptomology
i) motor symptoms
ii) somatosensory symptoms
iii) visual symptoms
iv) auditory symptoms
v) olfactory and gustatory symptoms
vi) visceral and autonomic symptoms
b) with complex symptomology
i) automatisms
ii) cognitive symptoms
iii) psychic experiences
iv) emotional and mood changes
v) impaired consciousness
c) secondarily generalised
3 UNILATERAL SEIZURES
4 UNCLASSIFIABLE
TABLE 2.2 Classification of epileptic seizures (International League 
Against Epilepsy, 1969).
Unfortunately, as Trimble and Thompson (1981) point out, many studies 
have failed to describe their patients adequately. The problem is 
exacerbated by the fact that classification schemes have changed overtime 
- the old idiopathic and symptomatic distinction has lost popularity to the 
more functional classification schemes based on seizure type.
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The populations examined in studies of the effects of the anticonvulsants 
on cognitive function have varied widely and have been of three general 
types: epileptic; non-epileptic-but-clinical; and non-epileptic-and-non- 
clinical. Epileptic populations, although clearly the most directly relevant, 
have not always been well described in papers examining the effects of the 
drugs on memory. Classification schemes have changed. Severity of 
epilepsy (that is, seizure frequency and type) is commonly inadequately 
reported even though it is well established that seizures, particularly grand 
mal seizures, may impair cognitive performance. Non-epileptic-but-clinical 
populations have included children with behavioural and learning 
problems and elderly patients (Salzman and Shader, 1973) - highly 
heterogenous samples likely to reduce the sensitivity of the experiment to 
drug effects. Non-clinical populations have included such groups as 
medical students (e.g. Thompson et al, 1981). The use of such diverse 
populations may at least partially be responsible for the wide variation in 
the results obtained.
Many studies of the cognitive effects of epilepsy have assessed severe 
epileptics. Most studies have examined patients treated poly- 
therapeutically. This may imply that these epileptics are more severely 
affected than those treated with only one drug. Shorvon and Reynolds 
(1977) have shown that as many as 90% of newly diagnosed epileptics 
can be satisfactorily controlled on one drug if the dose is optimised within 
the therapeutic range. On the other hand, it has also been common 
practice to prescribe too many drugs (Reynolds and Shorvon, 1981). 
Nonetheless, many of the important studies in this area by Dodrill, 
Thompson and Trimble have been drawn from a pool of institutionalised 
subjects or subjects presenting to centres specialising in the treatment of 
epilepsy and who may, therefore, tend to be more severe cases. It is 
possible that many studies not citing seizure type or frequency have 
confounded the effects of epilepsy with the effects of the drugs.
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2.3 THE EFFECT OF EPILEPSY AT THE TIME OF TESTING
There is a growing awareness of the significance of sub-convulsive 
seizures (these are small discharges w ithout overt behavioural 
consequences) which may, nonetheless, have a significant effect on 
behaviour. The manner in which psychological function may be affected 
by sub-clinical discharges is not clear. Some studies have found an 
association between impairment on various cognitive tasks and the 
occurrences of discharges (Wilkus and Dodrill, 1976). Such discharges 
are believed to have an effect on attention (Mirsky, Primac, Marsan, 
Rosvold and Stevens, 1960), timed peformance (Parsons and Kemp, 
1960), and memory (Glowinski, 1973). There may even be effects on 
emotional behaviour as well, particularly in temporal lobe epileptics 
(Herman and Whitman, 1984).
Ostensibly EEG recordings during psychological assessments could 
measure the confounding effects of sub-clinical epileptic activity on 
cognitive performance. However, there are a number of practical 
problems. Firstly, interpretation of records is made difficult by the fact 
that, when a discharge is recorded during testing, it cannot be known 
whether this occurred spontaneously or as a consequence of the 
mental activity demanded by this test. (Although many discharges appear 
to be recorded at random in the substantially inactive patient, 
occasional cases present in which discharges result from specific mental 
activity such as arithmetic (Wiebers, Westmoreland and Klass, 1979) or 
reading (Hammond, Danta and Dowling, 1978).)
The second difficulty with the use of EEG recordings during psychological 
testing is that the recording may affect the performance of the subject. 
The process of attaching EEG electrodes can cause a degree of anxiety 
and recording procedures may interfere with attention. Such effects may 
impair performance on psychological testing.
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Two procedural recommendations can be followed. Firstly, avoid severe 
cases of epilepsy with poor seizure control (which have generally been 
studied because they have been easily accessible). Avoiding such subjects 
would not only yield a sample more representative of the general 
population of epileptics, but would also reduce the strength of possible 
effects of the disease on memory test performance. Secondly, EEG 
recordings could be made either immediately before or after (rather than 
during) a psychological testing session in order to examine the frequency 
of spontaneous subclinical discharges. While this would not guarantee that 
the frequency of discharge was not different during testing, it would permit 
exclusion from the analysis of patients with exessive frequency of neural 
disturbance (at the possible cost of impairing applicability of the results to 
more severe cases).
2.4 THE EFFECT OF MOOD AT THE TIME OF TESTING ON 
THE EXPERIMENTAL RESULTS
There is little direct evidence of an influence of mood on test performance 
amongst epileptics. However, in an extensive review by Herman and 
Whitman (1984) many factors associated with the development of 
psychopathology have been suggested. These are summarised below.
Many of the psychopathological changes refer to the development of 
anxiety or depression. As can be seen in Table 2.3 there are many reasons 
for this development. Seizures are essentially unpredictable and 
uncontrollable aversive events. It has been suggested that Seligman’s 
theory of learned helplessness may account for the high rates of anxiety 
and depression (Herman, 1979). Fears about their seizures and medical 
misinformation are common amongst epileptics (Mittan and Locke, 
1982a,b). These authors concluded that such fears are a significant factor 
in the development of anxiety and depression. Other important factors are 
the social stigma which is still associated with epilepsy and frequently
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results in social exclusion and ostracism (Bagley, 1972; Schneider and 
Conrad, 1980) and existence of social discrimination in the granting of 
drivers’ licences or gaining access to educational and employment 
opportunities.
NON-BRAIN RELATED FACTORS OBSERVATIONS
Chronic illness 
variables
Presence of a chronic disorder; 
economic stress; 
limitations of activites; 
limitations of aspirations; 
other
Epilepsy variables Nature of epilepsy;
medical ignorance;
fear of seizures;
stigma (real and perceived);
social consequences;
discrimination
Developmental/epilepsy
variables
Familial considerations; 
effects of epilepsy on family; 
altered expectations of child; 
general adjustment of parents; 
familial psychiatric history; 
age at onset; 
early experiences
Demographic/subject
variables
Socioeconomic status;
age;
sex;
premorbid personality; 
psychological status; 
other (e.g. employment status)
TABLE 2.3 Non-brain related factors associated with psychopathology in 
epilepsy adapted from Herman and Whitman (1984).
High levels of anxiety and depression may impair cognitive performance 
(Hamilton and Warburton, 1979). Anxious patients may have difficulty in 
concentration, and depressed patients may not be motivated to perform 
well. Such influences on performance may result in increased
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test-performance variability. Higher levels of variability will reduce statistical 
power and can consequently obscure small effects. This may affect the 
interpretation of results, particularly when comparisons are to be made 
between epileptic and non-epileptic groups, or where the design involves 
re-examination of subjects. Relatively few studies of the effects of the drugs 
on cognition have attempted to examine the effect of mood on their results. 
(The studies by Thompson (1981) which employed the Mood Adjective 
Check List are an important exception to this.)
Since most of these psychosocial factors are difficult to control 
experimentally, the only practical strategy is to measure them and take 
them into consideration when interpreting the results. Such assessments 
have usually been done subjectively. The objective measurement device 
most commonly used has been the MMPI, but this assessment has been 
critisised on the grounds that it has been developed and standardised on 
non-epileptic patients and may confuse psychopathology with the effects of 
seizure disorders (Dodrill et al, 1980). Dodrill has instead chosen to 
develop a specially designed inventory for the assessment of psychosocial 
problems amongst epileptics - the Washington Psychosocial Seizure 
Inventory (WPSI). The WPSI will be considered in more detail in the next 
chapter.
Although there is little direct evidence for an effect of mood on 
neuropsychological test performance amongst epileptics, there is 
considerable evidence to suggest that changes in mood do occur as a 
result of epilepsy. It is generally accepted that changes in mood, 
particularly anxiety (Lezak, 1976) can have a profound influence on 
neuropsychological test performance. Changes in test performance due to 
mood may result in a higher level of test performance variability which can 
be expected to confound the results of experiments on the effects of the 
drugs.
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2.5 THE EFFECT OF INTER-ICTAL BEHAVIOUR CHANGES  
ON THE EXPERIMENTAL RESULTS
While the concept of an epileptic personality has generally fallen from 
favour (Hermann and Whitman, 1984) there is some evidence to suggest 
that there are some specific behavioural changes which are associated 
with complex partial seizures or temporal lobe epilepsy (TLE). Waxman 
and Geschwind (1975) proposed that patients with TLE exhibit 
hypergraphia, hyposexuality and increased religiosity. Subsequently, Bear 
(1979) identified 18 separate personality traits associated with TLE. He 
proposed that TLE patients undergo a process of "sensory-limbic 
hyperconnection" in which new associations are formed between the 
neocortex and the limbic structures. Unfortunately, well controlled studies of 
personality differences between TLE and matched non-TLE groups (e.g. 
Hermann and Riel, 1981; Bear et al, 1982) failed to identify consistent 
personality discriminators. Clearly, further work is required to clarify the 
influence of personality changes due to the onset of epilepsy.
The possibility exists that some epileptics may undergo personality or 
behavioural changes as a result of the onset of epilepsy which is 
independent of psychopathology. Such changes could influence the results 
of studies of the effects of drugs using certain research designs. In 
particular, these changes would be confounded with comparisons between 
epileptic and non-epileptic groups and comparisons of repeated tests in 
epileptics.
Many aspects of these possible effects on test performance are speculative. 
However, a number of methodological implications follow from such 
considerations. Firstly, in the absence of satisfactory measures of 
psychopathology or personality change, non-epileptics may be unsuitable 
as controls because these effects will be confounded with those of the 
medication. Secondly, the possible confounding of personality, behavioural 
or psychopathological changes with the effects of the medication between
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groups of epileptics may be reduced by the measurement of such effects 
and careful subject matching.
2.6 THE EFFECT OF DRUG LEVELS ON THE EXPERIMENTAL 
RESULTS
In studies of the effects of the drugs on cognitive function it is essential to 
control the level of the drug in the brain. However, relatively few 
assessments of anticonvulsant effects on memory function have been 
carried out with concurrent serum blood level assessments (Trimble and 
Reynolds, 1976). The need for such assessments has only become 
apparent in the last 10 to 15 years with the recognition of therapeutic 
ranges for most anticonvulsants. Before this, anticonvulsants were 
administered in increasing doses until fitting ceased or side-effects became 
apparent. With the introduction of serum level testing it became evident that 
a substantial proportion of patients were either over-treated or 
under-treated (Vajda et al, 1978).
The wide variations in the serum levels of the drugs have been due 
substantially to the non-linear relationship between dose and serum level 
for most anticonvulsants. The theoretical relationship between dose and 
serum anticonvulsant level is presented in Figure 2.2. The dose required to 
produce a serum anticonvulsant level within the therapeutic range is 
variable and does not correlate well with age, sex or weight (Houghton, 
Richens and Leighton, 1975). However, it is the serum level, not the dose, 
of the drug that correlates best with fit control and determines whether the 
patient will develop side-effects such as nystagmus, ataxia, apathy, 
somnolence or mental slowing. The appreciation of this fact led to the 
development of therapeutic ranges and the current popularity of serum 
level monitoring in the treatment of epilepsy.
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FIGURE 2.2 Theoretical relationship between dose and serum anti­
convulsant level for several individuals.
Bearing in mind that many of the studies referred to in Table 2.1 do not cite 
serum anticonvulsant levels, it is possible that some of the inconsistencies 
between their results are due to variations in drug levels. Indeed 
comparative studies of toxic and non-toxic populations of epileptics have 
shown precisely these kinds of differences. Matthews and Harley (1975) 
examined the performance of epileptics with toxic and non-toxic levels of 
phenytoin, phenobarbitone and primidone. They found that the toxic group 
consistently performed at a lower level than the non-toxic group on 
measures of attention, concentration, motor co-ordination and static 
tremor although no differences were observed on the Knox Cube 
Imitiation Test. In addition, some patients may have had levels of the drugs 
which would now be regarded as too low for therapeutic effect. The use of 
serum assays reduced the numbers of such patients who are inadequately 
medicated and presumably not experiencing the putative adverse effects of 
the drugs on cognition to the same degree. The inclusion of such subjects 
within the anaysis of previous studies would tend to bias the results 
towards concluding that the drugs had no effect on cognition.
It would, therefore, appear essential to measure serum anticonvulsant 
levels concurrent with testing. This would permit the exclusion of those
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subjects with levels of the drugs outside the accepted therapeutic ranges 
so that the effects of the drugs within these limits can be studied.
2.7 THE EFFECT OF DIFFERENT DRUG REGIMENS ON THE 
EXPERIMENTAL RESULTS
Drug administration protocols are another potentially important variable 
which might influence the cognitive effects of the anticonvulsants. Studies 
have generally fallen into one of three categories : single dose; short-term 
treatment (a few weeks to a few months); or long-term treatment (a few 
years to decades).
Studies of the long-term effects of the drugs are most relevant to the 
epileptic population. Nevertheless, side-effects may be observed during 
short-term administration which may disappear after habituation. Thus, 
short-term studies may provide important information about effects which 
are significant at the time but unimportant during long-term treatment. The 
value of single dose studies is questionable. The time between ingestion 
and assessment has a critical effect on the results obtained because of 
the gradual change in the blood level as the drug is metabolised. Whether 
or not adverse effects are observed in the very short-term cannot imply that 
such effects do or do not exist in the long-term. Ideally, studies should be 
carried out over a long period of time.
The study of the drugs used polytherapeutically may also yield 
misleading results. The effects of the drugs on cognition may be 
confounded with interactions or alterations in the free and bound 
proportions of the drugs. The pharmacological action of the drug arises 
from the free, rather than the bound, proportion of the drug in the serum. 
Serum anticonvulsant level assessments measure the total (free and 
bound) levels of the drug. The addition of a second drug may not 
necessarily change the total level in the serum but can significantly 
increase the free proportion of the first drug. Thus side-effects normally
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associated with toxic levels of a drug may be experienced at levels that 
are apparently within the normal therapeutic range if multiple drugs are 
used.
In order to study the effects of anticonvulsants on cognition as used in 
modern clinical practice, the effects of the drugs should be studied in 
monotherapy and within the therapeutic ranges. Failure to do so has made 
the interpretation of many studies of the cognitive effects of the drugs 
difficult.
2.8 THE MEASUREMENT OF FOLATE LEVELS
As noted earlier, there is a possibility that alterations to the metabolism of 
folate by anticonvulsants may be a factor in the development of cognitive 
deterioration among epileptics. However, there is currently no generally 
accepted method of measuring folate level in the body when assessing the 
effects of the drugs or folate deficiency on cognition.
There are three measures of folate levels which are used in studies of the 
effects of anticonvulsants on folate metabolism - cerebrospinal fluid (CSF) 
folate, serum folate and red cell folate. A number of different assay methods 
have been used for each, and each method may give a slightly different 
result (Säuberlich, Dowdy and Skala, 1974). CSF folate measures are the 
most direct measures for estimating the level of folate in the brain and 
hence the only direct measure of the effect of folate on neuronal and 
cognitive function. Measurements of CSF folate are not routinely carried out 
as this measurement requires a lumbar puncture. This method was, 
therefore, considered unsuitable for this study.
The most commonly obtained measures of folate have been red cell and 
serum folate. Serum folate is affected by dietary intake of folic acid over 
periods of only a few hours. Serum folate levels do not reflect the level of 
tissue stores, although consistent measures of low serum folate levels may
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indicate depleted levels throughout the body (Säuberlich, 1977). 
Nonetheless, there is a good correlation between serum folate levels and 
CSF folate levels (Reynolds, 1976). On the other hand, red cell folate levels 
may be influenced by dietary intake over periods of several days and may 
better reflect general levels of tissue stores.
Studies of the effects of folate on cognition have produced conflicting 
results (as noted in Chapter 1). However, the choice of method has been 
unrelated to whether significant correlations were found between cognition 
and folate level, and the difference between these measurement 
techniques is probably marginal (although Reynolds (1976) in a detailed 
and extensive review of the neurological aspects of folate and B12 
metabolism concluded that red cell folate may be the best index of 
deficiency).
2.9 THE EFFECT OF P SY C H O LO G IC A L  M EA SUR ES ON 
C O N C L U S IO N S
There have been wide variations in the manner in which psychological 
measures have been used to assess the effects of medication. At one 
extreme, some authors have used large batteries of tests of cognitive 
function in order to assess a broad range of behaviours (for example, 
Dodrill, 1975a,b; Dodrill and Troupin, 1977). This approach may 
demonstrate that the cognitive effects of the drugs are either causing global 
deficits, or deficits in particular aspects of cognitive function. However, such 
an approach has the disadvantage of not identifying the nature of specific 
deficits. On the other hand, other workers have carried out intensive 
investigations on particular individuals using collections of tests specially 
selected for each individual subject (for example, Royo and Martin, 1959). 
Although allowing the thorough examination of the effects of the drugs on 
specific aspects of cognition which may be impaired in particular 
individuals, this approach makes extrapolation of the results to all 
epileptics difficult.
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A compromise may be to investigate a specific cognitive function using a 
large sample and a standardised test battery. In designing the battery, an 
investigator must bear in mind that even when there is an interest in a 
specific cognitive skill, it is still important to sample a broad range of 
individuals' experiences and behaviour, in order to assess both the 
specificity and the consequences of particular drug effects (Tomlinson and 
Stores, 1980). In effect, memory function cannot be assessed in isolation. 
Aspects of general cognitive, emotional and psychosocial functioning 
which may affect memory test performance need to be examined, in order 
to appreciate the significance of any memory dysfunction.
Few attempts have been made to design specific test batteries for the study 
of epilepsy. The study by Dodrill (1978) is one exception. He selected 16 
test variables from a large pool of items which appeared to discriminate 
epileptic groups from controls and could be used to evaluate epileptics on 
important areas of cognitive functions. However, less than half of these 
measures specifically relate to memory functions.
Thompson et al (1980b) after careful examination of the literature, used a 
broad spectrum of tests, many of which had been shown to produce 
significant drug effects. These tests were largely concerned with assessing 
memory performance. Marchesi et al (1981) developed a memory test 
battery largely based on standard clinical tests which was also successful 
in demonstrating statistically significant changes in memory test 
performance attributable to the drugs. Unfortunately, neither memory 
battery was available to the experimenter at the commencement of this 
study.
In view of the above considerations, it seemed desirable, in designing the 
present study, to develop a broad range of specifically designed memory 
measures, with a level of sensitivity, suffucient to measure any small effects 
of the medication on memory.
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2.10 SUMMARY
Various aspects of the design and execution of studies of the effects of 
anticonvulsants on memory function can have a significant effect on the 
results obtained and their interpretability. The salient aspects may be 
summarised as follows.
(1) Ethical Considerations. For practical and ethical reasons, it is difficult to 
manipulate the epilepsy and drug factors independently for purely 
experimental reasons.
(2) The Choice of Experimental Design. Studies using epileptic subjects as 
their own controls are more sensitive than studies using cross-sectional 
analysis and are therefore more likely to detect small effects.
(3) The Selection of Subjects. Epileptic subjects should be selected to be 
as representative of the general epileptic population as possible and the 
study of severe cases alone should be avoided in order to minimise 
confounding the effects of epilepsy and the effects of the medication. In 
addition, accurate diagnosis is an important aid in separating these two 
effects.
(4) Assessment of Drug Levels. Concurrent serum anticonvulsant level 
assessments with psychological assessments are essential to permit the 
proper interpretation of the results.
(5) The Nature of the Test Battery. By using a battery of tests of memory, it is 
more likely that the results will reveal the nature of any memory dysfunction. 
Tests of general cognitive function need to be used in conjunction with any 
memory battery in order to exclude more general deficits of cognitive 
function.
CHAPTER 3
GENERAL INTRODUCTION
TO THE METHODOLOGY OF THE STUDY
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3.1 INTRODUCTION
The present study investigated the effects of anticonvulsant drugs on 
memory function in epileptic patients. This chapter describes and discusses 
the methods used.
To study the effects of anticonvulsants on memory function, one can use a 
variety of different subjects. Non-epileptic human and animal studies offer 
the advantage of a greater degree of control over extraneous variables, but 
present certain problems if the results are to be extrapolated to clinical 
situations. The alternative use of epileptics bears directly on problems in 
existing clinical practice. Unfortunately, most clinical studies do not allow 
clear conclusions to be drawn because of the methodological flaws 
discussed in the previous chapter.
This study was carried out on a clinical population of epileptics. The 
decision to study this group of subjects was made for the following reasons. 
Firstly, only by studying the effects of the drugs on epileptics is it possible to 
determine the relative significance of the effects of the drugs on cognition in 
clinical practice. Secondly, there is now sufficient evidence from studies of 
non-clinical populations, such as those by Thompson et al (1981) to 
indicate that the drugs have an adverse effect on cognition and memory. 
There is a need for direct studies of clinical populations, using therapeutic 
levels of medication, to complement the results of Thompson on 
non-epileptic populations.
This study was designed to examine the following questions:
(1) Do anticonvulsants in common use have an effect on memory function 
in epileptic patients?
(2) Do these effects correlate significantly with blood levels of the drugs?
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(3) Are the effects of the drugs on memory reversible?
(4) How do the effects of the drugs change with time during long-term 
treatment?
(5) What is the nature of the effects of the drugs on memory function in 
epileptics?
(6) Are the effects of the drugs mediated by changes in folic acid 
metabolism?
3.2 SUMMARY OF THE STUDY
Patients were obtained from the outpatient neurology clinics of Royal 
Canberra Hospital and Woden Valley Hospital between 1979 and 1982. 
All subjects included in the analysis of experiments fulfilled the following 
criteria:
(1) a diagnosis of epilepsy, established on the basis of two or 
more clinically definite fits having been documented;
(2) aged between 16 and 55 years;
(3) normal intelligence;
(4) normal brain scan;
(5) absence of progressive neurological disorder;
(6) no medication being taken other than that prescribed for 
the treatment of epilepsy*;
(7) suitable for treatment by monotherapy with phenytoin, 
carbamazepine or sodium valproate; and
(8) serum anticonvulsant levels within or below the therapeutic 
ranges defined below.
*With the exception of oral contraceptives.
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Phenytoin 
Carbamazepine 
Sodium valproate
- 1.0 to 2.0 milligrams percent
- 0.4 to 0.8 milligrams percent
- 6.0 to 16.0 milligrams percent
Patients were tested as they became available. It was intended to study 
newly diagnosed epileptics before drug treatment was commenced and 
then 'follow' them over as long a period as possible. The first retest was to 
occur after three months of treatment and the second retest after nine 
months of drug therapy. As many subjects as possible were tested who 
were treated by monotherapy with any one of the three drugs under 
investigation. If these subjects switched drugs or altered dose then they 
were retested. Wherever possible, test-retest periods were kept to about 
three months. A subject who was about to undergo any drug change was 
tested before and then three months after that change. By assessing the 
patient pool in this way it was planned to analyse the results in terms of a 
series of independent 'experiments'.
Experiment 1 compared the effect of the three drugs on the memory 
function of newly diagnosed and previously untreated epileptics. 
Comparisons of performance, before and after drug treatment, could be 
expected to provide evidence of whether memory performance was altered 
by the drugs. Examination of the groups on post-test would allow 
comparison of memory function on different drugs.
In subsequent experiments, the effects of changing medication were 
examined. It was hoped to find a group of subjects who were administered 
all three drugs at different times. In addition, comparisons could be made 
between drugs by comparing subjects who altered medication with those 
who remained on the same drug. Such investigations could also be used to 
examine the long term effects of the medication.
Finally an examination was made of the performance of groups of patients
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established on medication for a number of years. The effects on memory 
function of different doses of the drugs, blood levels of the drugs and levels 
of red cell folate were examined.
At the commencement of the study it could not be predicted which subjects 
would complete any of the above experiments. For the purposes of 
analysis, the study was conceived as a set of independent experiments and 
will be presented as such in subsequent chapters. However, the subject 
pool was insufficient to allow experiments to be executed independently 
and sequentially. As a result, various components of the study were carried 
out concurrently on overlapping samples of subjects. Some subjects were 
used in only one of the experiments, while others were used in several. 
Over two hundred subjects were tested during a period of almost four 
years, most subjects being tested two or more times. However, when 
testing ceased, not all experimental designs had sufficient subjects for 
analysis and some changes in experimental design proved necessary in 
view of the subject pool which was finally obtained.
A further complication in the interpretation of the results was the fact that 
alterations were made to the test battery over the course of the study. As is 
common with investigations conducted over many years, during the course 
of the study it became apparent that changes to the battery were necessary. 
The reasons for this decision will be considered later.
The general procedure for the study was as follows. For their first 
assessment, patients were given a shortened form of the WAIS (shortened 
by excluding the Comprehension and Object Assembly Subtests) one of 
four parallel forms of a Memory Battery and blood tests for red cell folate 
and serum anticonvulsant levels. In addition, EEG’s were arranged on the 
same day, or within a few days of testing wherever possible. Assessments 
were then repeated approximately three months later. Subsequently, if 
alteration to the drug therapy was contemplated, patients were tested
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before the intervention and then three months after the change.
Four experiments are presented in this thesis. These are :
3.2.1 Experiment 1. Short-Term Effects of Anticonvulsants on the Memory 
of Previously Untreated Epileptics
Experiment 1 was designed to assess, using a longitudinal design, 
changes in drug-induced memory performance in newly diagnosed 
epileptics who were previously untreated. The effects of three major 
anticonvulsants (phenytoin, carbamazepine and sodium valproate) on 
memory function were assessed before and after the first three months of 
drug treatment.
3.2.2 Experiment 2. The Effect of Changing from Phenytoin to 
Carbamazepine on the Memory of Chronically Medicated Epileptics
Memory function among patients switching from phenytoin to carbamazepine 
was compared with patients remaining on phenytoin.
3.2.3 Experiment 3. The Effect of Changing from Carbamazepine to 
Sodium Valproate on the Memory of Chronically Medicated 
Epileptics
Experiment 3 compared the effects of switching from carbamazepine to sodium 
valproate with the effects of remaining on carbamazepine.
3.2.4 Experiment 4. The Relationship Between Blood Level of 
Anticonvulsants, Red Cell Folate Level and Memory in Chronically 
Medicated Epileptics
Experiment 4 examined the relationships between blood level of 
anticonvulsant, dose of anticonvulsant and folic acid level with memory 
performance in the available epileptic population.
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3.3 THE MEMORY TESTS
The battery was designed to distinguish memory disorders from other more 
general cognitive deficits, such as mental and motor slowing, and to 
determine the nature of any memory deficit that might become apparent. 
Since Experiments 1-3 employed a longitudinal design, it was necessary to 
devise parallel forms of the memory battery.
3.3.1 The Order of Administration of Parallel Forms of the Test Battery
If the same battery of tests was used repeatedly, then improvements in 
performance would be expected due to recall items from previous testing 
which could mask the memory impairing effects of the drugs. Parallel forms 
of the Memory Battery were developed by the use of similar, but not 
identical, test items, in the same test procedures in order to reduce 
test-retest effects.
The experimenter attempted to administer the parallel forms of the battery 
in a random order to avoid systematic effects which might arise from one 
form of the battery being significantly different in difficulty from any other. 
However, perfect counterbalancing was not possible as the decision to use 
any particular form of the memory battery had to be taken before group 
assignments were made. In addition, since previously untreated epileptics 
would present at only the very slow rate of one or two per month, testing 
was commenced as soon as the first form of the memory battery was 
developed. While this maximised the amount of data collected, some bias 
in the frequency of use of the parallel forms of the memory battery resulted. 
These problems must be accepted as part of the difficulties in conducting 
clinically applied research in this area.
In view of the potential difficulties from imperfect counterbalancing of 
parallel forms of the test battery, considerable care was exercised in the 
selection of test items. An analysis of the different forms of the battery is
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presented in Appendix 3.1. This suggests that the parallel tests were of 
equal difficulty. In this case, the potential confounding of order of the 
administration of different test forms with drug effects is unlikely to have 
significantly influenced the results of the study.
3.3.2 Changes to the Test Battery
In carrying out longitudinal research, a balance needs to bestruck 
between changes in tests designed to improve sensitivity and the need to 
maintain test protocol in order to satisfy the requirements for statistical 
analysis. In addition, any change in test protocol may bring with it subtle 
alterations in the performance of subjects on other tests, due to different 
levels of effort and sustained attention required for different 
configurations of tests.
If sufficient subjects are available for study, then the effect of test battery 
modifications can be examined by analysing the data for different memory 
batteries independently. However, in the present study sufficient patients 
were not available. For this reason major alterations to the memory battery 
were avoided, even though the possibility of improvements was evident. 
Nevertheless, it became apparent during the course of the study that 
certain tests were insensitive to the effects of the drugs due to ceiling 
effects. In some cases it was decided to modify the test concerned. In 
others, it was decided to discard the test altogether and replace it with a test 
with higher senstivity. Only those tests which have been analysed as part of 
the experiments will be described here. Discarded tests are descibed in 
Appendix 3.2.
3.3.3 The Nature of the Memory Battery
The tests used in the memory battery are summarised in Table 3.1. The 
first version of the memory battery was designed to assess both short- and
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long-term memory using different types of memory items including both 
verbal and non-verbal material. Some tests were initially developed based 
on the observations of Brown (1958) and Peterson and Peterson (1959) 
that distractor tasks, preventing the rehearsal of items to be remembered, 
could result in item lists as short as three being totally forgotten in just thirty 
seconds. This procedure was adapted to involve the recall or recognition of 
lists of items after delays of thirty seconds which were either 'empty' or 
'filled' with an interpolated task. Test items used in the memory battery in 
free recall or recognition were words, sentences, prose, dots on a matrix 
and faces. The interpolated memory task was always a memory task using 
the same type of test items. The Rey Auditory Verbal Learning Task was 
used to measure word span, verbal learning and delayed recall and 
recognition (using a thirty minute delay). Non-memory tests included simple 
choice reaction times, a simultaneous vigilance task and a simple 
structured interview.
After two years of testing it became apparent that the results from most of 
the tests were not yielding any systematic changes in memory test 
performance attributable to the effects of the drugs. Lack of an effect of the 
drugs on memory test performance could have been due to a number of 
factors, as noted in Section 3.3. On the other hand, many tests suffered 
from obvious ceiling effects and were unlikely to yield significant results 
even if there were effects of the drugs on memory performance. (These 
problems will be discussed when descibing test procedures).
Changing the tests at this stage of the study, had a number of significant 
disadvantages. In particular, alterations in the test battery could have 
resulted in sample sizes too small for meaningful analysis. After careful 
consideration, and with the full understanding of the potential 
disadvantages of such modifications on the study, changes were made to 
the memory battery.
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In designing new, more sensitive memory tests, greater emphasis was 
placed on the qualitative aspects of memory performance. Most of the tests 
used up to this time had concentrated on the amount of information which 
could be stored or held in mind. The new tests for the battery were 
designed to test the speed of remembering as well as the amount of 
information that could be recalled.
This collection of memory and other tests, which is referred to as the 
'memory battery', was considered to provide an extensive examination 
of memory function. While no memory battery can expect to be 
exhaustive, it was felt that this battery did include a wide variety of tests 
which:
-contained memory items that were, on the whole, of real world 
significance;
-used both verbal and non-verbal material;
-examined both short term memory and long term memory;
-compared the effect of meaningfulness on memory performance; 
-manipulated levels of difficulty across many tasks;
-examined speed of processing as well as accuracy of recall; and 
-examined factors such as motor speed and attention so that 
general impairments could be distinguished from specific memory 
problems.
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3.3.4 The tests Used in the Memory Battery
Test No. Memory Test
1
2
3
4
5
6
7
8
9
10 
11 
12
13
14
15
16 
17
Verbal Memory
Digit span
Modified Rey Auditory Verbal Learning Task 
Words(1) and Words(2)
*Sentences(1) and Sentences(2)
*Prose(1) and Prose(2)
Long-Term Memory Recall 
Word Finding Speed 
Sternberg's Serial Scanning Task
Visual Memory
^Position Learning Task 
*Position(1) and Position(2)
*Rey Figure 
Faces(1) and Faces(2)
Motor Tasks
Simple choice reaction time task 
Simultaneous vigilance task
General Assessment
Structured interview
Washington Psychosocial Seizure Inventory 
Subjective Memory Questionnaire (SMQ)
TABLE 3.1 Summary of Memory Battery. * These tests are presented in 
Appendix 3.2. Test items Form A of the memory battery are presented in 
Appendix 3.3.
These tests will now be discussed individually.
3.3.4.1 Digit Span Test
This test is the digit span test from the WAIS. Digit Span forwards is usually 
regarded as a measure of the number of items which can be held in mind at 
any one time. The full test involves many other important functions such as 
auditory attention and the capacity to perform 'mental double tracking' 
(Lezak, 1976; p210). Nonetheless, Lezak argues that memory is the chief
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functional component of this test. Baddeley (1976) believed that digit span 
involves components of both short-term and long-term stores. For the 
purposes of this study this test is regarded as measuring the number of 
digits that can be held in mind at any one time, as well as the effect of 
increasing the difficulty of the task by the addition of further mental 
manipulation.
The procedure for administering the test was as follows. Subjects were 
asked to remember a series of numbers that were read to them, and then 
to repeat them back in the same order. The length of the series was 
extended until at least one error occurred on two consecutive lists of the 
same length. The test was then repeated with different sequences of 
numbers and the subject was instructed to recall the numbers in the 
reverse order. The length of the series was extended using the same 
protocol.
3.3.4.2 Modified Rey Auditory Verbal Learning Task
This test, slightly modified from the version described by Lezak (1976) 
assesses immediate memory span, provides a learning curve, measures 
confabulation and permits the measurement of forgetting from long-term 
memory over a thirty minute period.
Subjects were asked to remember 15 words from a list which was read out 
by the experimenter. The items were selected to be equally imageable, 
concrete and meaningful (Paivio, Yuille and Madigan, 1968) as well as 
having similar word frequency (Thorndike and Lorge, 1944). The list was 
repeated a number of times with the subject recalling as much of the list as 
possible after each reading. The number and order of words recalled were 
recorded for each trial as was the time taken from the start of the final trial 
until the last word was recalled. Approximately thirty minutes elapsed 
before subjects were asked to recall the list again. If the subject was
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unable to recall all of the list then 30 words were read out and the subject 
was asked to identify with a 'yes' or a 'no' whether the word came from the 
original list. (If a subject was able to recall all of the list after a 30 minute 
delay it was assumed that they would be able to recognise all of the list 
without error). The number of words, the order of recall and the time taken 
to recall the list were recorded as were recognition responses.
This ten-trial procedure proved unsatisfactory for a number of reasons. 
Firstly, many epileptics were able to learn the list to criterion before ten 
trials had elapsed and these results had to be compared to the 
performance of subjects in which learning had not reached the criterion. 
Poor performance on either of these two measures could have occurred as 
a consequence of lack of exposure to the list during the learning phase, or 
because of poor memory. Secondly, because the task was so easy, there 
was a powerful 'ceiling' effect operating on both of the delayed recall 
measures. Most subjects attained a perfect or near perfect score. Thirdly, in 
terms of every day memory performance, opportunities for carrying out 
learning to completion do not always occur. If memory tests are intended to 
examine how memory functions in the real world, then the tests should 
mirror the circumstances which arise in the real world.
For the above reasons, the procedure for the wordlist learning task was 
changed by reducing the number of learning trials from ten to five and 
reading the list five times for every subject, even if the learning criterion 
was met. The number of subjects for which both procedures were used 
was balanced as closely as possible in each experiment throughout the 
study. Unfortunately, even with this modification, the ceiling effects noted 
already for the delayed recall measures, were only partly reduced.
3.3.4.4 Long-Term Memory
This test was included on the assumption that a memory disorder that was
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present for a long period of time would have a cumulative effect on memory 
for general information. Memory for general information is one of the few 
intellectual functions that improves fairly consistently over time. Thus, a 
person whose long-term memory was impaired would fall further and 
further behind the performance of his or her peers over a number of years. 
In addition, information may be recalled more slowly when the subject finds 
recall difficult or is unsure about the accuracy of recall. A subject with 
impaired memory of this nature would be expected to not only have a 
poorer accuracy for general information but also to have a longer latency of 
recall.
This test involved the presentation of 25 questions about information that 
the subject was highly likely to know. Subjects were told that the critical 
measure in the test was not so much the accuracy of the response, but the 
speed at which the answer was made. They were encouraged to repond as 
quickly as possible. The time taken to respond to each of the 25 questions 
was recorded, as was the correctness of the reponse. The average latency 
for all correct responses was then calculated.
3.3.4.5 Word Finding
This test was similar to the long-term memory test in its general procedure. 
Subjects were asked to find a word that fitted an Oxford Dictionary 
definition. The target words were selected on the same basis as for the 
wordlist learning task. As in the long term memory test, subjects were told 
that the critical measure for the test was the speed of their recall. The time 
taken to respond to each of the 25 definitions presented was recorded, as 
was the correctness of the reponse. The average latency for all correct 
responses was then calculated.
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3.3.6.6 Sternberg's Serial Scanning Task
Sternberg’s serial scanning task (Sternberg, 1975) was included in the 
battery for a number of reasons. The relevant measures offered by this 
technique are access speed to short-term memory and the rate at which 
items in memory can be processed. It is assumed that subjects have an 
immediate memory span of at least six items (Miller, 1956). The task 
measures latency to recall information as well as the length of time it takes 
to scan each item in short-term memory. MacLeod et al (1978) used this 
task to demonstrate the difference between high and low levels of 
phenobarbitone in slowing the rate of processing from short term memory 
in epileptic subjects. The fact that the test was able to distinguish between 
high and low therapeutic levels of the drugs is a clear indication of the 
sensitivity of the test.
The task involved the slide presentations of a series of numbers. Numbers 
were displayed one at a time for 1.2 seconds. The series of numbers varied 
in length from two to six items. After the presentation of each series there 
was an empty delay of 2 seconds and then another number was displayed. 
Subjects were asked to press one of two keys indicating that the final 
number displayed was either present in the series or not present. Decision 
time was recorded. Average decision time from the last 30 series (after 
presenting the series a total of 90 times) was also recorded.
3.3.4.7 Faces(1) and Faces(2)
The great significance of memory for faces is the relevance it has to 
everyday memory function. Failure to recall a face can not only be 
embarrassing but, if severe enough, may contribute to the development of 
social isolation often observed in epilepsy. The present facial recognition 
tests differed from Benton's facial recognition test, which is more accurately 
termed a facial matching task.
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The design of these tests was similar to the other tests of memory with filled 
and empty delays. In the Faces(1) test, ten black and white photographs 
were shown to the subject for two seconds each. Thirty seconds was 
allowed to elapse in silence and then the subject was handed a pack of 
thirty faces (comprising ten target faces and twenty distractor items) and 
instructed to make a decision as to whether each item in the pack was one 
of the original ten faces or not. The time taken to go through the pack was 
recorded.
The procedure for the Faces(2) test was similar to that for Faces(1) except 
that the thirty second period intervening between the set of ten faces and 
the recognition set was 'filled' with a second set of ten faces which the 
subjects were instructed to remember also.
3.3.4.8 Simple Choice Reaction Times
It was considered important to exclude the possibility that anti-epileptic 
drugs may affect cognitive and motor skills which result in impaired 
performance on tests without memory itself necessarily being impaired. 
Slowing of mental activity is clearly correlated with delayed reaction times. 
Disrupted attention is a frequent problem in epilepsy (Lezak, 1976; p174). 
This has been attributed to the effects of interictal epileptic activity. As noted 
earlier, subconvulsive discharges may affect performance on a variety of 
different psychological tests. In addition, anticonvulsant drugs have 
frequently been reported to be the cause of 'mental slowing'. Such 
generalised effects must be distinguished from effects on specific aspects 
of memory function.
The simple choice reaction times task required the subject to respond on 
one of two Morse keys using either hand in response to two Light Emitting 
Diodes (LED's) which were turned on by a computer. One light was turned
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on every two seconds and the time taken to respond on either key was 
recorded by the computer to the nearest millisecond. Subjects were 
instructed to respond as quickly as possible on the left hand morse key if 
the LED on the left was illuminated and similarly for the right hand. The 
lights were illuminated 50 times in a pseudo-random sequence with an 
equal number of presentations to the left and right. To avoid the problems 
of anticipation of the regular onset of the lights, errors in handedness were 
not included.
This test was included to provide simultaneous measures of motor speed 
and vigilance, either of which could be impaired by the anticonvulsant.
3.3.4.9 Simultaneous Vigilance Task
This task was included in the battery as a more precise measure of the rate 
of mental processing than simple choice reaction times. If subjects were 
able to perform at normal levels on both this task and the simple choice 
reaction time task, then the more general effects of impaired motor 
performance and general motor slowing could be excluded as causes of 
impaired performance on tests of memory.
The task was a 'simultaneous choice-reaction-time, pursuit-tracking task' 
(Lee, 1970). It required the subject to attend to two sets of three colored 
lights and to track with two sets of buttons the one light illuminated in each 
set at any one time. In addition, another two sets of colored lights were 
used to provide feedback to the subject on the accuracy of his or her 
response. The stimulus screen is presented schematically in Figure 3.1. 
The object of the test from the subject's point of view, was to see how fast 
(s)he could learn to track the two sets of lights.
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Stim ulus
LEDs
Response
LEDs
FIGURE 3.1 Layout of information processing task stimulus screen.
3.3.4.10 Structured Interview
The interview was intended to provide simple information about the 
subjects' expectations about the effects of anticonvulsants on their 
cognition. As with other tests, modifications and additions were made to 
the content of the interview over time.
The interview was carried out for two main reasons. Firstly, it was possible 
that the performance of the subjects could be influenced by the demand 
characteristics of the experiments. If subjects reported on the first interview 
that they anticipated that the drugs would affect their memory and on 
follow-up claimed that the drugs affected it, this would suggest that any 
changes in performance were due to the demand characteristics of the 
experiments rather than a true drug effect. On the other hand, if the subjects 
did not anticipate a drug effect and/or did not believe that the drugs had 
impaired their memory on post-test, then the experimenter could more 
confidently predict that the results of the experiment were a true reflection of 
an actual drug effect.
The other purpose of the structured interview was to collect subjective 
information about the effects of the drugs on aspects of memory which may 
not have been examined by the tests. As stated previously, no memory 
battery can hope to exhaustively examine such a complex function as 
memory. Subjective reports about changes in memory performance may
o o o 
o o o
o o o ^  
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reveal effects of the drugs on memory not formally tested.
Interviews before anticonvulsant medication was used contained the 
following questions:
(1) Was the patient expecting any side-effects from the medication, 
and, if so, which?
(2) Did the patient have trouble with his/her memory and if so what sorts of 
things gave difficulty?
(3) What other medication, aside from the anticonvulsants that had just 
been prescribed, was being taken?
(4) How many and what type of seizures had occurred over the last ten 
days?
On retest the questions were as follows:
(1) Were there any side-effects from the anticonvulsant medication and 
what was their nature?
(2) Did the patient have any difficulty with his/her memory and if so, in what 
way was it affected? Had it become more noticeable since starting 
anticonvulsant therapy?
(3) Had the use of anticonvulsants had any effect on their memory?
(4) What other medication, other than the anticonvulsants, had been taken 
since anticonvulsant therapy began?
(5) How many fits occurred over the last ten days?
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3.3.4.11 Washington Psychosocial Seizure Inventory
The Washington Psychosocial Seizure Inventory (WPSI) was developed by 
Dodrill et al (1980) in response to the need for an accurate and objective 
means of assessing many of the psychological and social problems which 
affect epileptics. The WPSI is an inventory designed for the assessment of 
difficulties in adult epileptics with respect to family background, emotional 
adjustment, interpersonal adjustment, vocational adjustment, financial 
status, adjustment to seizures and medical management. As such, the 
WPSI served as a screening assessment for psychosocial adjustment 
problems which may influence performance on formal tests of memory.
3.3.4.12 Subjective Memory Questionnaire
The Subjective Memory Questionnaire (SMQ) was developed by 
Bennett-Levy and Powell (1980). It samples a wide variety of everyday 
memory situations and asks subjects to rate the situation according to the 
frequency with which they have some problem with their memory. The 
questionnaire was included in order to collect subjective reports of memory 
problems which might not have been apparent from the formal tests of 
memory. The self-report of memory difficulties is difficult to interpret as the 
subjects report their problems in different ways, using different language, 
and it can be difficult to rate or group the responses in a meaningful way. 
The SMQ provides an opportunity to report on memory problems using 
standardised responses so that individuals and groups may be compared.
This questionnaire was developed because of differences between 
performance in real life memory situations and performance on clinical 
tests of memory. Performance on the SMQ has a weak positive correlation 
with performance on standard clinical tests of memory. This correlation 
strengthens if both the subjective and objective tests of memory are
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attempting to measure the same memory skill (Bennett-Levy and Powell, 
1980). This last finding supports the observation that self-report information 
may provide useful data concerning the possible influence of the drugs on 
memory functions not objectively tested elsewhere in the battery.
3.4 THE SELECTION OF DRUGS FOR INVESTIGATION
The range of anticonvulsant drugs which could be studied was large (Table 
3.2). Of the many anticonvulsants, phenytoin, carbamazepine and sodium 
valproate are the most commonly used (Table 3.3) and have, therefore, 
been examined in this study.
GROUP DRUGS
Acetylureas phenacemide, pheneturide
Barbiturates phenobarbitone, 
methylphenobarbitone, 
phenylmethylbarbituric acid, 
primidone
Benzodiazepines diazepam, oxazepam, 
nitrazepam, clonazepam
Hydantoins phenytoin, methoin, ethotoin, 
albutoin
Iminostilbenes carbamazepine
Oxazolidine troxidone, paramethadione
Succinimides phensuximide, methsuximide, 
ethosuximide
Sulphonimide
derivatives acetazolamide, sulthiame
Valproates sodium valproate, valproic acid
Hormonal agents corticotrophin.corticosteriods
Miscellaneous mepracine, beclamide
TABLE 3.2 Available anticonvulsant drugs (Reynolds and Shorvon, 1981).
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DRUG NUMBER OF PRESCRIPTIONS DISPENSED
1980 1981
Carbamazepine 114,627 132,973
Phenytoin 253,488 261,989
Sodium Valproate 43,351 56,141
Phenobarbitone 39,085 41,396
Primidone 37,333 35,845
Ethosuximide 9,073 8,866
Clonazepam 14,238 16,242
All others 79,271 68,651
TABLE 3.3 Total number of prescriptions for anticonvulsants in the years 
1980 and 1981 obtained through retail chemists, doctors and approved 
private hospitals and excluding those obtained at public hospitals, private 
prescriptions and repatriation scheme prescriptions in Australia.
The study of carbamazepine, phenytoin and sodium valproate was 
considered most worthwhile from a clinical point of view. There is general 
agreement that the choice of first line drug for the treatment of generalised 
and partial seizures probably rests between phenytoin and carbamazepine 
(Reynolds and Shorvon, 1981). This selection is largely based on clinical 
efficacy as defined by seizure control, and the relative lack of toxic effects of 
these two drugs. There is reasonable evidence that there is little difference 
between phenytoin and carbamazepine in controlling generalised and 
partial seizures (Troupin Ojeman and Dodrill 1976; Dodrill and Troupin, 
1977; Wilkus, Dodrill and Troupin, 1978). Phenobarbitone and primidone 
are well established therapeutic agents which Rosenbloom and Upton 
(1983) consider to be as effective as phenytoin and carbamazepine in 
controlling tonic-clonic seizures. However, both Shorvon and Reynolds 
(1981) and Rosenbloom and Upton (1983) note that phenobarbitone is 
associated with toxic effects which may impair cognition. Indeed, the review 
of the effects of phenobarbitone on memory function, presented in Chapter 
1, suggests that there is reasonable evidence that phenobarbitone has an 
adverse effect on memory. Certainly, the tendency for this substance to 
produce drowsiness and ataxia is well established (Plaa and Hine, 1960).
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Similar effects have been associated with phenytoin and carbamazepine. 
Phenytoin may cause nystagmus and ataxia (Kutt et al, 1964). 
Carbamazepine may cause vertigo, drowsiness and diplopia (Meinardi, 
1972). However, these effects tend to occur at high levels of the drugs, 
generally close to the upper bound of the therapeutic range. For these 
reasons phenobarbitone and primidone are less well tolerated drugs than 
carbamazepine or phenytoin.
Sodium valproate, a relatively new drug, enjoys a high level of popularity 
which is probably due to its broad spectrum of effectiveness across many 
seizure types (see Figure 3.2). The extent of its toxic effects remain to be 
defined. .
Each of the three drugs studied are effective in the treatment of tonic-clonic 
seizures. Reynolds and Shorvon (1981) point out that these drugs are 
equally effective for major epilepsy and there is little to choose between 
them. It follows then that the three drugs can ethically be prescribed in a 
random fashion in the treatment of new cases of tonic-clonic seizures, a fact 
that is important in the design of a well-controlled experiment.
Type of epilepsy Drugs of choice
Tonic-clonic (grand mal) phenobarbitone
or partial (focal) +/- tonic clonic phenytoin 
primidone 
carbamazepine 
clonazepam 
sodium valproate
Petit mal ethosuximde 
clonazepam 
sodium valproate
TABLE 3.4 Short-list of drugs for different types of epilepsy (Reynolds and 
Shorvon, 1981).
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Partial Seizures Generalised Seizures
Com plex  E le m e n ta ry
In fa n t i l e
T on ic -c lo n ic  Absence  M y o c lo n ic  A k in e t i c  Spasms
P h c n o b a rb i to n e E f fe c t ive E f fec t ive
Very
E f f e c t i v e
S o m e w h a t
Effective
S o m e w h a t
Effective
S o m e w h a t
Effective
S o m e w h a t
Effective
P h e n y to in
E f fe c t ive E f fe c t ive
Very
E f fe c t ive
A g g ra va te s
Greatly
In e f fe c t iv e In e f fe c t iv e In e f fe c t i v e
C arbam azep ine E f fe c t ive E f fe c t ive
Very
E f fe c t ive
In e f fe c t i v e In e f fe c t iv e In e f fe c t iv e In e f fe c t i v e
P r im id o n e E f fe c t ive E f fe c t ive
Very
E f fe c t ive
In e f fe c t i v e In e f fe c t iv e In e f fe c t iv e I n e f fe c t i v e
E th o s u x im id e In e f fe c t iv e E f fec t ive
A g g ra va te s
Somewhat
Very
E f fe c t ive
E f fe c t ive
M o d e ra te ly
Effective
S o m e w h a t
Effective
T r im e th a d io n e In e f fe c t i v e E f fe c t ive A g g ra va te s
Very
E f fec t ive
E f fe c t ive U n p r e d ic t ­
able
S o m e w h a t
Effective
C lonazepam In e f fe c t iv e E f fec t ive Agg rava tes
M o d e r a te ly
Effective
S o m e w h a t
Effective
S o m e w h a t
Effective
S o m e w h a t
Effective
S od ium
V a lp ro a te
M o d e ra te ly
Effective
M o d e ra te ly
Effective
M o d e ra te ly
Effective
Very
E f fe c t ive E f fe c t ive
M o d e ra te ly
Effective
S o m e w h a t
Effect ive
FIGURE 3.2 Effects of anticonvulsants on seizures. Adapted from 
Rosenbloom and Upton (1983).
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3.5 SUMMARY
(1) This study attempted to assess the effects of anticonvulsants on the 
memory of epileptics as used in clinical practice.
(2) The study examined subjects over a number of years and assessment 
prior to, and following, changes in medication. A small number of untreated 
non-epileptic controls was also studied.
(3) The study was divided, for the purposes of analysis, into five separate 
experiments. There was some overlap of subjects between these 
experiments.
(4) A number of memory tests were specially designed for the study. 
Modifications to this test battery proved necessary in the later stages of the 
study.
(5) The memory battery included a range of verbal and non-verbal tests of 
both short- and long-term memory.
(6) Subjects were selected so as to avoid severe cases of epilepsy.
(7) The study examined the effects of phenytoin, carbamazepine and 
sodium valproate only when these drugs were administered alone and not 
in combination with any other form of medication.
CHAPTER 4
SHORT-TERM EFFECTS OF ANTICONVULSANTS ON THE 
MEMORY OF PREVIOUSLY UNTREATED EPILEPTICS 
(EXPERIMENT 1)
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4.1 INTRODUCTION
The experiment described in this chapter was designed to assess memory 
function in previously untreated epileptic patients before and after three 
months of monotherapy with phenytoin, carbamazepine or sodium 
valproate.
The questions to be examined were:
(1) Do any of these drugs, as used in current clinical practice for the 
treatment of epilepsy, adversely affect memory?
(2) If such effects do exist, are some drugs better or worse than others?
4.2 METHOD
This analysis examined a group of previously untreated epileptics before 
and after three months of monotherapy with phenytoin, carbamazepine or 
sodium valproate and a group of untreated, non-epileptic controls.
4.2.1 Procedure
Previously unmedicated subjects were given the WAIS (excluding 
Comprehension and Object Assembly subtests ) and one of four forms of 
the Memory Battery. Blood for red cell folate assays was taken after 
testing, and EEG's were carried out, whenever possible, on the same day 
or within a few days of testing. The epileptic subjects were then treated by 
monotherapy with either phenytoin, carbamazepine or sodium valproate. 
Medical constraints (see Figure 3.2) meant that it was not possible to 
assign subjects randomly to the three drug groups. However, an attempt 
was made within these constraints to equate the numbers in the three 
groups by exercising choice in selection of medication (where this was
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possible) and by selecting the subjects to be included in data analysis. 
Non-epileptic controls remained untreated. All subjects were then 
retested after three months on a parallel form of the memory battery. 
Blood for serum anticonvulsant and red cell folate assays was taken after 
testing and, whenever possible, EEG's were given on the same day or 
within a few days of testing.
4.2.2 Subjects
All epileptic subjects were attending either Royal Canberra Hospital or 
Woden Valley Hospital. Control subjects were hospital staff volunteers, 
non-neurological patients attending the same two hospitals and volunteers 
found through the Australian Capital Territory Epilepsy Association. 
Control subjects had no neurological or psychiatric disorder, were not 
taking any medication and had no family history of epilepsy.
Subjects for this experiment were included on the basis of the general 
selection criteria for the study which were set out in Chapter 3. In addition, 
they had not taken anticonvulsants before the initial assessment. In order to 
obtain equal numbers in the three treatment groups, subjects were selected 
according to their highest therapeutic anticonvulsant levels.
As can be seen in Table 4.1, 56 subjects satisfied the criteria for analysis. 
All three epileptic groups were matched for age, IQ, and lateralising signs 
on the EEG. The average age was approximately 30 and the average IQ 
was 116. EEG records indicated that eight patients had left hemisphere 
abnormalities, five patients had right hemisphere abnormalities and the 
remainder showed no evidence of lateralised abnormality. There was little 
difference between the phenytoin and carbamazepine groups as to seizure 
frequency or type. However, these groups differed somewhat from the 
sodium valproate group as to seizure type and frequency of major 
convulsions. The mean number of reported major seizures for the
MEMORY CHANGES IN PREVIOUSLY UNTREATED EPILEPTICS 71
phenytoin and carbamazepine groups was 1.7, that of the sodium 
valproate group was 0.8. Both the phenytoin and the carbamazepine 
groups were well matched as to seizure type, with slightly more complex 
partial than tonic-clonic seizures. The sodium valproate group, however, 
included three patients with myoclonus - the remainder being complex 
partial or tonic-clonic seizures.
CONTROL PHENYTOIN CARBAMAZEPINE SOD. VAL
PRE POST PRE POST PRE POST PRE POST
DOSE(mg) - - - 300 - 585 - 986
BLOOD L. 
(mg%)
“ “ “ 1.1 0.71 “ 8.3
RCF* 240 263 210 228 232 295 195 293
(ug/ml) 
SAMPLE N 14 14 14 14
AGE(yrs) 31.9 32.0 29.2 26.9
IQ 120 113 116 111
TABLE 4.1 Characteristics of the sample obtained for Experiment 1. 
*Some red cell folate results were lost due to technical reasons. Normal 
range 100-500 ug/mol..
4.2.3 Analysis
Change scores from pre-treatment to post-treatment were analysed 
individually using either the Kruskal-Wallis One-Way ANOVA (Siegel, 
1956) or a parametric ANOVA. The tests of facial recognition were 
analysed using the non-parametric statistic because of the small range 
and the discrete nature of some of the assessment scales (indicated in 
Table 4.2). Conventional signal detection analysis was innapplicable to the 
data from all tests involving 'yes/no' recognition as one third, or more, of 
all subjects scored a perfect 'hit' rate*.
* The same difficulty arose on all subsequent Experiments.
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4.3 RESULTS
The mean pre- and post-treatment scores on each test for the three drugs 
are summarised in Table 4.2. The raw data for this experiment are 
presented in Appendix 4.1. Most tests yielded no statistically significant 
changes in performance associated with any medication. However, 
Kruskal-Wallis's non-paramentric ANOVA of the change scores from the 
Faces(2) test of facial recognition indicated a significant difference between 
the drug groups, (H = 33.8, p < 0.001). Figure 4.1 indicates that this 
difference was due to phenytoin impairing performance on retest. 
Insufficient red cell folate levels were available for analysis.
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FIGURE 4.1 Test-retest performance on Faces(2) of epileptics prior to and 
after three months of drug therapy, and controls without drugs.
untreated
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CONTROL PHENY- CARBA- SODIUM
TOIN MAZEPINE VALPROATE 
PRE POSTPRE POSTPRE POST PRE POST SIGNIF.
NONVERBAL TESTS
FACES(1) 27.2 27.3 25.9 26.2 26.2 26.5 26.8 26.6 NS K
FALSE +VE 1.86 1.54 2.93 2.69 2.21 1.57 1.70 1.50 NS K
FALSE-VE 0.86 1.15 1.14 1.08 1.57 1.79 1.50 1.86 NS K
TIME 1.15 1.07 1.64 1.24 1.37 1.23 1.28 1.33 NS
FACES(2) 24.2 25.2 25.2 21.9 23.9 23.6 24.2 23.2 Pc.001 K
FALSE +VE 3.00 2.28 2.86 4.71 3.21 1.57 1.80 2.20 NS K
FALSE-VE 2.79 2.50 1.93 3.07 2.93 4.14 4.00 4.60 NS K
TIME 1.27 1.40 1.82 1.71 1.52 1.51 1.43 1.91 NS
VERBAL TESTS
MODIFIED REY AUDITORY VERBAL LEARNING TASK
TRIAL 1 6.86 6.29 5.79 5.79 6.28 6.71 6.70 4.70 NS
TRIAL 5 11.6 13.9 12.6 13.3 13.1 12.9 12.7 13.4 NS
RECALL
TIME 0.86 0.95 1.16 1.00 1.08 1.18 0.89 1.00 NS
RECALL 13.2 12.2 11.6 11.6 11.4 11.4 12.7 13.8 NS
TIME 1.21 1.10 1.40 1.10 1.05 0.95 1.24 1.10 NS
RECOGNTN15.0 15.0 14.4 14.8 14.6 14.6 14.8 14.8 NS
DIGIT SPAN 12.6 12.4 11.4 12.1 12.8 12.8 11.0 11.2 NS
MOTOR TESTS
INFORMATION PROCESSING
RATE 1.43 1.25 1.49 1.31 1.41 1.33 1.60 1.39 NS
SIMPLE CHOICE REACTION
TIMES 0.346 0.320 0.3330.3100.357 0.338 0.325 0.309 NS
TABLE 4.2 Performance scores of epileptics prior to and after three months 
of drug therapy, and controls without drugs. A 'K' in the extreme right 
hand column indicates that the test was analysed using a Kruskal-Wallis 
One-Way ANOVA.
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4.4 DISCUSSION
4.4.1 The Nature of the Cognitive Deficit
The memory test battery was designed to assess performance in a wide 
range of memory functions and to sample performance in certain 
non-memory functions. It was anticipated that the pattern of test results 
might be used to identify the specific nature of any memory deficits 
produced by the drugs. Performance on the battery will be considered test 
by test.
4.4.1.1 Motor Performance
Both tests of motor performance (the simultaneous vigilance task and the 
simple choice reaction time task) showed improvements from pre-treatment 
to post-treatment. The simultaneous vigilance task showed the greatest 
amount of improvement. This was consistent with the view that performance 
on this task had not reached its asymptote by the completion of the first test. 
Nevertheless, there was no difference between the four experimental 
groups in the size of this improvement. Taken together, these results 
indicate that neither motor performance nor the overall rate of information 
processing was adversely affected by the drugs. These results indicate that 
any impaired performance on other tests in the memory battery cannot be 
attributed to generalised effects such as mental and motor slowing.
4.4.1.2 Digit Span
The drugs had no observable effect on the number of items which could be 
recalled on this test. However, this test may lack adequate senstivity. Digit 
span uses a quantitative measure, with the number of items which can be 
recalled being typically seven, plus or minus one or two (Miller, 1956). It 
would be expected that only gross disturbances of cognitive function would
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depress performance on this test to a level below five digits. Changes of at 
least this magnitude would be necessary before achieving statistical 
significance on small group analysis. The results from this test suggest that, 
if there are effects of the drugs on memory, the effects are small.
4.4.1.3 The Rey Auditory Verbal Learning Task (RAVLT)
None of the following variables showed any definite effects of the drugs: the 
number of words recalled on trial five; the time to recall words on trial five; 
the number of words recalled after thirty minutes delay; the time taken to 
recall the items after a thirty minute delay; the rate of recall; and the the 
number of words not recalled but recognised. On the other hand, the 
sodium valproate group did show a non-significant decline in performance 
on retest on their recall of the initial presentation of the wordlist. The 
negative results of this test should be treated with some caution, bearing in 
mind, firstly, that test scores were discrete variables covering only a narrow 
range of variation (contrary to the assumptions of analysis of variance) 
secondly, that the recognition test showed ceiling effects and thirdly, that 
Thompson and others did find that sodium valproate had an adverse effect 
on memory.
4.4.1.4 Facial Recognition
The Faces(2) test of facial recognition was the only test which yielded a 
statistically significant result indicating that phenytoin impaired memory 
function on retest (Figure 4.1). This finding may be contrasted with the 
absence of a significant result on Faces(1) which differed from Faces(2) by 
the absence of the interpolated task during the thirty second delay before 
recall of the target items. A number of hypotheses can be postulated to 
explain these observations and these will now be discussed.
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(1) Increased memory load.
The interpolated task in Faces(2) may have been more demanding 
because the number of items which the subject was attempting to 
remember was greater than in Faces(1). This increase in memory load may 
have increased the sensitivity of the test, enabling it to measure the 
adverse effects of phenytoin on memory. This hypothesis is supported by 
the possibility that there was a slight ceiling effect on the Faces(1) task as 
the mean number of faces correctly recalled was between 25.9 and 27.2 
and the standard deviation was approximately 3.
If the increase in memory load accounts for the results obtained with the 
Faces(2) test, then one might expect phenytoin induced impairment of 
memory would be apparent on other tasks where memory capacity was 
exceeded. However, this was not the case. It may be that no other test was 
sufficiently sensitive or that the result was specific to non-verbal material. 
However, the fact that very few of the large range of tests which yielded 
negative results showed ceiling effects, suggests that increased sensitivity 
was not the reason for the result obtained with the Faces(2) test.
There is insufficient evidence to support the hypothesis that the Faces(2) 
test yielded a significant difference in memory performance because of 
increased memory load.
(2) Deficit in recognition memory.
The statistically significant effect observed for the Faces(2) test could reflect 
a deficit confined to recognition memory. Only one other test in the battery 
assessed recognition performance. This was the RAVLT delayed 
recognition task. Ostensibly, the lack of a significant result on this second 
task argues against the suggestion that the drugs impair recognition 
memory. However, this task showed a marked ceiling effect and therefore
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the lack of significant difference is weak evidence.
The results of Thompson et al (1980a) support the suggestion that 
anticonvulsants may affect recognition memory. They found that a word 
recognition task was adversely affected by phenytoin but not by 
carbamazepine in a double blind cross-over trials procedure using normal 
volunteers. Subsequent work (Thompson and Huppert, 1980) in epileptic 
patients before and after reduction in drug therapy failed to replicate this 
effect due to ceiling effects. However, Loisseau, Strube, Broustet, 
Battelleichi, Gomeni and Morselli (1980) comparing epileptics with 
non-epileptics, found that there were differences between these two groups 
on a word recognition test. However, this effect was not related to plasma 
concentration of the drugs. There are few other studies of the effects of 
anticonvulsants which have specifically examined recognition memory 
(Tomlinson, Stirling, Merrifield and Reynolds, 1981).
There is insufficient evidence from the results of this study to exclude the 
possibility that the impairment of performance on the Faces(2) test can be 
attributed to phenytoin impairing recognition memory.
(3) Deficit in episodic memory
The Faces(2) test may have assessed episodic memory, that is, 
remembering 'what happened when'. The Faces(2) task can be construed 
as a task in which the subject is asked to distinguish which faces (s)he saw 
first in the list. Mistakes can be categorised, not only into false positive and 
false negative, but also into a subset of the false negative which are 
mistakes due to confusion about whether the face had appeared in the 
second set or the first. Subjects may have recalled an item but believed that 
it came from the interpolated list rather than the target set. Since this 
hypothesis had not been considered until after the study had been 
analysed, the value of recording such errors of intrusion from the
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interpolated task had not been considered. This omission does not allow 
this hypothesis to be examined further. However, it should be noted that 
other tests such as Words(2) did record 'intrusions' and no significant drug 
effects on performance were found (see Chapter 6) so that the results for 
the Words(2) test do not support the hypothesis of a general deficits of 
episodic memory.
4.4.1.5 Interpreting the Pattern of Test Results
The comprehensive assessment of memory in this experiment yielded a 
statistically significant effect for only one test of memory and no effects for 
other tests of non-memorial cognitive function. Ostensibly, the results 
contrast with the findings of Thompson (1981) who observed drug effects 
both on a broad range of memory tasks and on other cognitive functions. 
However, the serum levels of phenytoin and sodium valproate were in the 
low therapeutic ranges and this may have reduced the memory impairing 
effects of the drugs. The levels for the carbamazepine treated group were in 
the high therapeutic range and did not appear to impair memory but this 
consistent with the results of Thompson. Nonetheless, the results of this 
experiment suggest that, when phenytoin is used alone, within or below the 
currently accepted therapeutic range and in a therapeutically effective 
fashion, the cognitive effects of this drug are confined to specific aspects of 
memory and that even these effects are small, at least, after three months of 
therapy.
4.4.2 The Effect of Confounding Variables on the Results 
4.4.2.1 IQ and Test Performance
The average IQ of the subjects in this study was relatively high and the 
effect of intelligence on repeated neuropsychological test performance is 
uncertain. It can be argued that intelligent subjects, who are easily
MEMORY CHANGES IN PREVIOUSLY UNTREATED EPILEPTICS 79
motivated, perform more reliably and that the consequent reduction of 
variance in performance might enable small effects to become statistically 
significant. Indeed, Thompson et al (1981) found numerous effects of 
phenytoin when using medical students as non-epileptic volunteers. 
Alternatively, intelligent subjects may be calling upon a wide variety of 
cognitive strategies to compensate for impairment of specific intellectual 
function. In this case, the effects of the drugs may be underestimated in 
studies using intelligent subjects. Thompson and Trimble (1983) did find 
that many aspects of memory were affected by the drugs in subjects with 
IQs slightly lower than average, although their patients were treated by 
polytherapy.
The average IQ of the subjects was at least one standard deviation above 
the mean of the general population. The reason the sample should have 
such a high average IQ remains unclear. It is likely that this bias reflects 
some of the characteristics of the local region. Canberrra is a city with a 
very high proportion of public servants with well above average 
educational levels. Alternatively, it is possible that some bias in the 
selection of subjects for study by the referring source may have 
inadvertently resulted in only higher IQ subjects being selected for the 
study. This possibility seems possible since patients with obvious 
neurological and cognitive deficits were deliberately excluded and only 
relatively mild epileptics (previously untreated) were studied.
4.4.2.2 The Confounding Effects of Epilepsy
Because severe cases of epilepsy were avoided in this study, patients were 
unlikely to undergo any large amount of change in cognitive performance 
during the period of the study as a consequence of their epilepsy. It is 
possible that changes in memory performance could be attributed to the 
effects of hypoxic brain damage occurring as a consequence of seizures or 
by the confounding effects of changes in the rate of sub-clinical neural
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discharges or other behavioural or psychopathological changes. By 
selecting patients with a low frequency and total number of seizures, the 
possible influence of the epilepsy factor on retest performance was 
reduced.
Indeed, confounding of the postictal effects of seizures and memory test 
performance on the first test was potentially a greater problem than on 
retest. Patients diagnosed as epileptic are normally treated as soon as 
possible. Epileptics may experience disturbances of brain function, as 
measured by the EEG, for some days following a seizure. Postictal 
changes of this type have been associated with disturbances of 
cognition including memory and vigilance. It would have been desirable, 
therefore, to delay pre-treatment assessments for at least ten days from 
the last seizure. However, since some patients were unlikely to have ten 
days seizure free this protocol was considered unacceptable. Instead an 
attempt was made to reduce the likely impact of postictal changes in 
cognitive performance by only assessing patients at least 24 hours after a 
seizure. Of course, it could not always be known when a patient had last 
had a seizure.
4.4.2.3 Control Group
There were a number of problems in the selection of a suitable control 
group for this experiment. Ideally, the experiment would have included an 
untreated epileptic control group. However, this was not possible for 
ethical and practical reasons. It was therefore necessary to use a less 
adequate control group comprising untreated non-epileptics. This group 
was included as a control for test-retest effects.
There are several reasons why untreated non-epileptics were inadequate 
controls for this experiment. This design does not manipulate the effects of 
the drugs and epilepsy independently. A comparison of the performance of
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the control group with the epileptic subjects on the first test contrasts the 
effects of epilepsy (largely of very short duration) and normal non-epileptic 
behaviour. On the second test, however, the control group can only be 
used as a comparison with other groups which have suffered three months 
of epilepsy as well as the effects of the medication. No precise distinction 
can be made between the effects of the medication and the effects of the 
epilepsy.
The control group provides a measure of retest effect. However, even the 
value of using an untreated non- epileptic control group for this purpose 
may be doubtful. Such a control group's average memory performance is 
likely to be better than that of the epileptic groups, either because of the 
effect of the medication, or the effect of the epilepsy. If this is the case, 
the control group is likely to be more susceptible to retest effects than the 
other groups, because these subjects may be better able to recall the first 
test and prepare for subsequent tests.
4.4.3 Comparisons with the Results of Other Research
The results of this experiment suggest that the adverse effects of the drugs 
on memory are less severe than those reported by Thompson et al (1981) 
and Marchesi et al (1981). Although both studies used a similar design to 
that used here, one of the major differences between these studies is the 
length of the time between initial medication and follow-up. Thompson 
used a double blind cross-over trials procedure on non-epileptic volunteers 
with only two weeks before the cross-over was made. Marchesi used 
almost the same design as the one presented here, also using epileptic 
subjects, but with a minimum of only one month's delay. The present study 
employed a full three month test-retest period. It may be that the adverse 
effects of the drugs are greatest within the first few weeks and substantially 
decline to the point where, after three months, the adverse effects of the 
drugs are quite mild. Such a decline in the potency of the adverse effects of
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the drugs could occur as a result of physiological adaptation, or cognitive 
adaptation, or some combination of the two effects.
Another major variable that distinguishes this study from those of Marchesi 
and Thompson, referred to above, is the nature of the tests of memory. Both 
differences in the specific memory functions sampled and differences in test 
sensitivity may account for the differences in the severity of the effects 
reported in the different studies. Both studies used different memory tests 
which may have assessed slightly different memory functions and the 
number of significant results in each study may reflect the chance selection 
of tests assessing memory functions impaired by the drugs. In addition, 
differences in test senstivity to the memory impairing effects of the drugs 
could account for the differences in the apparent severity of drug effects 
between the two studies. .
4.4.4 Clinical Implications of the Results
The short follow-up period used in this experiment, although long in 
comparison with earlier studies, restricts the clinical significance of the 
results. Anticonvulsant therapy is usually instituted for a period of many 
years. This study was carried out over a period of only three months in 
previously unmedicated patients with epilepsy of recent onset. Therefore, 
the results may not reflect the effects of the drugs on memory over periods 
of several years, or even a whole lifetime. It was the experimenter's 
intention to follow-up the subjects in this experiment for a period of nine 
months. Due to an excessive 'drop-out' rate, the samples remaining at nine 
months were too small to be analysed. The main reasons for this loss of 
subjects were changes in medication due to adverse reactions, toxic levels 
at follow-up and subjects leaving the area and becoming unable or 
unwilling to continue testing.
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4.5 CONCLUSIONS
The results of this experiment provide little evidence of adverse effects of 
anticonvulsants on memory function in epileptics when used in 
monotherapy and within the currently accepted therapeutic ranges. In spite 
of the methodological deficiencies described above, the present 
experiment improved upon the methodology of earlier studies. It avoided 
severe cases of epilepsy, only analysing the results of subjects with blood 
levels of anticonvulsants within the therapeutic ranges, excluded cases 
with other progressive neurological disorders and only used subjects on 
monotherapy, thus avoiding the pitfalls of possible drug interactions.
The observation that, when such control measures were adopted the 
effects of the drugs was only slight (or not measureable) suggests that the 
impairments of cognition commonly seen in epileptics may be caused by 
the effects of the epilepsy itself and not the effects of the drugs. However, as 
noted previously, only the study of epileptics over much longer periods than 
three months can properly examine the effects of the medication on the 
clinical population. In addition, the observation of impairment on at least 
one test performance measure was associated with phenytoin does 
suggest that this drug may impair memory in epileptics treated at normal 
therapeutic levels.
^Shortening the WAIS to save time within the context of clinical 
neuropsychological evaluation is a common practise (Walsh, 1978, p. 302; 
Duke, 1967). In this case the WAIS was shortened by removing one Verbal 
subtest and one Performance subtest. Object Assembly was removed 
because it has the lowest correlation with the overall performance score 
(Wechsler, 1955) and adds little further information about possible 
localised mental dysfunction. Comprehension was removed as it has the 
lowest correlation with the Verbal Score of any of the Verbal subtests with 
poor relationships with specific areas of nerological damage. The only 
other two lower correlations were for Digit Span and Arithmetic and 
relatively poor scores on these subtests are associated with areas of 
specific neurological damage.
CHAPTER 5
THE EFFECTS OF CHANGING MEDICATION 
(EXPERIMENTS 2 & 3)
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5.1 INTRODUCTION
The results of Experiment 1 demonstrated a small adverse effect of 
phenytoin on one test of memory after the drug had been used for three 
months. The question arises whether this adverse effect remains stable, 
habituates or increases with continued medication.
Since anticonvulsants are usually administered for many years, it is 
important to study the long-term effects of the drugs. This could be done in 
Experiment 1 by re-assessing these subjects over a number of years. 
Alternatively, the effects of changing medication in groups of subjects who 
have recieved one medication for many years could be examined. By 
comparing the effects of the drugs on memory functioning before and after 
changes in medication, some aspects of the long-term effects of the drugs 
can be examined. This approach was adopted by Dodrill and Troupin 
(1977) who used a double-blind cross-over trials procedure with phenytoin 
and carbamazepine. The double blind cross-over design is probably the 
most satisfactory experimental procedure which can be applied to epileptic 
populations, but is subject to some ethical difficulties. Furthermore, perfect 
counterbalancing of the design using three drugs involves a rather 
daunting series of assessments of groups if the order of administration of 
the drugs is to be fully counterbalanced.
This chapter describes two experiments. In Experiment 2, the effects of 
switching from phenytoin to carbamazepine were compared with subjects 
remaining on phenytoin. Experiment 3 compared the effects of switching 
from carbamazepine to sodium valproate with subjects remaining on 
carbamazepine.
Subjects were invited to change medication in order to find which drug had 
the least undesirable ill-effect. Mant patients were satisfied with one or 
another drug and elected not to change. For this reason, and the fact that
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the first drug used was not selected at random but rather on the treating 
neurologist's view of which drug suited a given patient best, equal 
numbers of subjects for various treatment groups were not obtained. 
Similarly, forms of the battery were not fully counter- balanced and criteria 
for perfect experimental designs were not met. It was hoped that it would be 
possible to assess and compare epileptic subjects treated by monotherapy 
with phenytoin, carbamazepine and sodium valproate for at least three 
months, but by the end of the study only six patients had been tested on all 
three drugs and some of these had serum levels above the therapeutic 
range. In view of this limited sample, a statistical analysis of this group was 
not undertaken.
Comparison was sought between patients tested with one drug and who 
then switched to another. Among the patients who changed from one drug 
to another, sufficient numbers for meaningful statistical analysis were 
obtained only in two groups - those switching from phenytoin to 
carbamazepine and those switching from carbamazepine to sodium 
valproate. For other drugs, either the numbers in each group were too small 
or the drug levels at the time of testing were above the therapeutic range.
These experiments were intended to investigate a number of questions 
arising from Experiment 1.
(1) Were there any differences between the memory performances of 
epileptics established on phenytoin for a period of years and patients 
taking phenytoin for only three months ?
(2) Did taking phenytoin produce a reversible or permanent deficit in 
memory performance ?
(3) Were there any differences in the effects of carbamazepine and 
sodium valproate after patients had been established on these drugs for 
periods longer than three months?
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5.2 METHOD - EXPERIMENT 2
5.2.1 Procedure
The test battery was administered to subjects who were stabilised on 
phenytoin. They were then retested three months later. On retest, half of 
the patients had changed medication from phenytoin to carbamazepine 
while the other half remained on phenytoin.
5.2.2 Subjects
Twenty four subjects were drawn from the same patient pool as previously 
and were included in the analysis if blood levels were within the currently 
accepted therapeutic ranges. Those subjects who were to remain on 
phenytoin were selected on the basis that their blood levels did not vary by 
more than 0.1 mg% from pre-test to post-test.
CONTROL SWITCHING
TEST PRE POST PRE POST
DOSE(mg) 367 367 356 580
BLOOD L.(mg%) 1.28 1.27 1.23 0.66
RCF*(ng/ml) 206 229 256 338
SAMPLE SIZE 12 12
AGE(yrs) 29.1 32.5
IQ 112.4 115
TABLE 5.1 Sample characteristics for epileptics remaining on phenytoin 
(control) and those switching from phenytoin to carbamazepine (switching).
* See TABLE 4.1.
Table 5.1 summarises the main characteristics of the sample. Patients had 
been treated with phenytoin for an average of four years before testing. 
Almost all of these patients had been treated with monotherapy for this 
entire period. Patients had either complex partial or tonic-clonic seizures 
and over 80% of patients from each group had reported a total of five major
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convulsions or less. There were no significant differences between the 
groups on the basis of right and left hemisphere abnormalities on the 
EEG.
5.3 RESULTS OF EXPERIMENT 2
The results from the memory test battery are summarised in Table 5.2. 
There were no significant pre/post test differences for any variables with the 
exception of Faces(2). On this test there was a significant difference at 
post-test between the performance of patients on carbamazepine and 
phenytoin (H = 5.6, p < 0.02). Figure 5.1 shows that patients on 
carbamazepine performed, on average, at a superior level compared with 
those on phenytoin. Patients remaining on phenytoin on both test 
occasions showed no change in memory performance.
Folate levels were available for 17 out of 24 subjects in this experiment, 
and the relationships between the folate levels, the drugs and memory test 
performance could not be investigated.
PRE-TEST POST-TEST
FIGURE 5.1 Test-retest performance on Faces(2) for epileptics on 
phenytoin or switched to carbamazepine from phenytoin (Experiment 2).
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TEST
CONTROL 
PRE POST
SWITCHING 
PRE POST SIGNIF.
N O N V E R B A L TESTS
FACES(1 )/30 26.6 26.3 27.2 27.3 NS K
FALSE +ve 2.23 2.30 1.73 1.45 NS K
FALSE -ve 1.25 1.42 0.91 1.27 NS K
TIME 1.64 1.24 1.37 1.23 NS
FACES(2)/30 24.3 23.4 23.8 25.7 P<.02 K
FALSE +ve 2.08 3.25 3.17 1.50 NS K
FALSE -ve 3.25 3.50 3.00 2.83 NS K
TIME 1.58 1.63 1.31 1.39 NS
V ER B A L TESTS
MODIFIED REY AUDITORY VERBAL LEARNING TASK
TRIAL 1 /15 5.75 6.25 6.33 5.92 NS
TRIAL 5 /20 13.2 13.4 13.2 13.4 NS
RECALL TIME 1.34 1.52 1.10 0.90 NS
DELAYED
RECALL/15 12.9 13.3 11.1 12.2 NS
RECALL TIME 1.64 1.56 1.14 1.27 NS
RECOG'N/15 14.9 15.0 14.9 14.9 NS
DIGIT SPAN/17 11 .7 11.7 13.7 12.8 NS
M OTOR TESTS
INFORMATION PROCESSING
RATE 1.62 1.28 1.50 1.44 NS
SIMPLE CHOICE REACTION
TIMES 0.306 0.319 0.362 0.350 NS
TABLE 5.2 Performance scores of epileptics treated with phenytoin and 
then either remaining on phenytoin (control) or switched to cabamazepine 
and then tested three months later (switching). Maximum scores are 
displayed after test title where appropriate. A 'K' in the extreme right hand 
column indicates those tests analysed using the Kruskal-Wallis One-Way 
ANOVA (Siegel, 1956).
COMMENT
The results from Experiment 2 broadly confirm the results from Experiment 
1 that both phenytoin and carbamazepine have little effect on memory. As 
previously, the Faces(2) test appears sensitive to small effects and the 
results associate phenytoin with the poorest performance on this test alone.
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5.4 METHOD - EXPERIMENT 3
5.4.1 Procedure
This procedure was essentially the same as that for Experiment 2. In this 
experiment subjects were tested on carbamazepine and then tested three 
months later. On retest, half of these patients had changed to sodium 
valproate and the other half others remained on carbamazepine.
5.4.2 Subjects
Eighteen subjects were drawn from the same patient pool as previously 
and were included in the analysis if all blood levels on both pre and post 
test were within the therapeutic ranges. In addition, those subjects 
remaining on carbamazepine were included only if their blood levels did 
not vary by more than 0.2 mg% from pretest to post test.
CONTROL SWITCHING
TEST PRE POST PRE POST
DOSE(mg) 622 678 528 1114
BLOOD L. (mg%) 0.63 0.66 0.64 7.2
RCF*(ng/ml) 326 287 257 289
SAMPLE SIZE 9 9
AGE(yrs) 30 31
IQ 118 119
TABLE 5.3 Sample characteristics for epileptics remaining on 
carbamazepine (control) and those switching from carbamazepine to 
sodium valproate (switching). * See Table 4.1.
Table 5.3 summarises the main characteristics of the patient sample for 
Experiment 3. All patients were treated with carbamazepine for an average 
of six months before testing. Most of these patients had been treated with 
carbamazepine alone for this entire period. Patients had either complex
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partial or tonic clonic seizures, except for two with myoclonic epilepsy. 
Fourteen patients had fewer than 5 major seizures while two patients in 
each group had more. There were no significant differences between the 
groups on the basis of right and left hemisphere abnormalities on the EEG.
5.5 RESULTS OF EXPERIMENT 3
As can be seen in Table 5.4, there were no significant differences between 
the control group and the drug switching group any tests of cognitive 
function (using the ANOVA or non-parametric ANOVA as described 
previously) including the Faces(2) test of facial recognition. Insufficient 
folate levels were available to examine the effect of folate levels on memory 
test performance.
COMMENT
The results from Experiment 3 broadly confirm the results from Experiments 
1 and 2 that both sodium valproate and carbamazepine have no 
measurable effect on memory.
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TEST
CONTROL 
PRE POST
SWITCHING 
PRE POST SIGNIF.
N O N V E R B A L  TESTS
FACES (1)/30 26.2 27.1 26.4 25.8 NS K
FALSE +ve 2.3 1.8 1.9 1.4 NS K
FALSE -ve 1.4 1.1 2.3 2.9 NS K
TIME 1.73 1.42 1.33 1.35 NS
FACES (2) /30 23.5 24.5 23.9 23.7 NS K
FALSE +ve 3.8 2.3 2.3 2.2 NS K
FALSE -ve 2.7 3.1 3.8 4.2 NS K
TIME 1.90 1.96 1.54 1.49 NS
V E R B A L TESTS
MODIFIED REY AUDITORY VERBAL LEARNING TASK
TRIAL 1 /15 6.4 6.8 7.0 6.3 NS
TRIAL 5/15 14.4 12.6 14.0 14.0 NS
TIME 1.22 1.12 1.03 1.08 NS
DELAYED
RECALL /15 11.7 11.9 13.1 13.4 NS
TIME 0.86 1.25 1.05 1.39 NS
RECOG'N/15 14.9 14.7 14.9 14.9 NS
WORDS(1) 5.4 5.4 5.5 5.2 NS
TIME 0.17 0.27 0.17 0.16 NS
WORDS(2) 5.1 5.6 5.0 5.2 NS
TIME 0.50 0.63 0.46 0.39 NS
DIGIT SPAN/17 13.2 13.8 12.2 12.7 NS
MOTOR TESTS
INFORMATION PROCESSING
RATE 1.49 1.42 1.29 1.14 NS
SIMPLE CHOICE REACTION
TIMES .310 .303 .294 .317 NS
TABLE 5.4 Performance scores of epileptics treated with carbamazepine 
and then either remaining on carbamazepine or switched to sodium 
valproate and then tested three months later. Maximum scores are 
displayed after test title where appropriate. A 'K' in the extreme right 
hand column indicates which tests were analysed using the 
Kruskal-Wallis one-way ANOVA.
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5.6 DISCUSSION
As in Experiment 1, which examined previously untreated epileptics, 
significant drug effects were not found for any test except Faces(2). Figure 
5.1 shows that the group who switched from phenytoin to carbamazepine 
experienced a significant improvement in performance on the Faces(2) test 
of facial recognition after three months of treatment with carbamazepine, 
while patients who remained on phenytoin showed no change. This result, 
and that of Experiment 1, implicate phenytoin in a specific impairment of 
memory.
Improvements in memory test performance of patients switched from 
phenytoin to carbamazepine may be due to a number of factors. One 
explanation is that phenytoin causes the memory impairment that was 
found and this is maintained by drug taking and relieved when 
administration ceases. This assumes that the memory impairment 
produced by phenytoin is reversible. However, the mean level of 
performance of the previously untreated phenytoin group at three months 
follow-up in Experiment 1 was well below that of the phenytoin treated 
groups in Experiment 2. Indeed, the level of performance of the phenytoin 
group in Experiment 2 remained stable at a level similar to that of the 
untreated controls. This observation suggests that the effects of phenytoin 
may 'wear off' with time.
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FIGURE 5.2 Hypothetical relationship between memory performance and 
duration of therapy.
A second, related explanation is that memory performance is impaired by 
phenytoin when first administered but then improves with time (Figure 5.2) 
perhaps through cognitive strategies such as increased effort or the use of 
mnemonics. Such strategies may enable the patient to restore his/her 
memory function to a 'normal' level. When the drug ceases to be 
administered, memory performance overshoots the normal level because 
the memory impairing effects of the drug have ceased and the strategies 
developed to cope now yield superior performance.
Another explanation for the results presented in Figure 5.1 is that 
carbamazepine results in an improvement of memory function. One 
important observation, which remains essentially unexplained by a simple 
model that phenytoin impairment habituates over time, is that the memory 
performance of the group switched to carbamazepine showed a significant 
improvement in performance. As discussed in Chapter 1, there is some 
evidence that carbamazepine may have a beneficial effect on cognitive 
function. Thus the putative memory-impairing effects of phenytoin observed 
in recently treated patients may habituate over periods longer than three 
months. When the patients are switched to carbamazepine they experience
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a separate beneficial effect from this drug which improves memory 
performance. This is unlikely since previously untreated patients 
administered carbamazepine did not improve in Experiment 1.
The improved performance of patients who switched to carbamazepine 
from phenytoin may also be a placebo effect. That is, patients may have 
volunteered to change their medication in the belief that an alternative drug 
is less likely to impair their memory. However, the absence of a change in 
memory performance in patients switching from carbamazepine to sodium 
valproate argues against this. Both experiments employed the same 
procedures and were carried out over the same period and should 
therefore have been exposed to the same external effects on the results. It 
seems unlikely that volunteer effects would be present in one experiment 
and not in the other. Therefore, the possibility that volunteer effects may 
contaminate the results of the switch from phenytoin to carbamazepine 
seems remote. On the other hand, if carbamazepine were having a 
beneficial effect, and volunteer effects were also in operation, improvement 
of memory in Experiment 2 by treatment with carbamazepine may have 
been due to a combination of these two effects, whereas lack of change in 
Experiment 3 may have resulted from diminished performance due to 
cessation of carbamazepine counteracted by the beneficial volunteer effect 
- the two effects cancelling each other out. This rather less parsimonious 
account does mean that the possibility of volunteer effects contaminating 
the results cannot be excluded.
The experimenter was aware of the possibility of volunteer effects 
influencing the results, considerable care was taken to ensure that no 
indication was given to patients of the experimenter's expectation or that 
any change in memory function was even probable. Nonetheless, patients 
were, by necessity, aware that memory was being assessed and the 
experimenter could not control the assumptions or inferences patients
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might have made.
The effects of switching patients previously treated with carbamazepine to 
sodium valproate for an average of only six months are consistent with the 
results of both Experiments 1 and 2. This drug switch suggests that there is 
no significant difference between memory performance on either 
carbamazepine or sodium vaproate although the average blood levels of 
sodium valproate were in the low therapeutic range. Nonetheless, these 
results support the view that both carbamazepine and sodium valproate do 
not have an adverse effect on memory function.
Bearing in mind the large number of tests carried out, it is possible that the 
apparent improvement in memory function in patients treated with 
carbamazepine observed in Experiment 2 may simply be a Type 1 error. 
That is, the significant result found in Experiment 2 may have been due to 
sampling error. However, the fact that the same Faces(2) test was 
implicated in Experiments 1 and 2, makes this unlikely since the probability 
of this test occuring twice from two independent samples (the subjects from 
the first three experiments were independent) is 1/172 let alone the 
probability of the effect occuring in the same group. Such a level of 
probability makes the possibility that the results occured simply by chance 
as a consequence of the large number of tests carried out quite remote. Nor 
can it be argued that the positive result from Experiment 1 may have been a 
Type 1 error since the application of Bonferoni criteria to that experiment 
would have still yielded the same significant result.
5.7 CONCLUSIONS
As in Experiment 1, the results of these experiments suggest that the effects 
of the drugs on memory are, at most very small. In spite of using a battery of 
memory tests including both verbal and non-verbal items in a variety of 
conditions with both short-term and recent memory, there is little evidence
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that any of the drugs are having an adverse effect on memory. The fact that 
one of the tests has shown a significant effect with one drug supports this 
assertion since this one positive result in both experiments indicates that 
the experimental procedures were potentially sensitive to drug effects. It 
suggests that other tests would have yielded significant results if there were 
effects of the drugs. For these reasons one may conclude that there are 
relatively few adverse effects of the anticonvulsants tested when used in 
monotherapy within or below the currently accepted therapeutic ranges.
Nonetheless, Experiments 2 and 3 indicate either that phenytoin has some 
adverse effect or that carbamazepine has some beneficial effect on 
memory. The results from Experiment 1 do not support the view that 
carbamazepine has a beneficial effect on memory. The best explanation 
seems that phenytoin has an adverse effect on memory which is 
maintained by drug taking and relieved when the drug is withdrawn. 
However, other factors may have influenced the results of these 
experiments. In both of the drug switching experiments small numbers of 
subjects prevented adequate counter-balancing of the order in which the 
drugs were administered so that it is not known whether similar effects 
might have been observed when switching from carbamazepine to 
phenytoin or from sodium valproate to carbamazepine.
CHAPTER 6
THE RELATIONSHIP BETWEEN BLOOD LEVEL OF 
ANTICONVULSANT, RED CELL FOLATE AND MEMORY 
PERFORMANCE IN CHRONICALLY MEDICATED EPILEPTICS
(EXPERIMENT 4)
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6.1 INTRODUCTION
The experiments reported in Capters 4 and 5 found a small deleterious 
effect of phenytoin on memory in epileptics. However, several experimental 
deficiencies were present:
(1) the sample size was small and consequently the statistical power was 
low - conditions likely to lead to false negative conclusions;
(2) only changes in performance following recent alterations in medication 
were examined;
(3) the blood levels of phenytoin and sodium valproate were, on average, 
in the low therapeutic range; and
(4) the data obtained were insufficient to allow an analysis of the effects of 
folate on memory.
It was decided to examine further the effects of the anticonvulsants and 
folate level on memory using a larger sample of patients. It was also 
decided to examine patients who had been established on medication for 
periods longer than the three months which had been used in the previous 
experiments. A cross-sectional methodology was used to examine dose- 
performance correlations.
Cross-sectional designs require larger samples in order to achieve 
statistical power than longitudinal designs. Maximising sample sizes had a 
number of methodological costs. The numbers of patients treated with the 
three drugs were unequal. Various forms of the memory battery had been 
used and these different forms were not perfectly balanced across the 
groups. Early in the study, a relatively large number of patients was 
available who were stabilised on phenytoin. However, sufficient numbers of
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patients on carbamazepine or sodium valproate only became available 
after testing on various forms of the memory battery. Adhering to the first 
memory battery would have resulted in a sample that was impractically 
small. Thus the price paid for increasing the sample size was the relaxation 
of some of the criteria for analysis which had applied in previous 
experiments.
This experiment was designed to examine the following questions:
(1) Are there differences between the average memory performance of 
patients on different drugs?
(2) How is memory test performance correlated with serum anticonvulsant 
levels, dose of the drugs and level of red cell folate?
6.2 METHOD
6.2.1 Procedure
The WAIS was administered (if it had not already been given) together with 
one of four forms of the memory battery. Blood tests for anticonvulsant 
levels and red cell folate were taken at the end of testing and , whenever 
possible, EEG's were carried out on the same day or within a few days of 
testing. Subjects tested were on phenytoin, carbamazepine or sodium 
valproate.
6.2.2 Subjects
Subjects were drawn from the patient pool used in previous experiments. 
Subjects were included in the analysis provided their serum anticonvulsant 
levels were within or below the therapeutic range.
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One hundred and sixteen patients satisfied the criteria for analysis. Table 
6.1 summarises the characteristics of this sample. The phenytoin group 
was the largest available for analysis. Fifty seven patients were treated with 
phenytoin, thirty four were treated with carbamazepine and twenty five 
were treated with sodium valproate. All three groups had similar ages, IQs 
and range of seizure types. The average age and IQ was approximately 30 
and 115, respectively, for all three groups. Within each group the number of 
epileptics with tonic clonic seizures was approximately equal to the number 
of epileptics with complex partial seizures. However, the sodium valproate 
group had more epileptics with myoclonus, fewer major convulsions and a 
shorter average duration of epilepsy than either of the other groups. Twenty 
two percent of all subjects had levels of the drugs that were below the 
therapeutic range. The majority of these, 15%, were treated with phenytoin. 
However, half of these had levels within 0.2mg% of the lower bound of the 
therapeutic range. The red cell folate level of the phenytoin group was 
significantly less than that of the carbamazepine and sodium valproate 
groups (F = 4.81, p = 0.01).
6.2.3 Test Material
The tests used in this experiment were the same as those used in the 
earlier experiments. However, the larger sample size available for this 
experiment made it possible to include some additional tests.
6.2.4 Analysis
Results were analysed in two different ways. Firstly, the average 
memory performances for the different groups were compared. Secondly, 
partial correlation was used to examine the relationships between dose of 
anticonvulsant, serum anticonvulsant level, red cell folate level and 
psychological test performance. Since IQ and age were to influence 
memory test performance, these effects were partialled out. In addition,
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some post hoc analyses were carried out. The approaches used in the post 
hoc analysis were variations on the two approaches referred to above.
The following analyses were performed:
(1) comparison of the mean characteristics of each drug group;
(2) comparisons between mean memory test performance for each of the 
drug groups;
(3) correlation of folate and serum anticonvulsant level with memory 
performance;
(4) correlation of folate and serum anticonvulsant level with memory 
performance after partialling out the effects of age and IQ;
(5) correlation of folate with memory performance after partialling out age, 
IQ and serum anticonvulsant level of each drug;
(6) correlation of serum anticonvulsant level of drug with memory 
performance after partialling out the effects of age, IQ and folate; and
(7) comparisons between mean group performances, adjusted for age, IQ 
and folate.
6.3 RESULTS AND DISCUSSION
6.3.1 Characteristics of Each Drug Group Sample
The relevant characteristics of the patient sample analysed for Experiment 
4 are summarised in Table 6.1.
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Phenytoin Carbamazepine Sodium
Valproate
SAMPLE SIZE 57 34 25
AGE(yrs) 30 32 29
IQ
SEIZURE TYPE:
113 116 115
Tonic Clonic 29 15 9
Complex Partial 25 17 10
Myoclonus
NUMBER OF MAJOR
3 2 6
CONVULSIONS 
DURATION OF
8.4 7.5 3.55
EPILEPSY (yrs) 11.2 8.4 4.6
RED CELL FOLATE 
(ng/ml)
226 299 289
DOSE (mg) 338 553 958
BLOOD LEVEL 1.25 0.72 7.26
TABLE 6.1 Characteristics of the patient sample drug by drug.
Table 6.2 shows the frequency with which the various parallel forms of the 
memory battery were administered to each of the drug groups. Subjects on 
phenytoin were most frequently assessed with Form A of the battery 
whereas the carbamazepine and sodium valproate groups were more 
frequently assessed on Form B.
Parallel Form Phenytoin Carbamazepine Sodium
Valproate
Form A 43 7 4
Form B 12 17 13
Form C - 5 8
Form D 1 5 _
TABLE 6.2 Numbers of subjects tested with each form of the test within 
each group.
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The responses from the structured interview, the Washington Psychosocial 
Seizure Inventory (WPSI) and the Subjective Memory Questionnaire 
(SMQ) were also examined for this experiment. Since these self-report 
measures had been introduced some time after the commencement of the 
study, much of the data was missing. Consequently, these results did not 
merit formal statistical analysis. (The results have been reported in 
Appendix 6.5). Only selected observations are presented here.
In the structured interview, the majority of all subjects reported that they 
thought that the drugs had no effect on their memory. Approximately 60% of 
the phenytoin and the sodium valproate groups, and 90% of the 
carbamazepine group reported that they thought that their drug had no 
effect on their memory. Interestingly, approximately 20% of subjects on 
sodium valproate claimed that this drug improved their memory. However, 
a number of these subjects had changed medication from some other 
anticonvulsant or combination of anticonvulsants. Only one subject 
reported that she thought her memory was improved by phenytoin. Fifteen 
percent of those on sodium valproate and 10% of those on carbamazepine 
thought that the drug had made their memory worse. However, one third of 
those on phenytoin believed that their memory was impaired by this drug.
Forty nine percent of all subjects reported that they had difficulty with their 
memory, with the greatest percentage of difficulty reported by the phenytoin 
group (70%). However, no systematic pattern in the nature of memory 
difficulty was observed in these self-reports. When asked about any 
side-effects that they may have experienced, the most frequent comment 
was that they had felt drowsy at some time. Thirty percent of those on 
sodium valproate reported feeling drowsy as did 40% of those on 
carbamazepine and 50% of those on phenytoin.
The results from WPSI supported the view that, although the epileptics 
suffered from a variety of psychosocial problems, there did not appear to be
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any significant difference between the drug groups. For example, between 
50% and 85% of subjects reported that they had concerns in the vocational 
area, between 20% and 50% reported that they had family problems, 
between 35% and 50% felt tense or anxious much of the time and between 
12% and 50% felt trapped in their current living situations. Notably, less 
than 20% of the sample felt that they were losing their ability to think clearly.
Several points are worth noting about the characteristics of the sample. 
Firstly, as in earlier experiments, the average IQ of subjects was 
significantly higher (approximately 115) than the population average. 
Secondly, the drug groups were generally well matched, especially those 
on phenytoin and carbamazepine. However, the sodium valproate group 
was the smallest, had the largest number of epileptics with myoclonus and 
had the shortest duration of epilepsy.
6.3.2 Comparisons Between Group Performances (MANOVA)
Table 6.3 summarises the results of the comparisons of the mean memory 
scores from each drug group. These results indicate that there were no 
significant differences between the mean memory performance of patients 
on phenytoin, carbamazepine or sodium valproate. (See also Appendix 
6.3).
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TEST PHENYTOIN CARBA-
MAZAPINE
SODIUM SIGNIF.
VALPROATE
N O N V E R B A L T E S T S
FACES(1) 26.7 (57) 26.9 (32) 26.4 (24) NS
FALSE +VE 1.95 (57) 1.72 (32) 1.83 (24) NS
FALSE -VE 1.35 (57) 1.41 (32) 1.75 (24) NS
TIME 1.30 (51) 1.32 (31) 1.35 (22) NS
FACES(2) 24.3 (57) 23.8 (34) 23.8 (25) NS
FALSE +VE 2.78 (57) 2.94 (34) 2.20 (25) NS
FALSE -VE 2.91 (57) 3.29 (34) 3.96 (25) NS
TIME 1.55 (51) 1.62 (34) 1.43 (22) NS
V E R B A L  T E S T S
MODIFIED REY AUDITORY VERBAL LEARNING TASK
TRIAL 1 6.14 (57) 6.44 (34) 5.44 (25) NS
TRIAL 5 13.2 (57) 13.2 (34) 12.9 (25) NS
RECALL TIME 1.10 (50) 1.24 (34) 0.95 (24) NS
RECALL 12.2 (56) 11.7 (34) 12.9 (24) NS
RECALL TIME 1.22 (52) 1.23 (34) 1.08 (24) NS
RECOGTN 14.7 (54) 14.6 (33) 14.8 (24) NS
DIGIT SPAN 12.4 (42) 12.2 (28) 11.5 (21) NS
WORD FINDING
NO. CORRECT 15.1 (13) 18.2 (10) 14.7 (6) NS
RECALL(SEC) 2.36 (13) 2.13 (10) 2.49 (6) NS
LONG TERM MEMORY
NO. CORRECT 22.3 (13) 23.1 (10) 21.7 (6) NS
RECALL(SEC) 1.55 (13) 1.14 (10) 1.59 (6) NS
STERNBERG SERIAL SCANNING TASK
2 ITEMS 595 (8) 664 (13) 654 (6) NS
4 ITEMS 667 (8) 752 (13) 722 (6) NS
6 ITEMS 736 (8) 832 (13) 781 (6) NS
M O T O R  T E S T S
INFORMATION PROCESSING
RATE 1.44 (42) 1.36 (30) 1.42 (22) NS
SIMPLE CHOICE REACTION
TIMES 0.331(53) 0.344(31) 0.320(25) NS
TABLE 6.3 Mean performance scores of epileptics treated by monotherapy 
of phenytoin, carbamazepine or sodium valproate. Numbers in brackets 
represent sample size for each test. Maximum scores are displayed after 
test title where appropriate.
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The earlier experiments associated phenytoin with impaired memory 
performance (except in the phenytoin stabilised group in Experiment 2) 
while carbamazepine and sodium valproate were associated with 
improved or unaltered performance. It might, therefore, have been 
expected that, in the present experiment, patients on phenytoin would 
perform at a lower level on memory tests than patients treated with either 
carbamazepine or sodium valproate. However, this was not the case. This 
apparent inconsistency between this observation and earlier experiments
may have been due to a number of factors. Firstly, in the present
\
experiment, the number of subjects within each drug group was small 
bearing in mind the low statistical power of between subjects designs. 
Secondly, the relaxation of more rigid criteria for inclusion in the analysis 
may have resulted in increased variability in the data which could have 
masked small effects of the drugs. Thirdly, the memory impairing effects of 
phenytoin in epileptics treated with this drug for only three months may 
habituate over time so that performance may return to a normal level with 
longer treatment.
As has been noted earlier, it was not possible to take into account the 
influence of retest effects on the results. In previous experiments, few 
subjects had been tested beforehand. In the current experiment, most 
subjects had undergone some testing prior to the assessment that was 
analysed as part of the data for this experiment. It can be argued that 
although parallel forms of the memory battery were developed in order to 
reduce retest effects, performance may have tended to improve on 
subsequent tests because of reduced test anxiety resulting from familarity 
with the nature of the tests, test surroundings and the experimenter. 
However, the majority of phenytoin subjects included in the analysis for this 
experiment had not been tested previously and, although the performance 
of this group was expected to be lower, this group is arguably the least 
affected by retest effects. Thus the influence of retest effects on the results
ANTICONVULSANTS, FOLATE AND MEMORY RELATIONSHIPS 1 08
would appear to be minor.
As can be seen from Table 6.2, the phenytoin group was more frequently 
tested with Form A, whereas the carbamazepine and sodium valproate 
groups were more frequently tested with Form B. This raises the possibility 
that impaired performance on phenytoin may be due to a greater difficulty 
of tasks in Form A. However, earlier experiments have suffered from the 
same lack of counterbalancing but nevertheless produced significant 
differences in performance. In addition, the results of comparisons between 
the different test forms presented in Appendix 3.1 provide no evidence of 
significant differences in performance on the different forms of the test 
battery. In view of these considerations, it seems unlikely that the more 
frequent use of Form A of the memory battery in this experiment has 
influenced the results.
The third factor, referred to above, to account for the lack of significant 
differences between the mean memory performances of the phenytoin 
group and the carbamazepine and sodium valproate groups was that the 
impairment of cognition observed in patients treated with phenytoin for only 
three months, habituates with time so that after several years, memory 
performance has returned to normal. This hypothesis is consistent with the 
results of earlier experiments in which it was observed that the memory 
performance of previously untreated patients administered phenytoin was 
impaired after three months of therapy but subsequent analysis indicated 
that that the memory performance of phenytoin treated patients returned to 
normal after several years of treatment. However, the results of the partial 
correlation analysis (presented in Sections 6.3.5 and 6.3.6 below) indicate 
that this hypothesis is inadequate.
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6.3.3 Correlations Between Folate, Serum Anticonvulsant Level and 
Memory Test Performance
Partial correlations between blood tests and memory scores were 
calculated in order to examine whether red cell folate or blood level of 
anticonvulsant contributed to memory impairment in epileptic patients. 
Tables 6.4, 6.5 and 6.6 show that red cell folate and serum anticonvulsant 
levels, as well as dose of anticonvulsant, correlated significantly with 
certain memory test scores. (The full correlation matrices are presented in 
Appendix 6.3). In addition, significant correlations were found between 
dose and blood level of carbamazepine and sodium valproate but not 
phenytoin. There were no significant correlations between red cell folate 
level and either dose or blood level of any of the anticonvulsants.
Drug Memory Test r P
Phenytoin Rate of recall on Faces(1) 
Rate of recall on trial 5
.29 .032
wordlist recall .29 .030
Carbamazepine Serum level .38 .028
Rate of recall on Faces(2) 
Recall time on trial 5 of
.37 .033
the wordlist .36 .038
IQ .38 .026
Sod. Valproate Serum level
Words recalled on trial 1
.81 .003
of the wordlist -.41 .049
TABLE 6.4 Correlations between dose of anticonvulsant and memory test 
performance scores.
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Drug Memory Test r P
Phenytoin False -ve errors on Faces(1) .29 .032
Delayed recall of wordlist .28 .039
Carbamazepine Dose
Rate of delayed recall on
.38 .028
the wordlist .38 .030
Digit span -.38 .031
Sod. Valproate Dose .81 .003
False +ve errors on Faces(1) -.52 .014
TABLE 6.5 Correlations between serum level of anticonvulsant and
memory test performance scores.
Drug Memory Test r P
Phenytoin IQ .37 .016
Carbamazepine -
Sod. Valproate Time to recall trial 5 of
the wordlist .43 .043
Rate of recall of the
wordlist on trial 5 .43 .043
Digit span .42 .049
TABLE 6.6 Correlations between red cell folate 
performance scores.
level and memory test
The above findings cannot be taken at face value since there was 
heterogeneity between the groups with respect to age and IQ. If test 
performance was correlated with age and IQ, the significant positive 
correlations in Tables 6.4, 6.5 and 6.6 could have been spurious. Indeed, 
the full correlation matrix of all variables correlated with each other, 
presented in Appendix 6.2, shows that both age and IQ significantly 
correlated with a number of memory tests. It was, therefore, necessary to 
partial out the effects of age and IQ before assessing the effects of drug on 
performance.
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6.3.4 Correlations Partialling Out Age and IQ
Table 6.7 shows that after partialling out the effects of age and IQ, there 
were significant correlations between folate level and performance on 
several tests. The table also shows significant correlations between blood 
level of the drug and test performance. Specifically, the table shows that:
(1) the number of false negatives on Faces(1) was weakly correlated with 
blood level of phenytoin;
(2) the total time spent recognising faces on Faces(1) and the total recall 
time and average rate of recall of the wordlist after a thirty minute delay 
were mildly correlated with blood level of carbamazepine; and
(3) the number of false postive errors on Faces(1) had a medium negative 
correlation with blood level of sodium valproate.
Drug Memory Test r P
Phenytoin False negatives on Faces(1) .28 .042
Carbamazepine Time recognising Faces(1) .42 .025
Delayed wordlist recall time .36 .046
Delayed wordlist recall rate .36 .046
Sod. Valproate False positives on Faces(1) -.55 .012
TABLE 6.7 Correlations between serum anticonvulsant levels and 
memory test performance scores after the effects of age and IQ were 
partialled out.
Table 6.8 shows the correlations between red cell folate levels and memory 
test performance after the effects of age and IQ were partialled out. For 
subjects treated with phenytoin and carbamazepine, there was a weak to 
medium positive correlation of red cell folate level with the total number of
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faces correctly recognised on Faces(2). For the sodium valproate group, 
the time to recall the wordlist on the fifth trial had a medium correlation with 
red cell folate level and simple choice rection times had a weak to medium 
negative correlation with red cell folate level. All other correlations were 
non-significant.
Drug Memory Test r P
Phenytoin Faces(2) recognised .37 .020
Carbamazepine Faces(2) recognised .39 .035
Sod. Valproate Fifth wordlist recall rate .45 .045
TABLE 6.8 Correlations between red cell folate levels and memory test 
performance scores after the effects of age and IQ were partialled out.
These results suggest that both folate metabolism and serum level of 
anticonvulsant may have independent effects on the memory of epileptic 
subjects even after the effects of age and IQ have been partialled out. In 
order to examine the relative contribution of folate and blood level of drug 
to memory performance, a series of post hoc analyses were undertaken in 
which the effects of one variable were examined partialling out the effects 
of the other variable as well as age and IQ.
6.3.5 Correlations Between Folate and Memory Test Performance 
Partialling Out Age, IQ and Blood Level of Drug
The effects of folate, independent of those of drug, were examined by 
partialling out blood level of anticonvulsant and dose of anticonvulsant in 
addition to age and IQ. These results are presented in Table 6.9. This table 
shows that only one memory test measure (the number of faces correctly 
identified on the Faces(2)) was significantly correlated with red cell folate 
level in the phenytoin and carbamazepine groups. For the sodium
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valproate group, a medium to strong correlation was found between digit 
span and red cell folate level.
Drug Memory Test r P
Phenytoin Faces(2) recognised .37 .024
Carbamazepine Faces(2) recognised .39 .042
Sod. Valproate Digit Span .68 .002
TABLE 6.9 Partial correlations between red cell folate levels and memory 
test performance scores after partialling out the effects of age, IQ and 
dose and blood level of anticonvulsant.
The observation that the Faces(2) test was associated with memory 
performance, especially in the phenytoin group, confirms the observations 
of earlier experiments. It confirms an effect on memory and that the 
Faces(2) is sensitive to this effect.
The observation that memory test performance was correlated with red cell 
folate level in subjects treated with carbamazepine and sodium valproate is 
also particularly interesting in that these drugs, particularly carbamazepine, 
have been associated with normal memory performance. Is folic acid level 
correlated with memory performance in all individuals, regardless of 
whether they have epilepsy or not? Alternatively, is epilepsy, rather than 
drug, the factor involved in the observation of memory performance 
correlating with folate level? Answers to these questions could be 
potentially relevant to our understanding of the physiological bases of 
memory processes.
On the other hand, it was noted in Experiment 1 that performance on the 
first trial of the Rey Auditory Verbal Learning Task (RAVLT) was lower in the 
sodium valproate group. This difference was not significant and not 
considered important, as a related test, Digit Span, did not show any
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difference between the groups in Experiment 1. However, the appearance 
of a significant correlation in this experiment between Digit Span and 
sodium valproate is consistent with the results of Trimble and Thompson 
(1983) which indicated that sodium valproate may impair performance on 
some memory test measures.
6.3.6 Correlations Between Blood Level of Drug and Memory Test 
Performance Partialling Out Age, IQ and Folate
The effects of red cell folate were partialled out, in addition to the effects of 
age and IQ, in order to examine the remaining correlations with the 
effects of blood level of anticonvulsant. There were no significant partial 
correlations between blood level of anticonvulsant and any of the memory 
test scores after the effects of age, IQ and red cell folate level were 
partialled out.
Taken together, the results indicate that folate levels have a greater 
influence on the cognitive performance of epileptic patients than blood 
level of drug. This observation is not new. It has been proposed that 
depletion of folic acid may be related to the development of cognitive 
impairments in epileptics (Reynolds, 1979; Trimble, 1979). However, as 
noted in Chapter 1, investigations of the relationship between folate and 
cognitive impairments have yielded conflicting results.
6.3.7 Comparisons Between Group Performances Adjusted for Age, IQ 
and Folate (MANCOVA)
The fact that performance is correlated with folate level, together with the 
fact that the drug groups differ in mean folate level would lead one to 
expect a group difference in performance. The absence of this anticipated 
effect might suggest the existence of a drug effect independent of (and 
masked by) the folate effects. In order to test this hypothesis the differences 
between the mean performance levels of the drug groups were
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re-examined using a MANCOVA procedure in order to partial out the effects 
of age, IQ and red cell folate level. The overall MANCOVA was not 
significant (Hotellings F = 1.23, p = 1.67, see Appendix 6.3) indicating that 
there was no linear combination of memory test scores which could 
produce a significant difference between the drug groups after the memory 
scores had been adjusted for the effects of Age, IQ and red cell folate.
6.3.8 Summary of Results
(1) No differences were found between mean memory test performance 
scores for the different drug groups.
(2) A variety of memory tests significantly correlated with blood level of drug 
and red cell folate level but also with age and IQ.
(3) The number of correlations between memory tests and blood level of 
drug and red cell folate level were reduced when the effects of age and IQ 
were partialled out.
(4) When blood level of drug and red cell folate level were independently 
correlated with memory test performance, partialling out the effects of red 
cell folate and then again partialling out the effect of blood level of 
anticonvulsant (with both analyses partialling out the effects of age and IQ), 
only red cell folate level significantly correlated with memory test 
performance.
(5) When differences between the mean memory performance of the drug 
groups were re-examined using MANCOVA to adjust the means for group 
differences in red cell folate levels, age and IQ, no significant differences 
were found betweeen the mean performances of the three drug groups.
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6.3.9 Possible Effects of Folate on Memory
Taken together, the analyses of the results of this experiment, tend to 
suggest that reduced folate level may be more important in producing 
memory impairment in epileptics than the type of anticonvulsant or blood 
level of anticonvulsant. It is particularly striking that the memory test, 
Faces(2), which was associated with memory impairment in the earlier 
experiments, was again implicated in this experiment. The observations 
that, firstly, phenytoin may impair performance on the Faces(2) test, 
secondly, phenytoin results in a reduced folate level and, thirdly, folate 
level is correlated with performance on the Faces(2) test, make it tempting 
to conclude that the memory impairing effects of phenytoin are mediated 
through its effect on folate metabolism.
But if phenytoin impairs memory function through its action on folate then it 
is not clear why the phenytoin group, who had a significantly reduced folate 
level, did not have a significantly lower memory performance. Indeed this 
evidence suggests that the effects of folate and the effects of the drug may 
be independent. However, this hypothesis is not supported by the 
observations that when the effects of folate are removed from comparisons 
between means and from correlations between blood level of 
anticonvulsants and memory performance, no significant differences are 
observed. Clearly further investigation is needed to resolve this issue.
If it were the case that the memory-impairing effects of the drugs were 
mediated by the reduction of folate, it would be expected that the 
circumstances under which the greatest impairment of cognition occurs 
would be those where folate is most depleted. For example, Chanarin 
(1979) reviewing the effects of anticonvulsants on folate, concluded that 
phenytoin and phenobarbitone are most frequently associated with 
depletion of folate. In addition, folate deficiencies are more likely to occur 
inpatients treated by polytherapy (Reynolds, 1975). These aspects have
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not been examined in the current study but are an important area for future 
study.
Conversely, the possibility that memory impairment observed in patients 
treated by monotherapy with either phenytoin, carbamazepine or sodium 
valproate, may be correlated with folate deficiency raises the question of 
whether folic acid supplements might improve memory test performance of 
those patients treated with anticonvulsants. Reports on the effects of folic 
acid on cognition have been conflicting. Some studies have reported a 
greater incidence of cognitive impairment amongst folate deficient patients 
(Reynolds, 1969; Snaith et al.,1970; and Trimble et a!., 1980). Other, better 
controlled studies, have failed to confirm these findings (Bowe et al., 1971; 
Grant and Stores, 1970; and Gibberd et al., 1981).
The time constraints of this study precluded a full examination of this 
hypothesis. However, a small pilot study of the influence of folate 
supplements on memory performance of patients treated with phenytoin 
alone was initiated. This is presented in Appendix 6.4. Although not 
conclusive, the results presented in Appendix 6.4 do not support the 
suggestion that the putative memory impairing effects of the drugs can be 
reversed by folate supplements. However, in view of the small magnitude of 
the effect of folate observed in the current experiment it is perhaps not 
surprising that investigators have produced such differing results. The lack 
of a significant difference between the folate supplemented groups and 
non-supplemented groups in the pilot study does not negate the 
hypothesis that folic acid supplements given to phenytoin treated patients 
may improve memory performance. There were several significant 
weaknesses in the design, such as the lack of a double-blind 
placebo-controlled procedure, lack of information about dietary variations, 
inadequate sample size and lack of selection of folate deficient subjects. 
In addition, the length of time required for the effects of the added folic acid 
to become apparent is not clear. Herbert (1962) reported that
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improvements in 'forgetfulness' were subjectively apparent after only 48 
hours of folate supplement therapy. However, other workers have failed to 
observe such effects in folate deficient patients after only 48 hours, 
although significant changes were observed after two weeks (Botez et al, 
1979). Lindenbaum (1975) suggests that folate stores may be depleted 
over a period of a few months by drugs such as phenytoin, but he gives no 
index of the rate at which folate levels in the brain may be increased.
Spaans (1970) reported no significant rise in serum folate after three 
months of folate supplements in epileptic patients, as did Mattson, 
Gallagher, Reynolds and Glass (1973) after six months of folate therapy, in 
spite of a marked rise in serum folate level. Spaans suggested the 
presence of a blood-brain barrier mechanism and this has been supported 
by the finding of Hommes et al (1973) and Mattson et al (1973). However, 
studies of animals (Levitt Nixon, Pincus and Bertino, 1971) and humans 
(Chanarin et al, 1973) suggest that there is some circulation of folate 
between the serum and the CSF. Indeed Chanarin, Perry and Reynolds 
(1974) found that doses of 3H-labelled 5-MTHF was present in 
concentrations up to 20% of total CSF folate after only four hours but that 
this had fallen considerably after 24 hours. Reynolds (1976) suggests that 
this may reflect a rapid uptake by the neurones, or a redistribution of the 
folate back to the rest of the body.
It is clear from this discussion that no definitive statement can be made 
about the most desirable period over which to assess the influence of folate 
levels in epileptic patients. In the pilot experiment present in Appendix 6.4, 
it was decided in view of the above considerations, to keep the test-retest 
interval to a period of only six weeks. The lack of significant results can, 
therefore, not be used to argue that folic acid supplements are not 
beneficial.
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It can be asked why, if folate supplements reduce memory impairments in 
epileptics, prophylactic treatment should not be carried out. Unfortunately, 
reports on the effect of the concurrent administration of folic acid with 
phenytoin on seizure frequency have been conflicting. Some workers have 
noted an increase in the number of seizures (Reynolds,1973) whilst others 
have been unable to confirm this finding (Grant and Stores 1970; Ralston, 
Snaith and Hinley, 1970, Child et al, 1969) and still others have noted a 
reduction in seizures (Gibberd et al 1981). Makki, Perucca and Richens, 
(1979) studied the effect of administering 30 mg of folic acid per day on the 
metabolism of phenytoin and phenobarbitone. They found that there were 
only small changes in the plasma concentrations of these drugs after three 
months of replacement therapy. Thus it is not clear whether folate 
supplements increase seizure frequency and it is, therefore, premature to 
advocate the routine use of folic acid supplements on anything but an 
experimental basis.
6.3.10 The Possible Role of Other Metabolic Factors in the 
Production of Memory Impairment
While the evidence provided by Experiment 4 supports the hypothesis that 
folate metabolism may play a role in the development of memory disorders 
in epileptic patients, it is possible that other metabolic factors such as 
serotonin or noradrenalin metabolism may affect the cognition of epileptics. 
The metabolism of several other neurotransmitters such as acetylcholine, 
dopamine, noradrenaline, serotonin, and gamma-amino-butyric acid 
(GABA) are known to be affected by anticonvulsants (Eadie and Tyrer, 
1980). Most work has been carried out on the role of serotonin and 
GABA.
The administration of anticonvulsants has been associated with increases 
in serotonin levels in the brain (Bonneycastle, Giarman and Paasonen 
1957; Chadwick, 1978; Chase, Katz and Kopin, 1969; Green and
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Graham-Smith, 1975). Increased levels of serotonin have also been 
associated with alterations in the behaviour of rats which are believed to 
be caused by impairments of memory and learning (Hunter, Zornetser, 
Jarvik and McGaugh, 1977). Taken together, these results suggest that 
anticonvulsants may impair memory by increasing serotonin levels within 
the brain.
While such an hypothesis is plausible, the evidence is not altogether 
confirmatory. Some workers have failed to establish any relationship 
between serotonin levels and the administration of anticonvulsants, while 
still others have reported decreased brain serotonin levels in treated 
epileptics (Shaywitz, Cohen and Bowers, 1975). The hypothesis that 
anticonvulsants may impair memory via serotonin metabolism needs 
further investigation.
GABA is an amino acid which is believed to function as an inhibitory 
transmitter (Iversen and Iversen, 1975). It is widely distributed throughout 
the central nervous system and an increase in the level of GABA in the 
brain is believed to result in decreased arousal (Jasper and Koyanen, 
1969). Brain GABA levels in experimental animals are increased by 
phenytoin, phenobarbitone, ethosuximide, diazepam, and sodium 
valproate (Eadie and Tyrer, 1980). It is possible that anticonvulsants may 
impair cognitive performance through a decrease in the level of arousal. 
However, the results of this study tend to suggest that the deficit in memory 
attributed to anticonvulsants is rather specific and certainly not a 
generalised deficit which would be expected from a deficit in arousal.
6.3.11 The Effect of Confounding Variables on the Results
It can be argued that the finding that memory is impaired at higher levels of 
anticonvulsants was to be expected. Patients may have higher drug 
levels because seizures are not fully controlled at lower levels of the drugs. 
Therefore, such subjects may have had more seizures, which themselves
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may impair memory. Seizure frequency is, therefore, a crude determinant of 
blood level of anticonvulsant and the relationship between blood level and 
memory test performance may in fact reflect the memory impairing effects of 
seizures.
Although the number of seizures reported by the patients was 
systematically recorded, the actual number of seizures experienced by 
each of the subjects may have been greater because epileptics may be 
unaware of seizures or fail to report them. If a recently diagnosed epileptic 
reports persistent seizures, adjustments are usually made to the dose of the 
anticonvulsant until the seizures cease. It is therefore, extremely difficult to 
determine the degree to which seizure frequency may be related to blood 
level of anticonvulsant.
The effects of subconvulsive neural discharges remained uncontrolled in 
these experiments. Since correlations between red cell folate level and 
memory test performance scores were found on all drugs, such effects may 
be due either in part, or altogether, to the effects of epilepsy. It would be 
difficult to establish whether this was the case even if EEG recordings were 
made during the adminstration of the memory tests.
The correlation analysis employed in this study assumes a linear 
relationship between blood level of anticonvulsant (or folate level) and 
memory test performance, an assumption that may not be correct. Indeed, 
the rapidly increasing incidence of overt symptoms of drug toxicity (such as 
mental and motor slowing) at levels of the drugs exceeding the therapeutic 
range, suggests that the blood level-memory impairment relationship is 
more likely to be an asymptotic function with both linear and quadratic 
components, and not simply a linear function. In view of the small sample of 
subjects available for analysis, a complex analysis of the trends was not 
possible.
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6.4 CONCLUSION
The results of the cross-sectional analysis confirm the findings from the 
earlier experiments that the drugs do not substantially affect the cognition 
of most epileptics treated by monotherapy within or below the currently 
accepted therapeutic ranges. At the same time, this experiment has found 
that one particular memory test correlates significantly with folate level in 
patients on phenytoin or carbamazepine. In addition, phenytoin was 
found to reduce folate, whereas carbamazepine and sodium valproate 
have little effect. It is tempting to suggest that the memory impairing 
effects of the drugs may be mediated by the effects of the drugs on folate 
metabolism.
CHAPTER 7
GENERAL DISCUSSION
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7.1 SUMMARY OF THE STUDY
This study was undertaken to examine the effects of anticonvulsant 
medication on memory function in epileptic patients because of the 
common complaints from patients of cognitive impairments which may be 
due partly to anticonvulsant medication. Although the effects of drugs and 
the effects of the disease are difficult to separate in clinical practice, there is 
evidence from studies of non-epileptic volunteers, that anticonvulsants can 
impair cognition, particularly memory.
In this study, a specially designed memory battery was administered to 
epileptics receiving monotherapy with phenytoin, carbamazepine or 
sodium valproate. Multiple forms of the battery were developed to permit 
serial testing. Patients were tested at various stages of therapy - some 
patients were recently diagnosed and previously untreated, others were 
changing medication or dose, and others were not undergoing any 
alteration in treatment.
Using this procedure it was intended to:
(1) compare memory performance before and after three months of drug
therapy;
(2) compare the effects of changing from one drug to another for all three
drugs under investigation;
(3) examine dose dependent relationships in patients established of the
drugs; and
(4) examine the role of folate metabolism in relation to all of these types of
comparisons.
However, sufficient numbers of subjects were not available to allow 
assessment of all of the above comparisons. Data which could be 
meaningfully analysed were assembled into four experiments. The findings
GENERAL DISCUSSION 125
of these experiments are summarised as follows.
(1) An analysis of memory performance in newly diagnosed and previously 
untreated epileptics tested before and after three months of monotherapy 
on phenytoin, carbamazepine and sodium valproate (Experiment 1). This 
showed that only phenytoin was associated with a significant decline in 
memory, and this was manifested in only one memory test, the Faces(2) 
test of facial recognition.
(2) Switching chronically treated patients from phenytoin to carbamazepine 
resulted in an improvment on the same test of facial recognition. There was 
no change in memory test performance in patients continuing on phenytoin 
(Experiment 2).
(3) Patients switching from carbamazepine to sodium valproate showed no 
change in performance compared with those continuing on carbamazepine 
(Experiment 3).
(4) Cross-sectional comparisons of memory performance between groups 
of epileptics stabilised on either phenytoin, carbamazepine or sodium 
valproate yielded no evidence of differences in memory (or other) 
performance between the different drug groups. However, phenytoin was 
associated with a reduced red cell folate level.
(5) Correlation analysis of the same data yielded a significant correlation 
between red cell folate level and memory performance across all drug 
groups. Serum level of anticonvulsant and dose of anticovulsant were also 
significantly correlated with some memory test scores. However, these 
correlations were eliminated when the effects of age, IQ, and red cell folate 
were partialled out. On the other hand, significant correlations were found 
between red cell folate level and memory test performance when the effects 
of age, IQ and anticonvulsant were partialled out.
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Taking these results together, several conclusions can be drawn from this 
study:
(1) There is no evidence that any of the anticonvulsants studied has a 
substantial effect on memory performance in epileptic subjects when the 
drug levels are within or below the therapeutic ranges;
(2) There is evidence that phenytoin produces some impairment of 
memory, at least within 3 months of the commencement of treatment, but 
that most patients seem to recover when the drug is used within or below 
the currently accepted therapeutic ranges for longer periods of time;
(3) The memory-impairing effects of phenytoin are relieved by withdrawing 
the medication and substituting carbamazepine (or possibly sodium 
valproate); and
(4) Folate deficiency may be related to the development of impairment of 
memory.
7.2 PROBLEMS IN INTERPRETATION OF THE RESULTS
There are a number of methodological considerations which must be taken 
into account in assessing the significance of the results.
7.2.1 The Influence of EEG Activity on the Results
As noted previously, epileptic activity measured by the EEG, is associated 
with alterations in cognitive performance. Epileptic EEG activity was not 
monitored during testing in this study. EEG recordings were made after 
assessments, rather than during testing, because it was thought that 
continuous EEG monitoring during psychological testing could have 
adversely affected performance. In addition, the extent to which
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subconvulsive activity might have impaired performance is unknown.
However, it is unlikely that subconvulsive epileptic activity affected the 
results in this study since patients had relatively infrequent clinical seizures, 
being mild epileptics. Nontheless, it could be argued that the decline in 
memory performance observed in the phenytoin group in Experiment 1 was 
due to subconvulsive activity rather than the effects of the drug. However, 
this possibility seems remote. It is unlikely that subconvulsive activity would 
affect only one test in one group in this experiment. The effects of this type 
of epileptic activity, on a chance basis, would be expected to be equally 
distributed across both the epileptic groups and the different tests and, 
therefore, to produce generalised differences in performance between the 
epileptics and the non-epileptic controls.
It is, similarly, difficult to imagine how subconvulsive discharges might have 
infuenced the results of Experiment 2. The group switched to 
carbamazepine experienced a significant improvement in performance 
above that of other subjects. It can be postulated that such an effect would 
have been due to a reduction in EEG activity resulting from the change in 
medication which may have led to an improved performance. However, if 
this were the case, it is puzzling why only a single test should refect such 
changes. In addition, there was no significant change in seizure frequency 
in this group (which may not have been expected given the high level of 
seizure control in this sample) and both carbamazepine and phenytoin are 
similarly efficacious in controlling epileptic activity.
In the case of Experiment 3, no systematic changes in mean performance 
level were observed. It is difficult to postulate any simple hypothesis of an 
influence of subconvulsive discharges on this result, unless a number of 
counterbalancing factors are proposed.
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Again, in Experiment 4, no differences in memory test performance were 
observed, in spite of the fact that the group differences in folate level might 
indicate that there were group differences in seizure frequency.
In general, there are a number of reasons for regarding the possibility of 
significant confounding by epileptic activity as remote. Firstly, the results of 
these experiments have demonstrated changes in the performance of 
single groups of epileptics with other epileptic groups in the same 
experiments not showing similar changes in function. Secondly, in 
selecting subjects for this study, severe cases of epilepsy (in terms of the 
number of seizures) were avoided. It would be expected that the frequency 
of subconvulsive discharges is likely to be similarly low. Indeed, a high 
proportion of subjects in the study had normal EEG traces. For these 
reasons, the chances of the effects observed in these experiments being 
due to the influence of subconvulsive epileptic acitivity seem extremely low.
7.2.2 The Influence of Seizure Frequency on the Results
It is unlikely that seizure frequency confounded the results of this study. 
Seizures have been implicated in the causation of brain damage observed 
in epileptic patients (Dam, 1980; Dodrill, 1982; Trimble and Thompson, 
1981). Dodrill (1982) suggests that the total number of seizures must be 
quite high (around 50 or more) before changes in IQ are measureable. 
Less than 5% of the study sample reported a total of more than 50 seizures 
and none reported more than five during the periods between 
assessments.
In Experiment 1 several seizures must have occurred before treatment with 
drug therapy was considered appropriate. In the majority of patients no 
further seizures were experienced once anticonvulsant treatment was 
instituted and none had more than five. Therefore, there was some 
confounding between the effects of seizures prior to the initial assessment
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and their non-occurrence prior to the second assessment with the effects of 
the introduction of anticonvulsant medication. However, the influence of 
changes in seizure frequency would be expected to affect all epileptic 
groups, not just those subjects receiving phenytoin.
In Experiments 2 and 3, no changes in seizure frequency were observed 
during the experiments, nor were there any great differences between the 
average number of major convulsions between the epileptic groups. 
Therefore, it is unlikely seizure frequency could have influenced the results 
from these experiments. Since no change scores were used in Experiment 
4 and the mean seizure frquency was similar among all groups, it is 
unlikely that seizure frequency influenced the results.
7.2.3 The Influence of Social and Emotional Factors on the Results
Many epileptics have been reported to have psychological and social 
problems and these have often been ascribed to the effects of temporal 
lobe epilepsy (Flor-Henry, 1976; Sigal, 1976; Bear and Fedio, 1977). 
However, Rodin, Shapiro and Lennox (1977) found that more than half of 
their epileptic sample had some psychological or emotional problem and 
there is little doubt that such problems are found in patients with other 
seizure types as well. Since high levels of anxiety and depression may 
impair cognitive performance (Hamilton and Warburton, 1979) it is 
important to consider whether such effects influenced the results of this 
study.
The purpose of administering the Washington Psychosocial Seizure 
Inventory (WPSI) was to measure changes in psychosocial functioning 
which may have affected test performance. Prior to the publication of this 
assessment tool, psychosocial problems were either measured 
subjectively, or using tools which were standardised on non-epileptic 
populations (Dodrill et al, 1980). Clearly, the use of subjective assessment
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raises problems of interpretation, and the use of measures standardised for 
other clinical populations may fail to distinguish between effects of seizures 
and effects of psychosocial problems arising from seizures.
Unfortunately, the WPSI was not available at the commencement of this 
study and, therefore, was not administered to all patients. However, the 
results of those WPSI assessments which were made supported the view 
that the patients studied were relatively free of psychosocial problems. It 
was therefore unlikely that psychosocial problems materially affected the 
results of this study.
The results of Experiments 1, 2 and 3 were more susceptible to the 
effects of changes in psychosocial functioning than Experiment 4. In 
Experiment 1, patients had just been diagnosed and stronger psychosocial 
factors may have been in operation because of the implication of this 
diagnosis. However, this effect should have been distributed equally 
among the groups. In Experiment 2, subjects changing medication may 
have been motivated to change because of psychosocial problems. After 
three months, the level of psychosocial functioning could well have 
improved, either through expectancy or as a result of real life events 
producing an improvement in test performance. However, such an effect 
would be expected to operate globally on test performance rather than on 
any one specific test. Since Experiment 4 did not rely on change scores 
and it is assumed that this sample was similar to that used in Experiments 2 
and 3, psychosocial functioning should not have affected interpretation of 
the results. Once again it seems unlikely that this factor may have 
significantly affected the results.
7.2.4 The Influence of Parallel Test Administration on the Results
Multiple forms of the memory battery were designed in order to reduce 
retest effects. Great care was taken in the selection of memory test items for
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the different forms of the memory battery in order to reduce differences in 
memory test performance which could be attributed to differences in the 
items used for the memory tests. Results presented in Appendix 3.1 show 
that performances on the different forms of the memory battery were not 
statistically different under standard conditions. This is not unexpected, 
bearing in mind the low statistical power of small sample analysis and the 
variability of memory test performance, even in subjects with normal 
memory functioning. Therefore, the possibility that there may have been 
subtle differences in difficulty between the different forms of the test battery 
cannot be wholly dismissed.
Ideally, the different test batteries would have been standardised on a pool 
of epileptic subjects. Since this was not possible owing to a limited subject 
pool and time allotted for the study, counterbalancing the use of the 
different forms of the memory battery was attempted. Using this method, if 
Form A consistently produced a higher performance than Form B, then the 
differences attributable to the form of the memory battery could be balanced 
by administering Form A and Form B each to half of the subjects on the first 
assessment and vice versa on follow-up. However, this counterbalancing 
tends to increase the variance in the data which may mask small effects. A 
number of practical constraints prevented perfect counterbalancing of the 
different forms of the memory battery. It is, therefore, important to examine 
how the use of multiple forms of the memory battery in an imperfectly 
counterbalanced fashion may have influenced the results.
In Experiments 1 and 2 significant changes in memory performance were 
observed in a single epileptic group. If the form of the memory battery had 
a signifcant effect, one would have expected it to influence all groups. 
Therefore, it seems unlikely that the results of these two experiments were 
significantly influenced by either retest effects or the effects of imperfect 
counterbalancing of the memory batteries. In Experiment 3, no differences 
in performance were observed, making it difficult to see how imperfect
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counterbalancing of the memory tests might have influenced the results.
In Experiment 4, the use of parallel forms of the memory battery was 
unnecessary since patients were tested only once. The sample size for this 
experiment would have been considerably reduced if only subjects 
receiving one particular form of the memory battery had been selected for 
analysis. Subjects received different forms of the battery as a consequence 
of the methodological requirements of the other experiments. While the use 
of multiple forms of the memory battery served to maximise the subject 
pool, it may have increased variance in the data.
7.2.5 The Influence of the Memory Tests on the Results
Most of the memory tests were developed especially for this study because 
sensitive methods of assessing memory function were needed to measure 
small drug effectsand because the tests had to be repeatedly administered. 
Once testing had started, changes in test protocol would have confounded 
test change with changes in performance due to drug taking. However, 
some simple alterations had to be made and these will now be discussed.
The wordlist learning task was based on the Rey Auditory Verbal Learning 
Task. The original procedure involved a maximum of ten verbal 
presentations of the list followed by free recall or until two consecutive 
perfect free recalls were completed. There was approximately a thirty 
minute delay before another free recall followed by a recognition test. 
Ceiling effects were present in the recognition measure and present to a 
lesser exent in the delayed free recall. As a conseqence, the learning 
sequence was restricted to a maximum of five trials. While this did 
ameliorate ceiling effects in the delayed free recall measure, ceiling 
effects remained in the recognition test and this measure was effectively 
useless. This test would be improved if the level of difficulty was 
increased by either reducing the number of trials in the learning sequence
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to three or increasing the number of words in the list or introducing an 
interference list.
The tests of facial recognition could also have been improved in a number 
of ways. Faces were presented on individual cards which were handled by 
the experimenter. The test could have been much more rigorously 
controlled if the items had been presented by projectors under 
micro-computer control as was the case with some of the other tests which 
were developed after the study had commenced. This would have enabled 
the precise control of exposure to the stimulus and permited the collection 
of response latencies to individual test items. Another aspect of the 
Faces(2) test was that 'yes' or 'no' responses were recorded when 
subjects were faced with recognising whether the face came from the first, 
second or neither set of test faces. After conducting the analysis of the 
results it became apparent that the interpretation of the finding on the 
Faces(2) were hampered by the failure to collect intrusions. In addition, it 
might have been better to advise the subjects of the actual proportion of 
target faces in the recognition set in order to avoid differences in 
performance due to expectancy effects.
7.2.6 The Influence of Blood Levels of the Drugs on the Results
The results of this study have been interpreted to mean that the effects of 
the drugs are small when used within or below the therapeutic range. 
However, as can be seen in Table 7.1, the blood levels of both phenytoin 
and sodium valproate were in the low therapeutic range and the blood 
levels of carbamazepine were in the high therapeutic range throughout the 
study. It can be argued that since the blood levels of phenytoin and sodium 
valproate were low, it is not surprising that the results indicated that the 
adverse effects of these drugs were small. Carbamazepine, although 
having levels typically in the high therapeutic range, is not generally 
suspected of producing impairment of memory.
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EXPERIMENT PHENYTOIN CARBAMAZEPINE SODIUM VALPROATE
1 1.1 0.7 8.3
2 1.3 0.7
3 0.7 7.2
4 1.3 0.7 7.3
TABLE 7.1 Average blood levels for each of the drugs for each of the 
experiments.
The results of Experiments 1, 2 and 3 are influenced by the low levels of 
both phenytoin and sodium valproate in a manner which is likely to result in 
the conclusion that the effects of the drugs are small. However, Experiment 
4 is less influenced by the low levels of these drugs because of the nature 
of the correlation analysis which could have shown that memory was 
impaired at high levels of the drugs. The fact that this experiment did not 
show such effects argues that the effects of all three drugs are, indeed, 
small.
An attempt to equate levels of one drug with those of another raises 
definitional problems. However, it would be possible to do so, in principle, 
on the basis of effectiveness in controlling seizures. The fact that the 
therapeutic effectiveness of the drugs used in this study was high in all 
cases suggests that the conclusions drawn here - that the effects of the 
drugs on memory are small - may be extrapolated to that large group of 
mild epileptics for whom a single drug, administered within the therapeutic 
range, is sufficient to control seizures. It may well be, however, that the 
adverse effects of the drugs on memory (and other aspects of cognition) are 
more severe at high blood levels or when used in polytherapy.
7.3 IMPLICATIONS FOR EPILEPSY
In considering any adverse effects of the anticonvulsant drugs on cognition, 
one must bear in mind the multifactorial nature of the problem. Factors such
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as EEG abnormalities, brain damage, social and psychological problems 
and seizures all interact and may have adverse effects apart from 
anticonvulsant medication. The effects of the anticonvulsant drugs on 
cognition have been variously studied using animals such as rats and 
monkeys, non-epileptic human volunteers and epileptics. Animal 
experimentation allows the greatest degree of experimental control and the 
influence of single factors on behaviour can be precisely determined. 
Studies of epileptics allow poor control over extraneous experimental 
variables and consequently, the ability to attribute changes in behaviour to 
the effects of the drugs alone is weakest. Unfortunately, that end of the 
continuum where experimental control is best offers the poorest basis for 
generalising the results to the treatment of epilepsy. Studies of epileptics 
may prove so diffuse or unwieldy in the real world as to defy systematic 
analysis. Nonetheless, once basic theoretical work, under properly 
controlled conditions, has been completed (as is the case in the study of 
the effects of anticonvulsants on non-epileptics) there is a need to conduct 
carefully controlled studies in the clinical context.
The aim of this study was to examine the effects of phenytoin, 
carbamazepine and sodium valproate on memory function in epileptics as 
used in clinical practice. The results do not totally contradict the 
increasingly prevalent view that impaired cognition observed in many 
epileptics may be due, at least in part, to the effects of the medication rather 
than being related almost wholly to the effects of the disease. Furthermore, 
there is reasonable agreement between this study and others that 
phenytoin does have an adverse effect on memory and that 
carbamazepine does not. However, the results presented here do not 
support the generalisation from the studies of Thompson (1981) on 
non-epileptic volunteers, that the effects of the drugs on cognition may be 
quite profound. In fact, the results of this study on epileptics seem to 
suggest that the effects of the drugs are small and the adverse effects may 
be related to phenytoin's effect on folate metabolism.
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This study indicates that the effects of the drugs in impairing cognition are 
not as severe as has been previously feared. Many studies of clinical 
populations cited in the introduction suffered from important methodological 
flaws which made their interpretation difficult and which have been avoided 
or minimised in the present study. These factors include: interactions with 
other drugs; monitoring levels of the drugs; study of both medium and long 
term effects; exclusion of severe cases; EEG monitoring; monitoring of 
psychosocial factors; studying a broad range of memory functions; 
minimising the confounding influence of seizure type and seizure 
frequency; and minimising the confounding influence of repeated test 
administration. Nonetheless, the present study is far from free of 
methodological flaws particularly for want of assessing the influence of 
interictal EEG activity, imperfect counterbalancing of test forms and 
changes in medication, small sample sizes under study, high IQ's of 
subjects, deficiencies in tests selected and limitations in the interpretations 
of statistical analyses.
7.3.1 Comparison of Carbamazepine With Phenytoin
Phenytoin has been used for over forty years and is still the most frequently 
used anticonvulsant in Australia and, indeed, in many other parts of the 
world. Bearing in mind the results of workers such as Thompson (1981) 
and Marchesi (1981) and the small differences in therapeutic effectiveness 
between phenytoin and carbamazepine, the remarkable popularity of this 
drug may seem surprising. However, the results of this study suggest that 
the concerns raised by the results of these workers and expressed by 
Webster (1981) may be overemphasised. Nonetheless, carbamazepine 
may be as good, if not better, first choice of anticonvulsant for many 
previously untreated epileptics as phenytoin - a position which is not 
reflected by the current frequency of use of these two drugs.
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7.3.2 Benefits of Monotherapy and Therapeutic Ranges
One significant aspect of this study has been the finding that cognition in a 
sample of mild cases of epilepsy was relatively unimpaired when the drugs 
are used alone and within the accepted therapeutic ranges. This 
conclusion is consistent with the growing view that polytherapy should be 
avoided where possible. It may be that polytherapy is used because 
seizures are hard to control with a single drug. However, the procedure that 
has often been adopted in the past has been to add drugs to the first 
anticonvulsant that is tolerated without significant side-effect, without 
necessarily exploring the therapeutic efficacy of each anticonvulsant alone 
(Reynolds and Shorvon, 1981). The observation that memory and other 
global aspects of cognition are relatively unimpaired when the drugs are 
used alone, suggests that either the sample examined here have lower 
drug levels than have been studied in the past, or that the use of single 
medication within the therapeutic ranges may be better tolerated than 
polytherapy.
A similar argument may be used to defend the value of the currently 
accepted clinical ranges. If few relationships can be found between the 
level of the drug and memory test performance, then it can be argued that, 
when the drugs are used within the therapeutic ranges, there are few 
side-effects on cognition. While such a statement cannot be taken as 
implying that the use of therapeutic ranges should be a substitute for 
clinical judgement, it does suggest that the currently accepted therapeutic 
ranges are probably a good guide in most cases.
7.3.3 Benefits of Routine Assessments in Clinical Practice
A significant aspect of this research is that it was conducted in a clinical 
setting. Much was learned, and even more could be learned, from the 
systematic analysis of the behaviour of epileptics treated in normal clinical
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practice. This systematic analysis was achieved by the inclusion of routine 
neuropsychological examination of epileptics in the normal course of their 
treatment. Such a process not only had the benefit, at a research level, in 
enabling the identification of factors contributing to mental deterioration in 
epilepsy but also at a personal level - directly benefiting those that were 
tested. The benefits of the assessments to the epileptics themselves were: 
the identification of specific areas of intellectual weakness or impairment, 
which they could then be counselled to avoid; the demonstration of levels 
of the drugs which were too low or too high to fall within the therapeutic 
range through routine serum-level testing; the documentation of 
idiosyncratic reactions to medication, allowing better adjustments of 
medication to suit the individual; and the identification of folate levels which 
were clearly abnormal. These benefits were not relevant to the study, and 
so were not discussed in detail, but they contributed significantly to the 
value of this project for the experimenter and the neurologist, as well as 
demonstrating the value of attaching routine neuropsychological evaluation 
to the treatment of epilepsy.
7.4 FUTURE RESEARCH
7.4.1 Effects of Folate Supplements on Cognition
As noted in the previous chapter, the influence on cognition of folate 
supplements in combination with anti-epileptic drug treatment (particularly 
in relation to phenytoin) remains to be adequately explored.
The evidence presented here supports the contention by Reynolds, 
referred to earlier, that folate metabolism may well play a role in mediating 
the cognitive impairment produced by phenytoin. Phenytoin is a 
well-established and effective treatment for epilepsy, which will not be 
withdrawn from use, even though some evidence is gathering for its 
adverse effect on cognition. Many patients are unable to tolerate other
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medications, including carbamazepine, owing to adverse side-effects, and 
phenytoin is sometimes the only effective medication which is acceptable. 
In such circumstances, the control of adverse side-effects of the drug 
through the administration of a simple vitamin would be of obvious value. 
Therefore, the effects of folate on cognitive function in epileptics warrants 
further investigation especially in relation to the influence of folate 
supplements on cognition.
7.4.2 Relationship of Folate Level to Normal Memory
The observation in the cross-sectional experiment that memory 
performance correlated with folate level, regardless of the drug type, has 
several interesting implications. Either epileptic memory function is directly 
related to folate level, or normal memory function is directly related to folate 
level. Neither sodium valproate nor carbamazepine appeared to have any 
effect on folate level and yet memory performance was still correlated with 
folate levels in these groups. Is such an effect related to the subjects' 
epilepsy or is this a feature of normal memory?
The literature reviewed earlier suggested that folate deficiencies are 
related to impairments of memory. The study of folate supplements has 
failed to produce such a clear relationship, even when such supplements 
are administered to reverse folate deficiencies. Thus the possibility that 
such a simple vitamin supplements may improve normal memory function 
remains to be adequately explored.
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APPENDIX 3.1 Comparisons Between Different Forms of the
Memory Battery
The scores from forty four subjects initially administered one of the four 
forms of the final version of the memory battery were compared. The results 
are summarised in Table 3.1. Approximately half of the sample was treated 
with phenytoin and the remainder was unmedicated in any way. There 
were no significant differences between the different forms of the memory 
battery on any of the memory tests.
FORM A B C D
n 16 12 9 7
n on phenytoin 10 6 4 4
AGE 26.5 24.9 26.6 27.9
IQ 100 103 108 110
TABLE A3.1.1 Epileptics on initial administration of the memory battery 
using all different forms.
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FORM A B C D SIGNIF.
N O N V E R B A L  TESTS
FACES(1) 25.4 25.2 25.3 27.0 NS
FALSE +VE 3.63 2.50 1.50 1.86 NS
FALSE -VE 1.19 1.83 3.25 1.14 NS
TIME 1.33 1.43 1.65 1.28 NS
FACES(2) 24.6 23.7 23.2 24.8 NS
FALSE +VE 3.38 2.75 2.63 3.00 NS
FALSE -VE 2.06 3.58 4.25 2.14 NS
TIME 1.43 1.56 1.34 1.54 NS
V E R B A L TESTS
MODIFIED REY AUDITORY VERBAL LEARNING TASK
TRIAL 1 6.7 5.5 4.1 5.6 NS
TRIAL 5 12.0 11.5 10.9 12.3 NS
RECALL
TIME 0.88 0.85 0.71 1.07 NS
RECALL 9.6 8.9 9.0 11.4 NS
TIME 0.94 0.93 0.98 0.85 NS
RECOGNT'N 14.6 14.9 14.8 15.0 NS
DIGIT
SPAN 11.1 11.3 11.5 12.3 NS
WORD FINDING 16.1 11.8 15.4 15.8 NS
AV. TIME 2.29 0.38 2.48 2.54 NS
LONG-TERM MEM. 21.7 22.4 17.1 21.3 NS
AV. TIME 1.63 1.53 1.33 1.99 NS
STERNBERG*
2 IN SERIES 905 729 817 730 NS
4 IN SERIES 807 721 728 701 NS
2 IN SERIES 772 655 614 651 NS
MOTOR TESTS
INFORMATION PROCESSING
RATE* 1.68 1.43 1.41 1.58 NS
SIMPLE CHOICE REACTION
TIMES* 0.312 0.323 0.340 0.285 NS
TABLE A3.1.2 Mean performance scores of epileptics on in itia l
administration of the memory battery using all different forms. * Refers to
tests with only one form.
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APPENDIX 3.2 Summary of Tests Used But Not Analysed
3.2.1 Words(1) and Words(2)
The subject was asked to remember the words which were read out at the 
rate of approximately one word per second. This presentation was 
followed by an 'empty' delay of thirty seconds. At the end of the delay 
subjects were asked to recall as many words as possible. The time taken 
from the begining of the free recall period to the last word recalled was 
recorded. Words(1) presented a list of words whose length was adjusted to 
equal the number of words recalled by the subject on the first trial of the 
wordlist learning task. As previously, each word had been rated as 
similarly imageable, concrete and meaningful (Paivio et al 1968).
The procedure for Words(2) was similar to Words(1). However, instead of 
an empty delay of thirty seconds, another list of words was presented in the 
thirty second delay, and subjects were told to remember this list also. At the 
end of the thirty second period, subjects were asked to recall as many 
words as they could from the first list. The time from the start of the recall 
to the last word recalled was recorded. Then subjects were asked to recall 
as many words from the second list as possible. Time was recorded as 
previously.
3.2.2 Sentence Span
The use of tests of memory employing sentences as memory items is 
relatively unusual (Lezak, 1980; p359) but has a more realistic character 
than either digits or words as sentences have a more obvious relationship 
to real world memory functioning. The normal adult has an average 
sentence recall of 24 or 25 syllables (Williams, 1965). By comparing 
performance on tests of sentence span with performances using digits and 
words, the effect of meaningfulness of the material can be examined.
The sentence span of each subject was measured by the 
presentation and immediate recall of sentences which increased in length 
by four syllables at a time, starting at a minimum of eight, until the subject 
could no longer recall the entire sentence perfectly. This procedure was 
based on Ostreicher's (1973) norms for The Unrelated Sentences Test. 
The words of the sentences were taken from Thorndike and Lorge (1944) 
list of the 500 most common English words.
3.2.3 Sentences(l) and Sentences(2)
Once the span for sentences had been determined, subjects were asked 
to remember a sentence that was equal in length to their span. However, 
on this occasion, instead of an immediate recall, subjects were asked 
to wait for thirty seconds and then asked to recall the sentence. The 
number of errors was recorded.
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The procedure for Sentences(2) was similar to that used for the 
Sentences(l) test except that the thirty second delay was'filled'with a 
second sentence which the subjects were asked to recall the first 
sentence. The number of errors in each sentence was recorded.
3.2.4 Prose(1) and Prose(2)
Memory for prose, like memory for sentences, also has a naturalistic 
quality. Since it was clearly impractical to measure the span of the subject 
for the number of ideas, standard prose passages were used which 
contained more information than the subjects were likely to be able to 
recall. The procedure allowed the examination of the influence of 
meaningfulness on the memorability of the material as well as the effect of 
blocked rehearsal on the forgetting rate of prose.
The procedure used for the Prose(1) test was identical to that of the 
Words(1) test except that the items to be remembered were presented in 
the form of a news item which was similar in style and length to the prose 
passages used in the logical memory test of the Wechsler Memory Scale. 
The rules for the formation and scoring of units of ideas within each prose 
passage were the same as those used by Rubin (1978). In that study, 
subjects were asked to remember a short story which was then read out 
and followed by an 'empty' delay of thirty seconds. Subjects were then 
asked to recall as much of the story as they could, either as a story or as 
individual 'snipets' of information and the time for recall was recorded as 
previously.
The procedure for Prose(2) was similar in form to that used for Words(2). 
Subjects were asked to remember a short story which was followed by 
another story during the thirty second 'delay' This second story was also to 
be remembered. Then subjects recalled the first story and the recall time 
was recorded. Following this, subjects were asked to recall the second 
story and the time to recall this story was also recorded.
3.2.5 Position Learning Task
This task was similar to that used by Barbizet and Cany (1968) and was 
devised as a non-verbal analog of the series of word tests. Subjects were 
shown a 4" by 6" card that was subdivided into 1" squares for ten seconds. 
On this matrix were placed blue dots (approximately half an inch in 
diameter), one dot in each of seven squares. At the end of the 
presentation, subjects were given a similar card carrying an empty matrix. 
Blue colored dots were supplied and the subjects were asked to place the 
dots on the matrix to match the arrangement previously seen. If the 
placement of the dots was not correct then the subjects card was removed, 
the original matrix was presented again for a further ten seconds and a 
second attempt at recall was made. This procedure was continued until the 
recall of the position of the dots was correct on two consecutive 
presentations, or a maximum of ten attempts at recalling the positions was
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reached. After a tewnty minute delay, subjects were asked to recall the 
position of the dots on the matrix once more, to measure their delayed 
retention of the postion.
3.2.6 Position(1) and Position(2)
Position(1) involved presenting a four by six matrix card with the same 
number of dots on it as the subject had recalled correctly on the first 
recall trial of the position learning task. On this occasion, the dots were 
red in color. Subjects were shown the red dot matrix for a period of ten 
seconds which was then followed by an 'empty' thirty second delay. At the 
end of the delay, subjects were asked to recall as many of the positions on 
the matrix as possible.
The procedure for the Position(2) test was identical to that used for the 
Postition(1) test except that the 'empty' thirty second delay was filled with a 
second matrix recall memory task. Subjects were asked to recall the first 
matrix and then the second matrix.
3.2.7 Rey-Osterrieth Complex Figure Test
The Rey-Osterrieth Complex Figure Test, or Rey Figure, is a complex 
geometric figure devised by Rey (1941) for the assessment of perceptual 
organisation as well as visual memory. Like most of the other memory tests 
in the battery, this test is a complex task, but unlike most of the other tests, it 
is not readily obvious what aspects of real life memory function are 
examined by this task. Nonetheless, this test was included in the battery 
because it is does involve a variety of different intellectual functions which 
may be impaired in addition to or instead of memory. Furthermore, there is 
some normative data available and it is suitable for the examination of 
incidental memory, (something rarely tested in clinical assessments of 
memory), as well as delayed recall over a thirty minute period.
The Rey Figure was used in copy, immediate recall and delayed (thirty 
minute) recall conditions using a standard scoring procedure (Lezak, 
1980). This served as a measure of incidental memory as subjects were 
not told, when they were asked to copy the figure, that they would be asked 
to remember it.
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APPENDIX 3.3 Form A of the Memory Battery
Position Learning
r  n
o
v y
Position(1)
r  rn
\  y
\  y
/  'T 
w
v. y
if T1Py y
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Position(2)
Target Image
( y
1 0
v y V y
1  y
/  N 
v y
Distractor
S y
y y
r. S 
1  y
y y
y y
y y
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Modified Rey Auditory Verbal Learning Task
Word list A Recognition List
book glass
daffodil
flower dog
acrobat
train baby
chimney
rug button
engine
meadow hall
train
harp priest
rug
salt salt
iron
finger apple
hound
apple rattle
fisherman
chimney harp
temple
button flower
animal
key finger
lemon
dog chair
key
glass stagecoach
book
rattle mast
meadow
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Prose(1)
A women member / of the U.S. / Air Force / has been charged / with wilful 
damage / to a B52 bomber / armed with nuclear weapons. / At the time / of 
the alleged incident / on February 2nd / the bomber was parked / at Robins 
/ Air Force Base / in Georgia / in an area / guarded by men / with instuctions 
/ to shoot to kill. / The damage / to the B52 / involved the plane’s electrical / 
and hydraulic systems.
Prose(2)
Long distance / runner / Tony Rafferty / yesterday / abandoned / his 1600 
kilometre / marathon / from the eastern edge / of the Nullabor / to 
Melbourne. / Rafferty, who is 39 / called off the run / on medical advice. / He 
complained of fatigue / blisters / sore feet / and constant pain / from an 
injured knee. / He had 208 kilometres / to run / when he gave up.
Distractor prose
The Sydney / driver / Warick Brown / made Australian / motor sport / history 
/ yesterday / when he won / the fourth / and final / round / of the $112,000 / 
Rothman's series at Oran Park. / The 28 year old driver / won all four 
rounds / of the series / the first time this has been achieved / in any 
Australian / racing series. / His wins / have netted him $32,000 / in prize 
money.
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Words(1)
tea
orange
pepper
table
pencil
floor
curtain
handle
stove
Words(2)
chair
plate
box
elbow
cow
orange
toe
milk
Distractor List
knife
petal
sun
cup
tree
rain
cat
spoon
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Sentence Span
(8) They take the water from the well.
(12) She went to the table to eat her food.
(16) My brother does not like him to sleep in his room.
(20) Each week they find a pretty flower and plant it in the garden.
(24) The teacher sent the bad boy out becouse he did not want to sit down 
with the rest of the children.
(28) Every day after school we run home as fast as we can so we can read 
a story to our little sister.
(32) If I do not feel too well when I wake up in the morning I ask my mother if 
I can rest in bed until I get better.
Sentences(1)
(8) The dog swam the length of the pool.
(10) The baby built a tall tower of bricks.
(12) Most young children love to play with sand and water.
(16) The wind was so strong that three of the trees came down in the night.
(20) One thing as country needs to be rich and great is a large secure 
supply of wood.
(24) During the evening the cleaners worked very hard to have the building 
ready for the new occupants.
(28) Orchids need care and humid surroundings in order to survive a winter 
away from their normal habitat.
(32) Every afternoon the three close friends set out to explore another part 
of the mysterious forrest behind their homes.
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Sentences(2)
(8) The sun was shining all day.
Distractor - A brave man caught the wild bullock.
(10) The white house on the mountain seemed empty.
Distractor - The girl caught many fish on her first trip.
(12) The girl followed the path down the hill toward home.
Distractor - Old fruit trees may sometimes need extensive pruning.
(16) The distance between these two cities is too far to travel by car. 
Distractor - The small island in the ocean was first noticed by the young 
boy.
(20) A judge here knows the law better than all those who must appear 
before him.
Distractor - The is a new method in making steel which is far better than that 
used before.
(24) Yesterday he said he would be near the village station before it was 
time for the train to come.
Distractor - His interest in the problem increased each time he looked at the 
report which lay on the table.
(28) On my way to work in the morning I have noticed a very large number 
of pelicans feeding by the lake.
Distractor - The old buildings in the city had recently been demolished to 
make way for a new block of appartments and shops.
(32) The man went to the nearby shop to have a cup of coffee to steady his 
nerves before his important interview.
Distractor - Children growing up in the bush may not experience the sight of 
an ocean until they go to high school in the city.
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Long Term Memory
(1) What is the capital of England?
(2) What was your mother's maiden name?
(3) What is the brand name of an Australian car?
(4) Where were you born?
(5) How many letters in the alphabet?
(6) What was an address of yours when you were young?
(7) Where did one of your grandmothers live?
(8) Who were the beatles?
(9) Who is Dennis Lilley?
(10) Where were the last Olympics held?
(11 )What is the freezing point of water?
(12) Who invented the steam engine?
(13) Who was Marilyn Monroe?
(14) Who was Blinky Bill?
(15) What do the initials GMH stand for?
(16) Where is Ayres Rock?
(17) Where is the grand canyon?
(18) What was the Magic Pudding?
(19) What is a taipan?
(20) What is a eucalypt?
(21) What do you use when you play tennis?
(22) What month is Christmas in?
(23) What letter comes before'd'?
(24) Who lost WWII
(25) How old were your when you left school?
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Word Finding
What is the word that means.....
(1) Able to use the left hand as easily as the right?
(ambidextrous)
(2) Game played on a special double board with draughts and die?
(backgammon)
(3) An amphibious broad tailed soft furred rodent that builds dams?
(beaver, otter)
(4) Barrier contructed to hold back water?
(dam)
(5) Pale yellow, oval, acid juiced fruit?
(lemon)
(6) Slice of bread browned on each side?
(toast)
(7) Light vessel with sails?
(yacht, dinghy)
(8) Larvae of the butterfly or moth?
(caterpillar)
(9) Ferrous metal largely used for tools?
(iron, steel)
(10) Slaughterer of animals for food?
(butcher)
(11) Roll of solid tobacco leaf for smoking?
(cigar)
(12) Educational institution that confers degrees?
(university, college)
(13) Member of the civil force responsible for maintaining civil order?
(police, plods, coppers, etc)
(14) Small domesticated member of the feline species?
(cat)
(15) One of the groups of atoms of which substances consist?
(molecules)
(16) Inhabited storey sunk below ground level?
(basement)
(17) Class of cold blood animals?
(reptiles, fish)
(18) Cold dish of various raw or cooked vegetables?
(salad)
(19) Writer of one or more books?
(author)
(20) Two or more axled vehicle used for heavy goods?
(truck, semi-trailer, etc)
(21) Critical judge in matters of taste?
(gourmet, connoisseur)
(22) Gas existing in air essential to respiration.
(oxygen)
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(23) Ancient gun with a large bore, firing many balls?
(blunderbuss, shotgun etc)
(24) Hardest known substance?
(diamond)
(25) The absence of noise?
(silence, quiet)
Faces(1) and Faces(2) 
Example of stimulus material.
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APPENDIX 4.1 Data For Experiment 1
Data for this experiment is listed using the following format. Missing values 
are coded with nines. E = sodium valproate; T = carbamazepine; C = 
control; D = phenytoin.
Example Variable
E1 
1 d 
000 
000 
306 
26 
f
129
120
127
29
01
00
1.45
26
01
03
1.53
7
17
0.75
15
0.83
15
8 
5
1.54
0.305
20
2.86
25
1.50
744
808
640
Group code and Subject number
Serial test number and test form
Milligram dose of anticonvulsant
Blood level of anticonvulsant in milligrams percent
Red cell folate level in ng/ml
Age in years
Sex
Verbal IQ 
Performance IQ 
Full scale IQ
Total true positive and true negative score on Faces(1)
False positive score on Faces(1)
True positive score on Faces(1)
Time taken to examine test items on Faces(2)
Total true positive and true negative score on Faces(2)
False positive score on Faces(2)
True positive score on Faces(2)
Time taken to examine test items on Faces(2)
Number of words recalled on trial 1 of RAVLT 
Number of words recalled on trial 5 of RAVLT 
Time to recall trial 5
Number of words recalled after 30 minute delay 
Time for recall
Number of words recognised after 30 minute delay 
Digit span forwards 
Digit span backwards
Estimated asymptote of performance on the simultaneous 
vigilance task
Average simple choice reaction time 
Number correct on word finding test 
Average time for recall of correct items 
Number correct on long term memory test 
Average time for recall of correct items 
Average time for Sternberg test with 2 digit series 
Average time for Sternberg test with 4 digit series 
Average time for Sternberg test with 6 digit series
Post test values follow the pre test scores for each subject.
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E1 1d 000 000 306 26 f 129 120 127 29 01 00 1.45 26 01 03 1.53
7 17 0.75 15 0.83 15 8 5 1.54 0.305 20 2.86 25 1.50 
744 808 670
2c 400 4.4 302 26 f 129 120 127 27 02 01 1.37 24 01 05 9.99 
6 16 1.45 15 0.75 15 8 7 1.22 0.268 23 2.70 25 1.38 
690 662 622
E2 2b 000 000 999 47 m 107 103 105 29 00 01 1.27 27 01 02 1.28
6 16 1.55 11 1.20 15 6 4 2.03 0.389 99 9.99 99 9.99 
999 999 999
3c 800 5.1 436 47 m 107 103 105 29 01 00 1.30 24 00 06 1.33 
4 13 1.15 10 0.93 13 7 5 1.80 0.369 99 9.99 99 9.99 
999 999 999
E3 1a 000 000 250 29 m 140 132 138 29 01 00 1.05 26 01 03 1.45
8 16 0.60 15 3.65 15 6 8 1.35 0.309 99 9.99 99 9.99 
999 999 999
2b1200 6.0 287 29 m 140 132 138 27 00 03 1.05 24 02 04 1.35
4 14 0.73 15 0.50 15 8 7 1.18 0.295 99 9.99 99 9.99 
999 999 999
E4 1a 000 000 999 21 f 112 112 113 28 02 00 9.99 27 02 01 9.99
9 16 9.99 99 9.99 99 7 4 9.99 0.357 99 9.99 99 9.99 
999 999 999
2b 600 999 168 21 f 112 112 113 28 01 01 1.00 22 03 05 9.99 
3 17 0.60 14 1.70 15 9 9 9.99 0.321 99 9.99 99 9.99 
999 999 999
E5 1 a 000 000 178 20 f 107 117 112 26 03 01 0.83 24 03 03 0.92 
8 7 2.00 13 1.32 15 6 4 1.34 0.281 99 9.99 99 9.99 
999 999 999
2b1600 6.0 406 20 f 107 117 112 26 03 01 0.80 25 00 05 0.98
5 15 0.67 14 0.93 15 6 4 1.35 0.256 99 9.99 99 9.99 
999 999 999
E6 1 b 000 000 204 23 f 999 999 999 28 02 00 2.55 23 02 05 3.80
7 11 0.85 12 1.00 14 6 4 9.99 0.348 08 1.79 21 1.73 
841 629 652
2a120010.6 363 23 f 999 999 999 28 01 01 2.02 20 05 05 2.58
6 13 1.17 12 0.83 15 5 4 1.75 0.267 10 5.85 15 2.01 
815 745 601
E7 1a 000 000 112 18 f 081 099 088 23 06 01 1.72 20 06 04 1.78 
6 10 0.55 12 0.62 15 5 3 2.10 0.351 99 9.99 99 9.99 
999 999 999
2b 800 6.9 337 18 f 081 099 088 28 02 00 1.53 26 02 02 1.30
6 13 0.88 10 0.67 13 6 4 1.54 0.236 99 9.99 99 9.99 
999 999 999
E8 1 a 000 000 219 16 f 109 123 116 28 00 02 1.40 27 00 03 1.13
7 13 0.75 15 0.40 15 8 5 1.08 0.288 99 9.99 99 9.99 
999 999 999
2b1000 8.1 238 16 f 109 123 116 28 00 02 1.30 27 00 03 1.60 
7 17 0.35 15 0.52 15 6 5 0.86 0.315 99 9.99 99 9.99 
999 999 999
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E9 3c 000 000 160 41 f 100 105 105 27 00 03 1.28 23 02 05 1.15 
5 14 9.99 13 1.00 15 6 4 9.99 0.288 99 9.99 99 9.99 
999 999 999
2b1200 7.4 159 41 f 100 105 105 27 02 01 1.20 18 06 06 1.60
3 08 1.70 13 1.30 15 9 9 9.99 0.388 99 9.99 99 9.99 
999 999 999
E10 1a 000 000 275 26 f 112 135 123 26 04 00 0.80 27 00 03 0.85 
5 12 0.30 14 1.20 15 7 4 1.05 0,322 99 9.99 99 9.99 
999 999 999
2b 400 5.3 252 26 f 112 135 123 27 01 02 1.25 27 01 02 1.25 
5 11 0.25 13 0.75 15 8 5 0.91 0.278 99 9.99 99 9.99 
999 999 999
E11 4d 000 000 999 18 f 107 098 103 25 02 03 1.12 24 00 06 0.87 
9 12 0.97 12 0.85 15 7 5 2.14 0.286 99 9.99 99 9.99 
999 999 999
3 d  60015.0 190 18 f 107 098 103 25 01 04 1.30 22 01 07 1.20 
5 14 2.35 12 2.50 15 9 9 9.99 0.306 99 9.99 99 9.99 
999 999 999
E12 1a 000 000 100 18 f 107 098 103 27 01 01 9.99 22 01 07 9.99 
7 13 9.99 99 9.99 99 8 5 9.99 0.377 99 9.99 99 9.99 
999 999 999
2b200012.3 245 18 f 107 098 103 25 01 04 1.40 26 00 04 1.10
4 12 1.00 15 1.10 15 9 9 9.99 0.347 99 9.99 99 9.99 
999 999 999
E13 1a 000 000 288 37 f 121 130 127 28 01 01 0.90 26 01 03 1.20
5 12 1.10 14 2.00 15 6 5 1.90 0.324 99 9.99 99 9.99 
999 999 999
2b 200 8.0 439 37 f 121 130 127 28 01 01 1.80 24 03 03 1.20 
5 13 0.10 15 1.30 15 5 4 1.84 0.374 99 9.99 99 9.99 
999 999 999
E14 1 a 000 000 355 36 f 081 091 085 22 01 07 1.00 17 05 08 1.15 
5 08 0.60 08 0.75 14 4 4 1.57 0.323 99 9.99 99 9.99 
999 999 999
2b 80012.3 365 36 f 081 091 085 29 06 05 1.52 16 07 07 1.32 
3 12 2.00 11 1.60 15 4 4 1.47 0.304 99 9.99 99 9.99 
999 999 999
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T1 1 b 000 000 181 45 f 100 100 100 29 01 00 1.10 25 02 03 1.62
3 09 0.93 06 1.57 11 8 5 1.58 0.343 11 6.70 22 1.28 
906 908 804
2a 600 0.6 460 45 f 100 100 100 29 00 01 1.40 23 01 06 2.93
4 10 1.25 06 0.67 13 7 7 1.36 0.275 11 7.26 20 2.74 
832 635 652
T2 1a 000 000 258 24 f 110 124 117 30 00 00 0.85 28 01 01 1.00 
7 16 2.50 13 2.00 15 6 6 0.95 0.386 99 9.99 99 9.99 
999 999 999
2b 600 0.8 469 24 f 110 124 117 28 02 00 0.75 26 01 03 1.70
6 15 0.42 14 1.03 15 6 5 0.92 0.298 99 9.99 99 9.99 
999 999 999
T3 1a 000 000 146 27 f 106 112 109 28 01 02 1.15 26 01 03 1.98
7 15 0.80 13 0.87 15 6 5 1.81 0.627 99 9.99 99 9.99 
999 999 999
2b 600 0.8 265 17 f 106 112 109 26 02 02 1.22 25 03 02 1.25
8 16 0.50 11 1.00 15 6 5 1.44 0.282 99 9.99 99 9.99 
999 999 999
T4 2b 000 000 277 43 f 113 105 110 24 03 03 1.43 22 05 03 1.08
6 13 1.43 14 1.33 15 7 5 1.37 0.204 99 9.99 99 9.99 
999 999 999
1 a 800 0.8 187 43 f 113 105 110 26 03 01 1.17 21 05 04 9.99
7 16 3.75 12 0.95 14 6 4 1.96 0.541 99 9.99 99 9.99 
999 999 999
T5 1a 000 000 140 31 m 145 135 143 29 01 00 1.80 28 02 00 2.00 
7 17 0.60 09 1.30 14 9 8 1.15 0.351 99 9.99 99 9.99 
999 999 999
2b 600 102 137 31 m 145 135 143 29 00 01 2.00 29 00 01 1.25
5 14 0.40 15 0.80 15 9 9 1.14 0.340 99 9.99 99 9.99 
999 999 999
T6 1a 000 000 650 27 f 123 112 119 29 00 01 1.25 27 01 02 1.00 
7 13 1.30 14 1.00 14 9 7 1.12 0.352 99 9.99 99 9.99 
999 999 999
2b 999 999 999 27 f 123 112 119 27 01 02 0.95 24 01 05 0.90 
7 13 0.70 15 0.75 15 9 7 0.96 0.425 99 9.99 99 9.99 
999 999 999
T7 1 a 999 999 200 27 f 136 122 131 27 02 01 9.99 26 02 02 1.25
6 17 0.50 14 0.75 15 8 8 1.48 0.282 99 9.99 99 9.99 
999 999 999
2b 400 0.6 377 27 f 136 122 131 30 00 00 1.46 27 00 03 2.05
9 17 1.50 14 1.25 15 8 7 1.21 0.308 99 9.99 99 9.99 
999 999 999
T8 1 b 000 000 201 22 f 103 099 101 23 06 01 0.88 24 03 03 1.08
6 12 0.78 10 0.62 15 8 6 1.58 0.318 12 1.90 21 0.97 
944 743 755
2a 600 000 233 22 f 103 099 101 30 00 00 0.97 20 03 07 1.50
7 12 0.92 10 0.50 15 8 6 1.36 0.298 21 1.77 21 1.00 
750 594 637
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T9 1 a 000 000 322 40 f 119 118 118 21 06 01 1.60 18 07 05 1.58 
8 12 1.22 12 0.77 15 5 5 2.07 0.470 99 9.99 99 9.99 
999 999 999
2b 600 0.8 199 40 f 119 118 118 24 03 03 1.02 24 03 03 1.02
6 13 0.52 12 0.98 15 7 5 1.55 0.379 99 9.99 99 9.99 
999 999 999
T 10 1d 000 000 999 32 m 110 112 112 22 06 02 0.90 20 09 01 1.30
5 14 0.65 11 0.60 15 6 4 1.50 0.276 17 2.54 23 1.82 
737 650 873
2c 600 0.5 283 32 m 110 112 112 25 04 01 1.95 21 06 03 1.78
7 09 0.80 09 0.90 15 7 4 1.56 0.293 19 1.81 21 1.01 
690 628 510
T 11 1a 000 000 210 32 f 114 118 116 27 02 01 1.40 25 03 02 2.00
6 11 0.80 13 2.00 15 6 4 1.55 0.368 99 9.99 99 9.99 
999 999 999
2b 600 0.8 186 32 f 114 118 116 26 03 01 1.50 18 05 07 1.60 
6 13 1.75 15 1.20 15 9 9 1.50 0.316 99 9.99 99 9.99 
999 999 999
T12 1a 000 000 215 35 f 128 081 114 24 02 04 2.97 21 02 07 2.17
5 09 1.00 08 1.27 15 6 5 1.36 0.443 99 9.99 99 9.99 
999 999 999
2b 300 0.6 315 35 f 128 081 114 21 01 08 2.25 21 00 09 1.21
6 10 0.52 02 1.07 12 8 4 1.38 0.478 99 9.99 99 9.99 
999 999 999
T13 1b 000 000 364 16 f 115 116 116 26 00 04 1.30 23 02 05 1.77
8 16 0.73 12 1.08 15 7 6 1.22 0.278 22 4.99 24 1.29 
486 439 455
2a 400 0.8 297 16 f 115 116 116 27 00 03 1.12 27 00 03 1.27 
8 14 1.23 12 10.. 15 8 5 1.17 0.282 13 3.07 23 1.48 
573 500 441
T14 1 a 000 000 179 18 m 121 106 116 26 02 02 1.20 21 05 04 1.40
6 10 0.84 10 0.65 15 9 5 1.05 0.307 99 9.99 99 9.99 
999 999 999
2b 800 0.8 270 28 m 121 106 116 26 03 02 1.50 25 03 02 1.27
7 09 2.28 12 1.20 15 8 6 1.09 0.217 99 9.99 99 9.99 
999 999 999
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C1 1 a 000 000 259 48 M 133 131 134 23 06 01 1.20 21 07 02 1.60 
6 12 1.40 12 1.10 15 7 5 1.56 0.405 99 9.99 99 9.99 
999 999 999
2b 000 000 456 48 M 133 131 134 24 05 01 1.20 23 04 03 1.70 
6 17 1.35 14 1.70 15 7 4 1.45 0.336 99 9.99 99 9.99 
999 999 999
C2 1a 000 000 366 37 M 106 112 109 22 05 03 1.40 20 03 07 9.99
5 09 0.42 99 9.99 99 7 5 9.99 9.999 99 9.99 99 9.99 
999 999 999
2b 000 000 359 37 M 106 112 109 26 03 01 1.40 22 03 05 1.40
6 09 1.50 12 0.70 15 7 5 9.99 0.290 99 9.99 99 9.99 
999 999 999
C3 1a 000 000 120 44 M 135 144 141 28 00 02 1.40 28 00 02 1.75 
8 10 0.40 15 3.10 15 9 8 1.05 0.315 99 9.99 99 9.99 
999 999 999
2b 000 000 298 44 M 135 144 141 28 00 02 1.60 25 01 04 1.95
6 13 0.60 11 1.75 15 9 8 1.02 0.259 99 9.99 99 9.99 
999 999 999
C4 1 a 000 000 362 24 M 140 116 131 29 00 01 1.80 25 02 03 9.99
8 09 1.20 13 1.25 15 7 6 1.45 0.454 99 9.99 99 9.99 
999 999 999
2b 000 000 220 24 M 140 116 131 29 00 01 0.90 27 00 03 1.80
7 10 1.45 15 0.60 15 9 9 1.20 0.397 99 9.99 99 9.99 
999 999 999
C5 1a 000 000 179 17 M 118 119 119 29 00 01 0.83 23 03 04 0.83 
10 16 0.80 10 0.53 15 8 5 1.03 0.276 99 9.99 99 9.99 
999 999 999
2b 000 000 323 17 m 118 119 119 28 01 01 0.73 24 01 05 0.90
9 17 0.70 09 1.13 15 7 5 0.92 0.265 99 9.99 99 9.99 
999 999 999
C6 1a 000 000 999 35 m 125 127 125 25 04 01 1.20 23 03 04 1.40 
7 10 1.20 12 1.00 15 7 4 1.50 0.322 99 9.99 99 9.99 
999 999 999
2b 000 000 999 35 m 125 127 125 24 03 03 1.02 24 03 03 1.50
6 11 0.85 13 1.20 15 7 4 1.37 0.275 99 9.99 99 9.99 
999 999 999
C7 1 a 000 000 336 26 m 93 108 100 28 02 00 0.95 20 08 02 1.80
4 07 1.45 13 1.23 15 5 3 2.10 0.286 99 9.99 99 9.99 
999 999 999
2b 000 000 166 26 m 93 108 100 99 99 99 9.99 21 09 00 1.72
5 10 0.55 11 0.67 15 4 4 9.99 9.999 99 9.99 99 9.99 
999 999 999
C8 1 a 000 000 183 18 m 128 132 132 30 00 00 0.90 28 02 00 1.10 
9 16 1.00 15 0.30 15 8 8 9.99 0.334 99 9.99 99 9.99 
999 999 999
2b 000 000 277 18 m 128 132 132 28 02 00 1.00 28 01 01 1.00
7 16 0.50 13 0.80 15 9 9 0.98 0.349 99 9.99 99 9.99 
999 999 999
APPENDICES TO CHAPTER 4 178
C9 1 a 000 000 180 19 f 139 126 135 28 01 01 0.80 22 03 05 0.65
8 14 0.30 15 0.40 15 8 5 1.30 0.346 99 9.99 99 9.99 
999 999 999
2b 000 000 180 19 f 139 126 135 27 01 02 0.65 25 03 02 0.70 
6 17 0.30 12 0.63 15 9 5 0.96 0.282 99 9.99 99 9.99 
999 999 999
C10 1a 000 000 173 33 f 105 114 109 27 03 00 0.60 25 03 02 1.10 
6 11 0.25 12 0.90 15 6 5 1.46 0.361 99 9.99 99 9.99 
999 999 999
2b 000 000 129 33 f 105 114 109 29 01 00 0.75 25 02 03 1.35 
6 11 1.00 14 1.10 15 7 6 1.47 0.332 99 9.99 99 9.99 
999 999 999
C11 1a 000 000 179 49 f 095 112 102 27 02 01 1.60 24 04 02 1.18 
4 10 1.19 12 1.40 15 9 9 9.99 0.397 99 9.99 99 9.99 
999 999 999
2b 000 000 179 49 f 095 112 102 27 02 01 1.05 27 01 02 1.10 
3 16 0.85 13 1.10 15 9 9 9.99 0.400 99 9.99 99 9.99 
999 999 999
C12 1 a 000 000 159 26 f 132 128 127 29 01 00 1.10 28 00 02 1.50 
6 13 0.70 15 0.30 15 7 5 1.22 0.278 99 9.99 99 9.99 
999 999 999
2b 000 000 328 26 f 132 128 127 29 00 01 1.10 30 00 00 1.85
9 17 1.20 15 1.55 15 7 5 1.11 0.260 99 9.99 99 9.99 
999 999 999
C13 1a 000 000 388 25 m 107 103 105 29 00 01 1.13 28 00 02 1.13 
8 14 0.87 14 3.05 15 7 5 1.83 0.383 99 9.99 99 9.99 
999 999 999
2b 000 000 999 46 m 107 103 105 29 00 01 1.27 27 01 02 1.28
6 16 1.55 11 1.20 15 6 4 2.03 0.389 99 9.99 99 9.99 
999 999 999
C1 4 1 a 000 000 999 32 m 119 117 118 27 02 01 9.99 24 04 02 1.30
7 12 0.90 14 1.10 99 6 7 9.99 0.345 99 9.99 99 9.99 
999 999 999
2b 000 000 999 32 m 119 117 118 27 02 01 1.20 25 03 02 9.99 
6 14 0.90 12 1.10 15 6 7 9.99 0.320 99 9.99 99 9.99 
999 999 999
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D1 3c 000 000 289 44 f 093 109 100 24 06 00 1.20 29 00 02 1.83 
5 12 1.67 10 1.43 14 5 4 9.99 0.311 99 9.99 99 9.99 
999 999 999
2b 200 1.3 172 44 f 093 109 100 26 04 00 1.30 24 04 02 1.20
5 12 1.40 13 1.40 15 9 9 9.99 0.236 99 9.99 99 9.99 
999 999 999
D2 1 a 000 000 124 17 m 110 107 109 26 02 02 1.02 15 03 02 1.27 
8 14 0.87 15 0.82 15 5 3 1.53 0.383 99 9.99 99 9.99 
999 999 999
2b 300 0.8 168 17 m 110 107 109 24 04 02 1.53 25 02 03 1.65 
7 17 0.57 10 0.73 15 5 4 1.27 0.313 99 9.99 99 9.99 
999 999 999
D3 2b 000 000 300 41 f 127 120 125 27 00 03 1.50 26 02 02 1.52
6 16 0.65 09 0.58 15 8 8 1.26 0.222 99 9.99 99 9.99 
999 999 999
1 a 300 1.9 225 41 f 127 120 125 29 00 01 1.08 26 02 02 1.40 
5 10 0.62 13 0.98 15 8 7 1.23 0.304 99 9.99 99 9.99 
999 999 999
D4 2b 000 000 163 27 f 106 101 104 28 02 00 1.40 26 03 01 1.70 
5 16 0.50 15 0.85 15 9 9 9.99 0.342 99 9.99 99 9.99 
999 999 999
1a 360 2.2 282 27 f 106 101 104 27 02 01 9.99 22 02 01 9.99 
5 16 9.99 99 9.99 99 9 9 9.99 0.381 99 9.99 99 9.99 
999 999 999
D5 1a 000 000 370 22 m 128 119 126 25 05 01 1.20 27 02 01 2.15
5 12 2.10 14 2.20 15 6 5 9.99 0.257 99 9.99 99 9.99 
999 999 999
2b 360 1.0 280 22 m 128 119 126 28 02 00 1.00 25 05 01 1.25
6 14 1.20 15 2.40 15 9 9 9.99 0.249 99 9.99 99 9.99 
999 999 999
D6 1a 000 000 295 33 f 133 141 138 25 03 02 1.57 25 03 02 1.50 
5 12 0.77 14 0.92 15 8 6 0.82 0.284 99 9.99 99 9.99 
843 563 464
2b 300 0.8 351 33 f 133 141 138 15 04 01 0.92 22 03 05 1.22
3 13 1.52 13 0.75 15 7 7 0.74 0.242 99 9.99 99 9.99 
555 460 438
D7 1 a 000 000 190 39 f 094 092 093 28 02 00 2.87 22 04 04 2.72
4 12 1.62 13 2.17 14 6 3 9.99 0.348 99 9.99 99 9.99 
999 999 999
2b 200 1.1 396 39 f 094 092 093 99 99 99 9.99 21 08 01 1.83
7 17 0.92 11 1.13 15 5 5 9.99 0.265 99 9.99 99 9.99 
999 999 999
D8 1c 000 000 246 28 m 135 120 130 26 00 04 2.53 22 04 04 2.72
5 12 0.90 14 0.98 15 7 8 1.44 0.344 19 3.28 24 1.60 
683 572 692
2d 400 1.2 187 28 m 135 120 130 23 05 02 1.88 16 10 04 1.75
6 14 1.27 12 1.50 15 9 8 1.37 0.289 15 2.23 24 1.10 
520 875 931
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D9 1a 000 000 095 44 m 113 118 116 23 04 03 1.75 25 02 03 1.80 
5 07 0.40 05 0.50 07 5 4 1.80 0.537 99 9.99 99 9.99 
999 999 999
2b 260 0.9 178 44 m 113 118 116 24 03 03 1.50 24 01 05 1.35 
8 13 1.00 12 0.50 13 9 9 1.73 0.532 99 9.99 99 9.99 
999 999 999
D10 1b 000 000 201 23 f 103 106 104 29 00 01 0.90 27 02 01 1.00 
5 11 0.88 09 1.35 15 8 5 1.77 0.326 11 2.71 23 1.05 
685 504 463
2a 450 0.7 104 23 f 103 106 104 27 02 01 0.93 25 00 05 2.15
7 13 0.92 09 1.47 14 8 4 1.39 0.401 13 3.62 23 2.23 
839 801 691
D11 1a 000 000 999 36 m 099 118 108 29 01 00 9.99 24 03 03 9.99
5 12 9.99 14 9.99 15 6 5 9.99 0.238 99 9.99 99 9.99 
999 999 999
2b 300 1.1 174 36 m 099 118 108 29 00 01 0.80 19 09 02 1.20 
4 12 0.70 15 0.90 15 9 9 9.99 0.259 99 9.99 99 9.99 
999 999 999
D12 1a 000 000 036 19 f 095 093 094 28 02 00 1.30 28 01 01 1.47
8 11 0.75 08 0.75 15 5 5 1.67 0.297 09 3.58 14 2.88 
868 846 991
2b 350 0.7 188 29 f 095 093 094 27 02 01 1.28 21 04 05 2.00
6 12 0.50 08 0.50 14 5 4 1.34 0.302 08 1.06 21 2.99 
624 654 522
D13 1a 000 000 105 31 f 113 095 106 21 09 00 2.40 25 05 00 2.60 
8 13 1.78 10 2.00 15 7 5 1.82 0.368 19 3.79 23 1.30 
13251069 984
2b 300 999 999 31 f 113 095 106 24 06 00 1.45 21 05 04 2.07 
6 12 1.00 06 0.75 14 5 6 1.38 0.390 20 4.82 25 1.02 
1205 956 731
D14 1a 000 000 315 46 f 121 125 124 24 05 01 1.70 23 06 01 3.30 
6 17 2.25 13 3.80 15 6 5 1.30 0.321 99 9.99 99 9.99 
999 999 999
2b 360 0.7 258 46 f 121 125 124 28 01 01 1.25 15 11 04 3.10 
6 11 1.35 14 1.30 15 9 9 1.31 0.274 99 9.99 99 9.99 
999 999 999
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APPENDIX 4.2 Analysis of Faces(2) Test On Experiment 1
Kruskal-Wallis One Way ANOVA (Siegel, 1956).
Sum of ranks on differences between pretest and post-test for the :
Phenytoin treated group = 250.5 
Carbamazepine treated group = 484.5 
Sodium Valproate treated group = 476 
Untreated control group = 525
H = 12/56*57(250*250/14+484.5*484.5/14+476*476/14+525*525/14) 
-3(56+1)
= 33.8, df = 3
p < 0.001 using critical values of Chi Square.
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APPENDIX 5.1 Data for Experiment 2
Data for this experiment is listed using the following format. Missing values 
are coded with nines. DT = phenytoin to carbamazepine; DD = phenytoin 
control.
Example Variable
E1 
1 d 
000 
000 
306 
26 
f
129
120
127
29
01
00
1.45
26
01
03
1.53
7
17
0.75
15
0.83
15
8 
5
1.54
0.305
20
2.86
25
1.50
744
808
640
Group code and Subject number
Serial test number and test form
Milligram dose of anticonvulsant
Blood level of anticonvulsant in milligrams percent
Red cell folate level in ng/ml
Age in years
Sex
Verbal IQ 
Performance IQ 
Full scale IQ
Total true positive and true negative score on Faces(1)
False positive score on Faces(1)
True positive score on Faces(1)
Time taken to examine test items on Faces(2)
Total true positive and true negative score on Faces(2)
False positive score on Faces(2)
True positive score on Faces(2)
Time taken to examine test items on Faces(2)
Number of words recalled on trial 1 of RAVLT 
Number of words recalled on trial 5 of RAVLT 
Time to recall trial 5
Number of words recalled after 30 minute delay 
Time for recall
Number of words recognised after 30 minute delay 
Digit span forwards 
Digit span backwards
Estimated asymptote of performance on the simultaneous 
vigilance task
Average simple choice reaction time 
Number correct on word finding test 
Average time for recall of correct items 
Number correct on long term memory test 
Average time for recall of correct items 
Average time for Sternberg test with 2 digit series 
Average time for Sternberg test with 4 digit series 
Average time for Sternberg test with 6 digit series
Post test values follow the pre test scores for each subject.
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DD1 2b 400 1.3 999 27 m 081 085 082 28 00 02 1.70 28 00 02 2.10 
5 15 1.70 14 2.30 15 9 9 2.40 0.395 99 9.99 99 9.99 
999 999 999
1a 400 1.3 215 27 m 081 085 082 29 00 01 1.80 25 01 04 2.60
3 11 2.90 14 0.90 15 9 9 9.99 0.420 99 9.99 99 9.99 
999 999 999
DD2 1a 500 2.0 192 24 m 124 129 128 26 03 01 0.75 24 02 04 1.10
4 14 1.10 15 1.00 15 9 9 9.99 0.267 99 9.99 99 9.99 
999 999 999
2b 500 2.1 127 24 m 124 129 128 28 01 01 0.60 25 04 01 9.99 
7 18 1.10 14 1.10 15 9 9 0.91 0.248 99 9.99 99 9.99 
999 999 999
DD3 1a 350 1.4 123 36 m 108 117 112 27 00 03 1.20 25 00 03 1.00
5 11 2.30 08 3.80 15 9 9 2.50 0.353 99 9.99 99 9.99 
999 999 999
2b 350 1.3 277 36 m 108 117 112 25 03 02 1.80 23 04 03 2.10 
9 12 2.50 12 3.50 15 9 9 1.73 0.317 99 9.99 99 9.99 
999 999 999
DD4 1a 260 1.6 320 42 m 135 126 133 24 06 00 1.00 21 04 05 1.25
6 09 2.25 11 1.15 15 8 7 1.32 0.289 99 9.99 99 9.99 
999 999 999
2b 260 1.4 433 24 m 135 126 133 23 05 02 0.92 22 05 03 1.33
4 08 2.38 07 0.83 15 8 6 1.43 0.351 99 9.99 99 9.99 
999 999 999
DD5 1a 500 0.6 999 33 m 092 122 105 30 00 00 9.99 24 01 05 1.80
7 10 1.90 15 0.80 15 9 9 9.99 0.360 99 9.99 99 9.99 
999 999 999
2b 500 0.7 242 33 m 092 122 105 26 01 03 1.25 21 04 05 1.25 
7 12 3.20 12 2.65 15 9 9 1.23 0.360 99 9.99 99 9.99 
999 999 999
DD6 1a 300 1.1 999 32 f 115 131 123 25 04 01 9.99 23 04 03 9.99 
7 13 1.20 15 9.99 15 9.9.9.99 0.200 99 9.99 99 9.99 
999 999 999
2b 300 1.2 196 32 f 115 131 123 25 02 03 1.50 24 01 05 1.60
5 14 1.00 13 1.00 15 9 9 9.99 0.232 99 9.99 99 9.99 
999 999 999
DD7 2b 300 0.9 112 17 f 111 113 113 29 00 01 1.20 28 01 01 0.90 
7 17 0.80 13 1.60 15 9 9 1.06 0.337 99 9.99 99 9.99 
999 999 999
1a 300 1.1 158 17 f 111 113 113 29 01 00 1.30 24 01 05 1.30 
9 14 0.60 15 0.40 15 9 9 9.99 0.353 99 9.99 99 9.99 
999 999 999
DD8 1a 350 1.3 999 40 m 133 116 127 27 03 00 1.15 26 02 02 2.30 
4 16 1.20 13 1.75 15 9 9 9.99 0.231 99 9.99 99 9.99 
999 999 999
2b 350 1.3 133 40 m 133 116 127 22 07 00 1.20 23 04 03 1.75 
9 15 0.90 14 1.60 15 9 9 1.29 0.249 99 9.99 99 9.99 
999 999 999
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DD9 1 a 300 1.1 206 20 m 106 123 114 21 07 02 2.30 24 04 02 2.60 
9 16 0.95 14 1.15 15 6 5 1.65 0.277 99 9.99 99 9.99 
999 999 999
2b 300 1.1 233 20 m 106 123 114 27 02 01 2.12 26 03 01 1.65 
8 16 0.85 14 2.85 15 6 5 1.36 0.371 99 9.99 99 9.99 
999 999 999
DD101a 330 1.1 201 18 m 999 999 114 29 00 01 1.30 27 00 03 1.50
3 12 1.60 15 0.65 15 9 9 1.13 0.291 99 9.99 99 9.99 
999 999 999
2b 330 1.0 192 18 m 114 999 999 27 02 01 1.70 25 01 04 1.70
4 13 0.60 15 1.90 15 9 9 1.08 0.294 99 9.99 99 9.99 
999 999 999
DD112b 460 2.2 308 41 m 099 110 104 26 01 03 1.10 23 03 04 0.90 
6 13 0.58 14 3.40 15 9 9 1.56 0.371 99 9.99 99 9.99 
999 999 999
3c 460 2.0 300 41 m 099 110 104 26 01 03 0.93 21 08 01 0.93 
6 12 0.58 14 1.37 15 7 3 1.45 0.363 99 9.99 99 9.99 
999 999 999
DD122b 350 0.7 188 19 f 095 093 094 27 02 01 1.17 21 04 05 2.00 
6 12 0.50 08 0.50 14 5 4 1.34 0.302 08 1.06 21 2.99 
624 654 522
3c 400 0.7 243 19 f 095 093 094 28 02 00 1.47 19 04 07 1.75 
4 16 1.67 15 0.67 15 5 4 1.04 0.270 12 5.43 19 3.13 
717 673 523
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DT1 1 a 999 1.8 230 28 f 999 999 119 28 01 01 0.87 24 04 02 1.10
7 13 1.00 10 0.50 15 9 8 1.12 0.319 99 9.99 99 9.99 
999 999 999
2b 999 0.4 140 28 f 999 999 119 28 01 01 0.50 28 01 01 1.40
5 13 0.77 10 0.85 15 7 7 1.40 0.295 99 9.99 99 9.99 
999 999 999
DT2 1c 450 1.2 999 26 m 118 107 114 24 02 04 2.12 24 00 06 2.00 
3 13 1.13 05 2.38 15 6 5 1.42 0.333 19 3.34 24 1.71 
668 512 458
2d 600 0.6 480 26 m 118 107 114 30 00 00 1.55 27 00 03 1.97
8 13 2.57 07 2.05 14 7 5 1.42 0.303 16 3.34 22 2.05 
715 713 559
DT3 4b 400 1.6 214 23 m 122 100 114 27 01 02 0.85 27 00 03 0.95
6 06 0.80 12 1.28 15 9 5 1.43 0.270 21 1.92 24 0.73 
893 888 817
5a 600 0.6 452 23 m 122 100 114 28 00 02 0.75 26 00 04 0.95 
6 16 0.37 15 0.40 15 7 6 1.42 9.999 21 1.10 25 0.82 
603 713 576
DT4 2a 350 1.3 254 19 f 081 098 088 28 01 01 1.27 23 03 04 1.15
5 12 0.95 10 0.65 15 6 5 9.99 0.317 0911.49 12 3.37 
770 663 644
3c 600 0.5 405 19 f 081 098 088 23 02 05 1.50 22 01 07 1.80
6 14 0.45 11 0.80 15 5 4 1.42 0.371 08 7.23 15 3.09 
950 947 757
DT5 4d 350 1.3 999 40 m 133 116 127 27 02 01 1.12 26 03 01 1.43 
10 17 0.37 15 0.68 15 8 6 1.19 0.289 15 1.34 22 0.82 
525 532 552
5c 600 0.6 999 40 m 133 116 127 29 01 00 1.13 24 05 01 1.37
7 17 0.87 14 1.03 15 8 5 1.20 0.339 20 1.15 25 0.66 
684 667 547
DT6 4d 300 0.8 420 40 f 119 118 118 99 99 99 9.99 21 06 03 1.30
5 14 0.72 13 0.82 15 7 6 9.99 9.999 99 9.99 99 9.99 
999 999 999
2b 600 0.8 199 40 f 119 118 118 24 03 03 102 24 03 03 0.98
6 11 0.52 12 0.98 15 7 5 1.53 9.999 99 9.99 99 9.99 
999 999 999
DT7 1a 360 2.0 231 28 m 113 120 116 27 03 00 1.40 26 02 02 1.20
6 10 3.50 10 1.70 15 9 9 9.99 0.312 99 9.99 99 9.99 
999 999 999
2c 600 0.8 155 38 m 113 120 116 28 02 00 1.52 24 01 05 1.48
8 12 0.70 13 2.95 15 7 3 0.93 0.271 99 9.99 99 9.99 
999 999 999
DT8 1a 190 0.9 260 30 m 999 999 130 28 02 00 0.70 27 00 03 0.70
7 16 0.60 11 0.90 14 9 9 9.99 0.275 99 9.99 99 9.99 
999 999 999
2b 600 0.7 399 30 m 999 999 130 30 00 00 0.85 28 00 02 1.10 
6 15 1.22 14 1.60 14 9 9 9.99 0.265 99 9.99 99 9.99 
999 999 999
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DT9 1 a 400 0.5 173 21 f 999 999 106 28 01 01 1.28 23 04 03 1.50 
9 13 1.90 13 2.28 14 8 7 1.19 0.629 99 9.99 99 9.99 
999 999 999
2d 999 9.9 118 21 f 999 999 106 28 01 01 1.28 27 02 01 1.57
5 15 0.87 14 1.72 15 9 7 1.23 0.551 99 9.99 99 9.99 
999 999 999
DT101 a 360 1.6 127 39 f 999 999 098 26 03 01 0.98 27 08 05 1.78
6 12 0.73 15 0.68 15 7 5 2.50 0.393 99 9.99 99 9.99 
999 999 999
2b 600 0.7 320 39 f 999 999 098 24 05 01 1.40 25 03 02 2.15
5 11 1.37 12 0.97 15 8 5 2.50 0.445 99 9.99 99 9.99 
999 999 999
DT111 a 400 1.4 999 47 m 999 999 130 26 03 01 9.99 23 07 00 9.99
6 09 9.99 99 9.99 99 9 6 1.40 9.999 99 9.99 99 9.99 
999 999 999
2b 200 0.5 668 47 m 999 999 130 28 02 00 0.88 27 02 01 0.90
5 14 1.48 11 0.87 15 8 4 1.37 0.333 19 2.13 24 1.13 
9.3 848 789
DT121 a 999 0.7 399 29 f 999 999 121 30 00 00 0.77 25 01 04 1.02
6 13 0.62 08 0.82 14 8 7 1.23 0.483 99 9.99 99 9.99 
999 999 999
2b 800 0.9 380 29 f 999 999 121 28 00 02 0.92 26 00 04 1.05 
4 10 0.72 13 0.97 15 9 8 0.95 0.329 99 9.99 99 9.99 
999 999 999
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APPENDIX 5.2 Data for Experiment 3
Data for this experiment is listed using the following format. Missing values 
are coded with nines. TE = carbamazepine to sodium valproate; TT = 
carbamazepine control.
Example Variable
E1 
1 d 
000 
000 
306 
26 
f
129
120
127
29
01
00
1.45
26
01
03
1.53
7
17
0.75
15
0.83
15
8 
5
1.54
0.305
20
2.86
25
1.50
744
808
640
Group code and Subject number
Serial test number and test form
Milligram dose of anticonvulsant
Blood level of anticonvulsant in milligrams percent
Red cell folate level in ng/ml
Age in years
Sex
Verbal IQ 
Performance IQ 
Full scale IQ
Total true positive and true negative score on Faces(1)
False positive score on Faces(1)
True positive score on Faces(1)
Time taken to examine test items on Faces(2)
Total true positive and true negative score on Faces(2)
False positive score on Faces(2)
True positive score on Faces(2)
Time taken to examine test items on Faces(2)
Number of words recalled on trial 1 of RAVLT 
Number of words recalled on trial 5 of RAVLT 
Time to recall trial 5
Number of words recalled after 30 minute delay 
Time for recall
Number of words recognised after 30 minute delay 
Digit span forwards 
Digit span backwards
Estimated asymptote of performance on the simultaneous 
vigilance task
Average simple choice reaction time 
Number correct on word finding test 
Average time for recall of correct items 
Number correct on long term memory test 
Average time for recall of correct items 
Average time for Sternberg test with 2 digit series 
Average time for Sternberg test with 4 digit series 
Average time for Sternberg test with 6 digit series
Post test values follow the pre test scores for each subject.
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TT1 3c 600 0.7 379 17 f 106 112 109 27 01 02 1.27 26 01 03 1.17 
6 14 1.30 12 0.83 15 5 5 1.05 0.332 99 9.99 99 9.99 
999 999 999
2b 600 0.8 265 17 f 106 112 109 26 02 02 1.22 25 03 02 1.25 
8 16 0.50 11 1.00 15 6 5 1.44 0.282 99 9.99 99 9.99 
999 999 999
TT2 2b 600 0.7 399 30 m 136 123 132 30 00 00 0.85 28 00 02 1.10
6 15 1.22 14 1.60 14 9 9 9.99 0.265 99 9.99 99 9.99 
999 999 999
3c 600 0.5 350 30 m 136 123 132 27 01 02 0.85 25 01 04 1.10
7 11 1.03 14 1.22 15 8 5 9.99 0.259 99 9.99 99 9.99 
999 999 999
TT3 4d 600 0.6 266 31 m 145 135 143 30 00 00 1.55 27 01 02 2.00
8 15 1.23 10 0.80 15 9 8 1.18 0.266 99 9.99 99 9.99 
999 999 999
3c 600 0.6 100 31 m 145 135 143 27 02 01 1.75 26 00 04 1.82 
7 11 0.90 14 1.15 15 9 8 1.10 0.291 99 9.99 99 9.99 
999 999 999
TT4 1a 600 0.6 192 18 m 128 127 129 28 02 00 1.13 16 10 04 1.80 
6 12 1.27 12 0.52 15 9 5 1.29 0.265 99 9.99 99 9.99 
999 999 999
2b 500 0.6 255 18 m 128 127 129 24 04 02 1.13 26 02 02 1.22
6 16 1.20 11 1.23 15 9 5 0.93 0.232 99 9.99 99 9.99 
999 999 999
TT5 3 d  000 0.9 633 29 f 123 115 121 24 01 05 1.00 27 01 02 0.80
7 17 1.72 04 0.75 15 9 7 1.08 0.264 99 9.99 99 9.99 
999 999 999
2b 800 0.9 380 29 f 123 115 121 28 00 02 0.92 26 00 04 1.05
4 10 1.43 13 0.97 15 9 8 0.96 0.329 99 9.99 99 9.99 
999 999 999
TT6 2c 400 0.6 131 34 m 133 118 128 28 01 01 1.27 22 05 03 1.73 
7 14 1.12 13 0.88 15 8 8 1.12 0.276 99 9.99 99 9.99 
999 999 999
3b 800 0.4 414 34 m 133 118 128 29 00 01 1.33 26 00 04 1.95
7 13 0.95 08 0.40 14 8 7 0.97 0.270 99 9.99 99 9.99 
999 999 999
TT7 2b 600 0.3 320 33 f 106 103 098 24 05 01 1.40 25 03 02 2.15
5 12 1.37 12 0.97 15 8 5 2.50 0.445 99 9.99 99 9.99 
999 999 999
3 d  000 0.7 234 33 f 106 103 098 28 02 00 1.65 26 01 03 2.17
5 10 0.50 07 0.75 14 7 5 2.50 0.346 99 9.99 99 9.99 
999 999 999
TT8 3c 600 0.6 300 52 m 091 099 094 19 07 04 4.07 15 10 05 5.05
6 14 2.13 15 0.95 15 5 3 2.50 0.428 99 9.99 99 9.99 
999 999 999
2b 600 0.9 264 52 m 091 099 094 27 03 00 2.27 18 09 03 5.80
8 12 3.20 14 3.80 14 9 9 2.50 0.458 99 9.99 99 9.99 
999 999 999
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TT9 1a 600 0.7 313 23 f 111 111 110 26 04 00 1.12 26 03 01 1.28 
7 16 0.63 13 0.42 15 6 5 1.20 0.258 99 9.99 99 9.99 
999 999 999
2b 600 0.5 317 23 f 111 111 110 28 02 00 1.23 23 05 02 1.28 
9 14 1.35 15 0.72 15 6 5 0.94 0.260 99 9.99 99 9.99 
999 999 999
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TE1 3c 600 0.4 314 16 f 109 123 116 27 01 02 1.15 25 00 05 1.23 
7 17 0.47 12 0.65 15 5 5 0.95 0.277 99 9.99 99 9.99 
999 999 999
2b1000 8.1 237 26 f 109 123 116 28 00 02 1.30 27 00 03 1.20
7 17 0.35 15 0.52 15 5 5 0.98 0.315 99 9.99 99 9.99 
999 999 999
TE2 3c 500 9.9 100 51 f 124 133 129 27 00 03 2.15 22 02 06 2.42
8 13 0.50 13 2.00 15 7 5 1.60 9.999 99 9.99 99 9.99 
999 999 999
2b 400 4.1 210 51 f 124 133 129 29 00 01 2.25 21 03 06 2.50 
4 11 1.60 14 4.00 15 9 9 1.55 0.330 99 9.99 99 9.99 
999 999 999
TE3 2b 8000 0.8 270 18 m 121 106 116 26 01 03 1,50 25 03 02 1.27 
7 09 2.28 12 1.20 15 8 6 1.09 0.257 99 9.99 99 9.99 
999 999 999
3c 800 6.2 276 18 m 121 106 116 20 04 06 1.10 22 02 06 1.03
6 12 1.85 13 1.10 15 9 6 1.08 0.286 99 9.99 99 9.99 
999 999 999
TE4d4 999 0.8 055 34 f 101 107 104 27 00 03 1.25 17 06 07 1.33
7 16 1.00 15 1.05 15 7 6 1.08 0.260 99 9.99 99 9.99 
999 999 999
e5 999 4.5 999 34 f 101 107 104 25 01 04 1.19 20 04 06 1.70
4 14 0.55 15 1.07 15 7 4 0.95 0.268 99 9.99 99 9.99 
999 999 999
TE5 2b 999 0.4 140 38 f 118 119 118 28 01 01 0.83 28 01 01 1.40
5 13 0.47 13 0.85 14 9 7 1.25 0.295 99 9.99 99 9.99 
999 999 999
3c 999 7.4 640 38 f 118 119 118 25 02 03 0.95 23 03 05 9.99
9 13 2.50 15 1.12 15 9 7 1.10 0.314 99 9.99 99 9.99 
999 999 999
TE6 2b 600 0.8 199 40 f 119 118 119 24 03 03 1.02 24 03 03 0.98
6 13 0.52 12 0.98 15 7 5 1.53 0.379 99 9.99 99 9.99 
999 999 999
3 d  200 8.6 257 40 f 119 118 119 26 01 03 1.25 18 06 06 1.58
6 11 1.10 13 1.67 15 6 5 1.36 0.428 99 9.99 99 9.99 
999 999 999
TE7 4d 400 0.3 290 19 f 119 132 126 99 99 99 9.99 23 03 04 1.10 
9 18 0.82 13 0.88 15 5 5 1.07 0.298 99 9.99 99 9.99 
999 999 999
5d 800 9.8 234 29 f 119 132 126 99 99 99 9.99 29 00 01 1.11
7 18 0.77 13 1.11 15 5 5 0.93 0.258 99 9.99 99 9.99 
999 999 999
TE8 2b 200 0.7 684 22 m 119 103 113 25 03 02 1.40 26 00 04 2.40
8 12 1.57 13 0.82 14 6 4 2.00 0.238 99 9.99 99 9.99 
999 999 999
4c1200 8.9 178 22 m 119 103 113 27 01 02 0.92 27 00 03 1.07 
7 14 0.57 10 0.33 14 9 7 1.24 0.305 99 9.99 99 9.99 
999 999 999
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TE9 1a 600 0.9 999 28 m 134 127 130 27 02 01 9.99 25 03 02 1.70
6 15 1.67 15 1.00 15 9 9 1.07 0.349 99 9.99 99 9.99 
999 999 999
2b2400 7.3 279 28 m 134 127 130 26 02 02 1.80 26 02 02 1.80
7 16 0.40 13 1.60 15 9 9 1.11 0.353 99 9.99 99 9.99 
999 999 999
APPENDICES TO CHAPTER 5 192
APPENDIX 5.3 Analysis of Faces(2) test on Experiment 2
Kruskal-Wallis One Way ANOVA (Siegel, 1956).
Sum of ranks on differences between pretest and 
post-test in Experiment 2 for the :
Phenytoin treated group = 109 
Phenytoin and Carbamazepine treated group = 191
H = 12/24*25(109*109/12+191*191/12) - 3(24+1)
= 5.6, df = 1
p < 0.02 using critical values of Chi Square.
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APPENDIX 6.1 Data for Experiment 4
Data for this experiment is listed using the following format. Missing values 
are coded with nines. E = sodium valproate; T = carbamazepine; D = 
phenytoin.
Example Variable
E1 
1 d 
000 
000 
306 
26 
f
129
120
127
29
01
00
1.45
26
01
03
1.53
7
17
0.75
15
0.83
15
8 
5
1.54
0.305
20
2.86
25
1.50
744
808
640
Group code and Subject number
Serial test number and test form
Milligram dose of anticonvulsant
Blood level of anticonvulsant in milligrams percent
Red cell folate level in ng/ml
Age in years
Sex
Verbal IQ 
Performance IQ 
Full scale IQ
Total true positive and true negative score on Faces(1)
False positive score on Faces(1)
True positive score on Faces(1)
Time taken to examine test items on Faces(2)
Total true positive and true negative score on Faces(2)
False positive score on Faces(2)
True positive score on Faces(2)
Time taken to examine test items on Faces(2)
Number of words recalled on trial 1 of RAVLT 
Number of words recalled on trial 5 of RAVLT 
Time to recall trial 5
Number of words recalled after 30 minute delay 
Time for recall
Number of words recognised after 30 minute delay 
Digit span forwards 
Digit span backwards
Estimated asymptote of performance on the simultaneous 
vigilance task
Average simple choice reaction time 
Number correct on word finding test 
Average time for recall of correct items 
Number correct on long term memory test 
Average time for recall of correct items 
Average time for Sternberg test with 2 digit series 
Average time for Sternberg test with 4 digit series 
Average time for Sternberg test with 6 digit series
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D1 1a 300 0.2 384 38 m 119 112 117 25 05 00 1.02 28 00 02 1.08 
5 15 9.99 11 1.18 15 8 4 2.50 0.316 16 2.04 24 0.88 
715 750 660
D2 2b 200 1.3 172 44 f 093 109 100 26 04 00 1.30 24 04 02 1.20 
5 12 1.40 13 1.40 15 0 0 9.99 0.345 99 9.99 99 9.99 
999 999 999
D3 2b 300 0.8 168 17 M 110 107 109 24 04 02 1.53 25 02 03 1.65 
7 17 1.57 10 0.73 15 5 4 1.27 0.313 99 9.99 99 9.99 
999 999 999
D4 1a 400 0.5 173 21 f 107 103 106 28 01 01 1.28 23 04 03 1.50 
9 13 9.99 13 2.28 14 9 7 1.18 0.629 99 9.99 99 9.99 
999 999 999
D5 1a 300 1.9 225 41 f 127 120 125 29 00 01 1.08 26 02 02 1.40
5 11 0.62 13 0.98 15 8 7 1.23 0.304 99 9.99 99 9.99 
999 999 999
D6 1a 360 2.0 231 37 m 113 120 116 27 03 00 1.40 26 02 02 1.20
6 10 3.50 10 1.70 15 0 0 0.97 0.273 99 9.99 99 9.99 
999 999 999
D7 1 a 450 2.0 999 48 m 133 131 134 22 05 03 9.99 16 07 07 9.99
7 12 9.99 12 9.99 99 0 0 9.99 9.999 99 9.99 99 9.99 
999 999 999
D8 1a 360 2.0 282 27 f 106 101 104 27 02 01 9.99 22 07 01 9.99 
9 16 9.99 99 9.99 99 0 0 9.99 0.381 99 9.99 99 9.99 
999 999 999
D9 1 a 190 0.9 999 30 m 136 123 132 28 02 00 0.70 27 00 03 0.70
7 16 0.60 11 0.90 14 0 0 9.99 0.275 99 9.99 99 9.99 
999 999 999
D10 1 a 360 1.6 127 33 f 106 103 098 26 03 01 0.98 17 08 05 1.78 
6 12 0.73 15 0.68 15 7 5 2.50 0.393 99 9.99 99 9.99 
999 999 999
D11 2b 360 1.0 280 22 m 128 119 126 28 02 00 1.00 25 05 00 1.25 
6 14 1.20 15 2.40 15 0 0 9.99 0.213 99 9.99 99 9.99 
999 999 999
D12 2b 330 0.8 253 27 f 124 115 121 30 00 00 0.97 23 03 04 1.48 
9 16 0.22 15 0.98 15 9 7 0.96 0.269 99 9.99 99 9.99 
999 999 999
D13 1a 260 1.3 274 17 f 103 108 106 25 00 05 1.50 28 00 02 1.20
8 17 0.58 14 1.37 15 8 5 1.65 0.438 10 3.01 12 1.03 
943 777 505
D14 1a 400 1.3 215 29 m 081 085 082 29 00 01 1.80 25 01 04 2.60 
3 11 2.90 14 0.90 15 6 3 9.99 0.420 99 9.99 99 9.99 
999 999 999
D15 1a 360 0.4 999 16 m 104 099 102 28 01 01 1.02 26 01 03 1.00 
8 13 0.75 12 0.55 14 8 7 1.72 0.286 99 9.99 99 9.99 
999 999 999
D15 4d 350 2.0 152 22 m 119 103 113 28 00 02 0.88 25 00 05 1.00 
6 10 0.40 06 0.33 13 9 7 1.24 0.286 13 1.02 22 1.09 
506 485 429
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D17 1 a 500 2.0 999 24 m 124 129 128 26 03 01 0.75 24 02 04 1.10
4 14 1.10 15 1.00 15 6 5 0.80 0.267 99 9.99 99 9.99 
999 999 999
D18 1a 350 1.4 123 36 m 108 117 112 27 00 03 1.00 25 02 03 1.20
5 11 2.30 08 3.80 15 8 5 2.20 0.353 99 9.99 99 9.99 
999 999 999
D19 1a 300 0.5 999 40 f 128 139 135 30 00 00 1.20 25 02 03 1.20
6 16 1.30 15 0.80 15 7 4 1.02 0.301 99 9.99 99 9.99 
999 999 999
D20 1 a 360 1.1 999 53 f 105 110 108 27 01 02 1.70 24 02 04 2.02
7 13 1.43 13 2.30 15 6 5 1.34 0.363 99 9.99 99 9.99 
999 999 999
D21 1a 300 1.5 234 39 m 098 103 100 27 02 01 1.22 23 03 04 1.20 
3 09 0.57 10 0.58 14 6 6 3.50 0.325 99 9.99 99 9.99 
999 999 999
D22 1a 450 1.2 999 26 m 118 107 114 24 02 04 2.12 24 00 06 2.00 
3 13 1.15 05 2.38 15 6 5 1.34 0.332 19 3.34 24 1.71 
668 512 358
D23 1 a 300 0.5 999 23 m 122 100 114 27 03 00 9.99 29 01 00 9.99
8 14 9.99 15 9.99 15 0 0 9.99 9.999 99 9.99 99 9.99 
999 999 999
D24 1a 460 1.4 999 47 m 132 126 130 26 03 01 9.99 23 07 00 9.99
6 99 9.99 09 9.99 99 9 6 9.99 9.999 99 9.99 99 9.99 
999 999 999
D25 1 a 400 1.3 387 20 f 111 117 115 28 02 00 0.73 30 00 00 0.32
7 13 0.68 15 0.77 15 7 6 1.06 0.388 99 9.99 99 9.99 
999 999 999
D26 1 a 360 0.7 399 29 f 123 115 121 30 00 00 0.77 25 01 04 1.02
6 99 0.62 08 0.81 14 8 7 1.21 0.483 99 9.99 99 9.99 
999 999 999
D27 1a 500 0.6 999 33 m 092 122 105 30 00 00 9.99 24 01 05 0.80
7 12 1.90 15 0.80 15 6 4 1.23 0.360 99 9.99 99 9.99 
999 999 999
D28 2b 400 1.2 187 28 m 135 120 130 23 05 02 1.88 16 10 04 1.75 
6 14 1.26 12 1.50 15 9 8 1.37 0.189 15 2.21 24 1.10 
999 999 999
D29 2b 300 0.9 200 16 f 117 119 119 27 03 00 1.05 21 04 05 1.4
9 14 0.40 14 0.90 15 8 4 1.05 0.357 99 9.99 99 9.99 
999 999 999
D30 2b 260 0.9 178 44 m 113 118 116 24 03 03 1.50 24 01 05 1.35
8 13 1.00 13 0.50 14 0 0 1.53 0.486 99 9.99 99 9.99 
999 999 999
D31 1a 300 2.4 166 24 m 104 091 099 46 02 02 0.55 28 00 02 1.25 
6 11 1.03 06 1.43 14 6 3 1.84 0.374 16 4.32 25 1.83 
993 959 919
D32 1 a 400 1.5 254 29 f 103 017 015 34 02 05 1.40 21 02 05 1.40 
8 14 1.40 15 1.50 15 9 7 0.92 0.311 99 9.99 99 9.99 
999 999 999
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D33 2b 300 1.1 233 20 m 106 123 114 27 02 01 2.12 26 03 10 0.65
8 16 0.85 14 2.85 15 6 5 1.36 0.371 99 9.99 99 9.99 
999 999 999
D34 1a 360 1.8 230 38 f 118 118 119 28 01 01 0.87 24 04 02 1.10 
7 13 1.00 01 0.50 15 0 0 1.12 1.419 99 9.99 99 9.99 
999 999 999
D35 1a 300 1.1 206 20 m 106 123 114 21 07 02 2.30 24 04 02 2.60
9 16 0.95 14 1.15 15 6 5 1.65 0.277 99 9.99 99 9.99 
999 999 999
D36 1 a 400 2.4 407 34 m 133 118 128 17 02 01 1.50 26 02 02 1.80
6 14 0.77 10 0.70 15 8 8 1.18 0.281 20 1.83 24 1.22 
999 999 999
D37 1 a 200 1.4 306 26 f 089 098 093 27 02 01 1.18 26 02 02 1.53 
3 09 0.51 09 0.92 10 6 4 1.74 0.282 13 1.93 18 1.49 
999 999 999
D38 1a 300 1.1 999 32 f 115 131 123 25 03 01 9.99 23 04 03 9.99
7 13 1.20 15 9.99 15 0 0 9.99 0.299 99 9.99 99 9.99 
999 999 999
D39 1a 300 0.9 112 16 f 111 113 113 29 01 00 1.30 24 01 05 1.3 
9 14 0.60 15 0.30 15 6 6 1.15 1.353 99 9.99 99 9.99 
999 999 999
D40 1 a 250 1.3 200 40 f 094 104 098 26 02 02 1.30 24 01 05 2.60 
3 13 1.90 13 0.55 15 0 0 1.15 0.342 99 9.99 99 9.99 
999 999 999
D41 1 a 460 9.9 089 21 f 099 083 093 28 00 02 1.17 27 02 01 1.03
5 17 0.72 14 0.62 15 5 4 1.45 0.284 15 0.78 23 1.34 
999 999 999
D42 1 a 330 1.1 201 18 m 109 120 114 29 00 01 1.30 27 00 03 1.50
3 12 1.60 15 0.65 15 6 5 9.99 1.291 99 9.99 99 9.99 
999 999 999
D43 2b 300 1.1 174 36 m 099 118 108 29 00 01 0.80 19 09 02 1.20
4 12 0.70 15 0.90 15 0 0 9.99 0.259 99 9.99 99 9.99 
999 999 999
D44 1 a 300 9.9 198 29 f 119 132 126 29 00 01 1.20 24 01 05 9.99
6 16 1.40 12 1.25 15 5 5 1.47 0.354 99 9.99 99 9.99 
999 999 999
D45 1a 300 1.6 177 27 f 105 107 106 29 01 00 0.40 23 01 06 0.10
6 13 0.40 14 1.10 15 0 0 9.99 1.312 99 9.99 99 9.99 
999 999 999
D46 1 a 350 1.6 141 24 f 085 073 079 25 01 04 2.82 27 02 01 2.35
5 12 1.00 09 1.15 13 5 3 2.16 9.999 11 4.29 24 3.44 
999 999 999
D47 1 a 300 0.5 232 17 f 122 108 117 28 01 01 0.74 26 02 02 0.65
8 17 0.38 14 0.72 15 6 5 1.07 0.264 22 0.85 24 1.09 
727 676 584
D48 1 a 300 0.7 340 35 M 113 106 111 29 00 01 1.68 26 02 02 1.02
7 11 1.13 11 0.62 15 7 5 1.40 0.343 99 9.99 99 9.99 
999 999 999
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D49 1 a 360 1.9 206 41 M 099 110 104 18 05 07 1.50 27 03 00 1.00 
6 12 9.99 12 0.80 15 5 5 1.60 0.332 99 9.99 99 9.99 
999 999 999
D50 1a 300 0.8 149 24 M 113 100 109 28 00 02 1.40 28 01 01 1.80 
5 13 1.43 11 0.47 15 9 5 2.13 0.281 14 1.76 22 2.44 
577 511 581
D51 1a 250 1.1 999 27 F 118 117 117 22 07 01 2.10 20 08 02 3.90 
5 09 2.10 11 2.00 15 9 5 1.40 0.469 99 9.99 99 9.99 
999 999 999
D52 1 a 330 1.4 295 27 M 999 999 116 28 01 01 1.50 26 00 04 2.60 
5 13 0.55 15 0.95 15 0 0 9.99 0.327 99 9.99 99 9.99 
999 999 999
D53 1a 350 1.3 999 39 m 133 116 127 27 03 00 1.15 26 02 02 2.30
4 16 1.20 13 1.75 15 8 7 9.99 0.231 99 9.99 99 9.99 
999 999 999
D54 1a 330 0.8 999 25 f 110 101 106 24 04 02 1.70 22 06 02 1.50
5 10 0.83 09 0.98 15 7 7 1.56 0.294 12 3.32 24 1.49 
759 662 625
D55 1a 999 0.9 999 27 f 119 124 122 27 03 00 2.00 26 04 00 1.65 
4 14 2.25 12 1.55 15 6 5 9.99 0.322 99 9.99 99 9.99 
999 999 999
D56 2b 360 0.7 258 46 f 121 125 124 28 01 01 1.15 15 11 04 3.10
6 11 1.35 14 4.30 15 0 0 1.31 0.273 99 9.99 99 9.99 
999 999 999
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T1 2b 600 0.8 469 24 f 110 124 117 30 00 00 0.85 27 01 01 1.00
7 16 2.50 13 2.00 15 6 6 0.95 0.384 99 9.99 99 9.99 
999 999 999
T2 3c 600 0.8 155 38 m 113 120 116 28 02 00 1.52 24 01 05 1.68
8 12 0.70 13 2.95 15 7 3 0.94 0.224 99 9.99 99 9.99 
999 999 999
T3 2b 600 0.8 265 17 f 106 112 109 26 02 02 1.22 25 03 02 1.25 
8 16 0.50 11 1.00 15 6 5 1.37 0.181 99 9.99 99 9.99 
999 999 999
T4 2b 600 0.7 399 30 m 136 123 132 30 00 00 0.85 28 00 02 2.00 
6 15 0.45 14 1.60 14 0 0 9.99 0.265 99 9.99 99 9.99 
999 999 999
T5 2b 600 0.3 320 33 f 106 098 103 26 03 01 0.98 17 18 15 1.78
6 12 0.73 15 0.68 15 7 5 2.50 0.373 99 9.99 99 9.99 
999 999 999
T6 2b 600 1.2 137 31 m 145 135 143 29 00 01 2.00 29 00 01 1.25
5 14 0.40 15 0.60 15 0 0 1.10 0.340 99 9.99 99 9.99 
999 999 999
T7 1a 800 0.8 187 43 f 113 105 110 26 03 01 1.17 21 05 04 9.99
7 16 3.75 12 0.95 14 6 4 1.78 0.541 99 9.99 99 9.99 
999 999 999
T8 2b 600 9.9 999 27 f 123 112 119 27 01 02 0.95 24 01 05 0.90
8 13 0.70 15 0.75 15 9 7 0.96 0.581 99 9.99 99 9.99 
999 999 999
T9 2b 400 0.2 349 17 m 104 109 107 29 01 00 1.08 29 00 01 1.12
6 13 0.80 10 0.62 15 7 4 1.33 0.294 15 2.09 21 1.39 
935 857 749
T10 1 a 600 0.8 192 18 m 128 127 129 28 02 00 1.13 16 10 04 1.80 
6 12 1.27 12 0.52 15 9 5 1.29 0.165 99 9.99 99 9.99 
999 999 999
T11 2b 600 1.2 513 53 f 105 110 108 22 03 05 1.95 24 04 02 1.97 
6 11 1.07 11 2.25 14 7 5 0.94 0.347 99 9.99 99 9.99 
999 999 999
T12 2b 400 0.6 377 27 f 136 122 131 30 00 00 1.47 27 00 03 2.05
9 17 1.30 14 1.25 15 8 7 1.22 0.308 22 3.97 25 0.95 
657 573 450
T13 2d 600 0.6 480 26 f 118 107 114 30 00 00 1.55 27 00 03 1.97 
8 13 2.57 07 2.05 14 7 5 1.40 0.302 16 3.34 22 2.05 
715 713 559
T14 5a 600 0.7 452 25 m 122 100 114 28 00 02 0.75 26 00 04 0.85 
6 16 0.47 15 0.40 15 7 6 1.42 9.999 21 1.10 25 0.82 
603 713 576
T15 4c 200 0.5 668 50 m 132 126 130 28 02 00 0.88 27 02 01 0.90
5 14 1.49 11 0.87 15 8 4 1.37 0.334 19 2.1324 1.13 
903 848 789
T16 1a 600 0.9 999 28 m 134 127 130 27 02 01 9.99 25 03 02 1.70
6 15 1.40 15 1.00 15 0 0 1.08 0.333 99 9.99 99 9.99 
999 999 999
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T 17 2b 800 0.9 380 29 f 123 115 121 28 00 02 0.92 16 00 04 1.05 
5 10 0.72 13 0.97 15 9 8 0.94 0.329 99 9.99 99 9.99 
999 999 999
T18 4d 600 0.5 248 33 m 092 122 105 99 99 99 9.99 25 02 03 1.25
4 12 1.05 10 0.68 15 6 4 1.20 0.336 99 9.99 99 9.99 
999 999 999
T19 2b 600 1.0 195 21 f 113 123 118 29 00 01 0.10 27 00 03 1.20
5 13 2.60 14 2.50 15 0 0 9.99 0.343 99 9.99 99 9.99 
999 999 999
T20 2b 600 0.8 185 49 m 090 084 087 19 09 02 2.98 17 08 05 2.53 
5 08 0.58 07 0.68 99 7 5 2.50 0.491 99 9.99 99 9.99 
999 999 999
T21 2b 400 0.4 140 38 f 118 118 119 28 01 01 0.80 28 01 01 1.40
5 13 0.77 13 0.85 15 9 7 1.25 0.295 99 9.99 99 9.99 
999 999 999
T22 1a 300 0.8 350 32 f 128 128 130 26 02 02 1.00 22 04 04 1.47
6 17 0.35 13 0.88 15 7 5 1.36 0.371 99 9.99 99 9.99 
840 832 713
T23 2c 400 0.6 131 34 m 133 118 128 28 01 01 1.27 22 05 03 1.73
7 14 1.08 13 0.88 15 8 8 1.20 0.276 23 1.82 24 1.12 
1200 968 818
T24 2c 600 0.5 283 32 m 110 112 112 25 04 01 0.95 21 06 03 1.78
7 09 0.80 09 0.90 15 7 4 1.38 0.292 19 1.81 21 1.01 
690 618 510
T25 2d 600 0.8 012 21 f 099 083 093 25 00 05 0.77 22 02 06 0.73 
5 13 1.13 09 0.58 15 7 5 1.56 0.297 14 0.81 21 0.81 
775 779 746
T26 2b 600 9.9 264 52 m 091 099 094 27 03 00 2.70 18 09 03 5.80
8 11 3.20 14 3.80 14 0 0 9.99 0.458 99 9.99 99 9.99 
999 999 999
T27 4d 400 0.3 290 29 f 119 132 126 99 99 99 9.99 23 03 04 1.10
9 18 0.82 13 0.88 15 5 5 1.07 0.298 99 9.99 99 9.99 
999 999 999
T28 4d 800 0.7 251 33 m 080 084 081 28 01 01 2.65 20 05 05 3.28
5 08 3.08 04 2.35 13 5 4 2.50 9.999 99 9.99 99 9.99 
999 999 999
T29 2b 600 0.8 186 32 f 114 118 116 26 03 01 1.50 18 05 07 1.60
6 13 1.75 15 1.20 15 0 0 1.48 9.999 99 9.99 99 9.99 
999 999 999
T30 5c 600 0.6 310 41 m 133 116 127 29 01 00 1.13 24 05 01 1.37
7 17 0.87 14 1.03 15 8 5 1.20 0.339 20 1.15 25 0.66 
684 667 547
T31 2b 300 0.6 315 35 f 128 081 114 21 01 08 1.25 21 00 09 1.20 
6 10 0.52 02 1.07 12 8 4 1.38 0.478 99 9.99 99 9.99 
999 999 999
T32 2a 400 0.8 279 16 f 115 116 116 27 00 03 1.12 27 00 04 1.27
8 14 1.23 12 1.00 15 8 5 1.02 0.281 13 3.07 23 1.48 
573 500 441
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T33 1a 600 0.7 313 23 f 111 110 111 26 04 00 1.12 26 03 01 1.28 
7 16 0.63 13 0.42 15 6 5 1.20 0.258 99 9.99 99 9.99 
950 756 768
T34 2b 600 0.8 467 59 m 116 116 117 24 04 02 1.30 24 04 02 1.12 
6 08 1.03 08 1.80 12 5 4 9.99 0.346 99 9.99 99 9.99 
1290 952 971
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E1 2b 400 9.9 190 57 M 096 097 097 26 04 00 2.50 19 07 04 2.90
5 15 1.00 15 1.10 15 4 2 2.50 0.439 99 9.99 99 9.99 
999 999 999
E2 4c1200 8.9 178 23 m 119 103 113 27 01 02 0.92 27 00 03 1.07 
7 14 0.57 10 0.33 14 9 7 1.24 0.306 11 1.32 24 1.29 
506 487 448
E3 2c 400 4.4 302 26 f 129 120 127 27 02 01 1.62 24 01 05 9.99
6 16 0.45 15 0.75 15 8 7 1.22 0.268 23 2.70 25 1.38 
690 662 622
E4 1c140011.0 335 16 m 111 113 113 25 01 04 1.22 18 03 09 1.18 
4 12 0.58 11 0.65 15 6 4 1.61 0.329 15 1.86 20 1.95 
1033 1051 887
E5 3c 800 5.1 346 46 m 107 103 105 29 01 00 1.30 24 00 06 1.33 
4 13 1.15 10 0.93 13 7 5 1.80 0.369 99 9.99 99 9.99 
999 999 999
E6 2b1200 6.0 287 29 m 140 132 138 27 00 03 1.05 02 04 2.48
4 14 0.73 15 0.50 15 8 7 1.18 0.293 99 9.99 99 9.99 
999 999 999
E7 2c 400 2.6 391 23 m 106 103 105 27 03 00 0.90 21 06 03 1.01
2 11 0.95 09 0.95 15 7 5 1.10 0.284 13 1.92 23 1.30 
770 663 566
E8 2b 600 9.9 168 21 f 112 112 113 28 01 01 1.00 22 03 05 9.99
3 04 0.60 13 1.70 15 0 0 9.99 0.321 99 9.99 99 9.99 
999 999 999
E9 2b1200 6.0 306 20 f 107 117 112 26 03 01 0.80 25 00 05 0.98
5 16 0.67 14 0.93 15 6 4 1.35 0.256 99 9.99 99 9.99 
999 999 999
E10 3c1200 8.6 257 40 f 119 118 118 26 01 03 1.25 18 06 06 1.58
6 11 1.10 13 1.67 15 6 15 1.36 0.428 99 9.99 99 9.99 
999 999 999
E11 2a120010.6 363 f 999 999 999 28 01 01 2.02 20 05 05 2.58
6 13 1.17 12 0.83 15 5 4 1.75 0.267 10 5.85 15 2.01 
815 745 601
E12 1a 600 9.9 999 33 f 106 115 111 19 09 02 1.42 23 03 04 1.15 
9 14 1.00 15 0.63 15 6 4 1.60 0.274 16 1.28 23 1.60 
872 724 797
E13 2b3200 9.7 127 34 f 116 114 116 29 01 00 0.95 28 00 02 1.20 
9 16 0.42 15 1.40 15 7 5 1.34 0.393 99 9.99 99 9.99 
999 999 999
E14 2b 800 6.9 337 28 f 081 099 088 28 02 00 1.53 26 02 02 1.30
6 13 0.88 10 0.67 14 6 4 1.63 0.236 99 9.99 99 9.99 
999 999 999
E15 2b1000 8.1 237 16 f 109 123 116 28 00 02 1.30 27 00 03 1.20
7 17 0.35 15 0.52 15 5 5 0.98 0.315 99 9.99 99 9.99 
999 999 999
E16 2b1000 8.1 237 16 f 109 123 116 28 00 02 1.30 27 00 03 1.20 
3 12 2.00 22 1.60 15 4 4 1.47 0.304 99 9.99 99 9.99 
999 999 999
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E17 3c 999 7.4 640 28 f 118 118 119 25 02 03 9.99 23 03 05 0.95 
9 13 2.50 15 2.12 14 9 7 1.10 0.314 99 9.99 99 9.99 
999 999 999
E18 2b 600 2.9 215 31 m 119 119 119 24 04 02 1.02 25 03 02 1.05 
5 01 0.53 09 0.33 15 7 3 1.54 0.401 99 9.99 99 9.99 
999 999 999
E19 2b 200 8.0 439 37 f 121 130 127 28 01 01 1.60 24 03 03 1.20 
5 08 0.60 15 1.30 15 6 5 1.98 0.374 99 9.99 99 9.99 
999 999 999
E20 1a120011.4 999 41 f 100 105 105 28 01 01 9.99 12702 01 9.99 
5 12 9.99 99 9.99 99 0 0 9.99 0.275 99 9.99 99 9.99 
999 999 999
E21 991200 9.8 234 30 f 119 132 126 99 99 99 9.99 29 00 01 1.11 
7 18 0.77 13 1.11 15 5 5 0.92 0.324 99 9.99 99 9.99 
999 999 999
E22 2b 400 4.1 210 51 f 124 133 129 29 00 01 2.25 21 03 06 2.50
4 13 1.60 14 4.00 15 0 0 1.59 0.330 99 9.99 99 9.99 
999 999 999
E23 2b 400 5.3 252 26 f 112 135 123 27 01 02 1.25 27 01 02 1.25
5 14 0.35 13 0.75 15 7 5 0.91 0.276 99 9.99 99 9.99 
999 999 999
E24 3c 800 6.2 276 18 m 121 106 116 20 04 06 1.10 22 02 06 1.03
6 12 1.85 13 1.10 15 9 6 1.08 0.286 99 9.99 99 9.99 
999 999 999
E25 2b160015.0 189 19 f 107 098 103 25 01 04 1.40 26 00 04 1.10 
4 12 1.00 15 1.10 15 0 0 9.99 0.347 99 9.99 99 9.99 
999 999 999
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APPENDIX 6.2 Full Correlation Co-efficients Matrix Between All
Variables
TEST Dose B.L. RCF Age IQ F1 +ve -ve time
Dose ★ ★★★
Blood L. .00#
RCF -.03 .06 ★ ★★★
Age -.07 -.13 .17#
IQ -.16 .01 .25# .06 ★ ★ ★★
F(1 )/30 .02 -.03 .06 -.15 .19# ****
+ve -.10 -.14 .01 .23# -.11 -.78# ★ ★★ ★
-ve .08 .20# -.09 -.04 -.17# -.67# .06 *★ ★ ★
time -.04 -.01 -.10# .26# -.31# -.32# .33# -| 2 ★★ ★ ★
F(2)/30 .03 .05 .14 -.29# .08 .32 -.35# -.09 -.25#
+ve -.11 -.16 -.10 .33# .06 -.28# .46# -.10 .28
-ve .11 .16 -.09 .04 -.05 -.16# -.04 .31# .01
time -.04 -.13 -.09 .31 -.21 -.08 .21 -.13 .67#
W(1)/15 .00 -.15 .06 -.11 .16# -.03 .10 -.06 -.05
W(5)/20 .06 -.01 .02 -.24# .33# .20 -.14 -.15 -.17
Time -.03 -.10 .06 .23 -.18 -.02 .03 -.08 .30#
Recall/15 .09 -.12 -.05 -.07 .29# .23# -.09 -.26# -.13
Time -.03 -.09 .01 .31# .03 .06 -.04 -.04 .31#
Recog/15 .06 .07 -.11 -.15 .32# .07 .03 -.13 -.10
D/S For. -.14 -.17 .08 -.01 .37# .04 -.09 .04 -.33#
Back. -.06 -.03 .08 -.09 .43# .13 -.17 .01 -.23#
Inf Proc -.06 -.05 -.16 .23 -.55# -.21 .27# .02 .36#
R. T. .02 -.08 -.06 .24 -.23# -.16 .08 .15 .22
WF/25 -.21 -.33# .26 .43# .65# .24 .02 -.41# -.21
WF Time .06 .24 .19 -.11 -.10 .03 -.06 .04 .58#
LTM/25 -.21 .31 .03 .37# .34# .06 .18 -.32 -.12
LTM Time .12 .26 -.14 -.26 -.52# -.16 -.07 .26 .63#
Sternberg 2 .04 .00 .16 .38 .01 -.28 .28 .04 .02
Sternberg 4 .13 .11 .21 .27 -.01 -.15 .15 .03 -.18
Sternberg 6 .08 .05 .12 .39#
cqo .38 -.00 -.21
TABLE A6.2.1a - Correlation coefficients for all epileptics regardless of 
treatment. # denotes significance at 0.05 or less.
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TEST F2 +ve -ve time T1 T5 time recall time
F(2)/30
+ve
-ve
time
W(1 )/15
W(5)/20
Time
★  ★ ★ ★
-.83#
-.59#
-.41#
.03
.31#
-.12
★ ★ ★  ★
.03 ****
.46# .07 
.01 -.06 
-.25# -.20 
.16 -.01
***★
-.06
-.22#
.41#
.43# ****
-.09# -.17#
Recall/15 .03 .03 -.08 .02 .23# .41# -.09 ****
Time -.19# .23# .01 .46# .02 -.17 .44 -.03 ★ ★ ★ ★
Recog/15 -.02 .09 -.08 -.06 .10 .34# .00 .54# -.03
D/S For. -.06 .04 .07 -.11 .21# -.06 -.10 .02 -.05
Back. .03 -.03 .00 -.15 .21# .11 -.15 .18# -.08
Inf Proc -.28# .29# .09 .31# -.31# -.34# .09 -.28# .03
R. T. -.20# .11 .19 .20# .14 -.16 .20# -.08 .09
WF/25 .01 -.03 .02 -.08 .24 .41# -.04 .33# .07
WF Time .01 -.03 .02 .72# .04 -.16 .39# -.23 .52#
LTM/25 .08 .00 -.14 -.14 .02 .14 .07 -.01 .00
LTM Time .09 -.09 -.03 .55# -.21 -.34 .31# -.32# .15
Sternberg 2 -.23 .35# -.06 -.05 -.04 -.20 .03 .01 .23
Sternberg 4 -.24 .25 .08 -.17 -.11 -.09 -.03 .06 .08
Sternberg 6 -.20 .26 -.00 -.25 -.15 -.24 .00 -.02 -.01
TABLE A6.2.1b - Correlation coefficients for all epileptics regardless of 
treatment. # denotes significance at 0.05 or less.
TEST Recog DS IP RT WF time LTM time S2 S4
Recog/15 **★ *
D/S/17 .11
Inf Proc -.26 -.31#
R.T. -.17# -.02 .21 ★ ★ ★ ★
WF/25 .32 .22 -.40 -.19 ★ ★ ★ ★
WF Time -.04 -.24 .27 .21 -.26
LTM/25 .18 .24 .22 -.32# .57# -.23 ★ ★ ★ ★
LTM Time -.28 -.42# .47# -.13 -.41# .52# -.09 ★ ★ ★ ★
Sternberg 2 -.21 -.41 .08 .29 .10 .16 -.25 .09
Sternberg 4 -.08 -.43 .21 .33 .12 .07 .04 .89# ★ ★ ★ ★
Sternberg 6 -.19 .46# .28 .13 .12 -.03 .06 .19 .85#
TABLE A6.2.1C - Correlation coefficients for all epileptics regardless of 
treatment. # denotes significance at 0.05 or less.
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APPENDIX 6.3 Correlation Co-efficients for epileptics treated 
by monotherapy with phenytoin, carbamazepine or sodium 
valproate and summary of MANOVA and MANCOVA
TEST Dose B.L. RCF Age IQ F1 +ve -ve time
Dose ★ ★ ★ ★
Blood L. .23
RCF .02 -.10 ★ ★ ★ ★
Age .09 .21 .12 ★ ★ ★ ★
IQ .07 -.01 .37# .20 ★ ★ ★ ★
F(1 )/30 -.11 -.21 .13 -.12 .06 ★ ★ ★ ★
+ve -.04 .05 .04 .11 .16 -.81 ★ ★ ★  ★
-ve .24 .27# -.25 .06 -.31# -.68# .12 ★ ★ ★ ★
time .05 -.07 -.11 -.03 -.24# -.50# .35# .39#
F(2)/30 -.16 -.09 .24 -.32# -.19 .20 -.27# .00 -.04
+ve .13 .04 -.15 .28# .17 -.28# .40# -.03 .16
-ve .07 .11 -.21 .12 .07 .08 -.14 .05 -.19
time -.01 -.01 -.05 .13 -.12 -.26# .32# .05 .58#
W(1 )/15 -.04 -.18 - .04 -.25 .20 -.04 .07 -.03 -.07
W(5)/20 -.00 -.21 .06 -.31# .31# .08 -.06 -.06 -.06
Time .19 .10 -.13 .32 -.09 -.10 .13 -.01 .33#
Recall/15 .00 -.28 -.03 -.08 .09 .18 -.05 -.25 -.11
Time .10 -.06 -.01 .22 .17 -.10 .07 .08 .18
Recog/15 .27# -.10 -.04 .11 .34# -.03 .09 -.06 .02
D/S/17 .23# -.13 .11 -.27 .02 .00 -.10 .12 .14
Inf Proc -.24 -.02 -.19 .11 -.50# -.23 .15 .20 .15
R. T. -.01 -.10 -.01 -.02 -.29# -.07 .00 .12 .17
WF/25 .34 -.05 .33 .22 .55# .22 .13 -.45 -.31
WF Time -.09 .27 -.06 .06 -.38 -.65# .22 .54# .48
LTM/25 .52# .02 -.17 .41 .18 -.05 .39 -.44 .04
LTM Time .01 .16 -.45 -.12 -.65# -.03 -.30 .40 .60#
Sternberg 2 -.44 .26 .23 -.17 -.65# -.43 .16 .29 -.17
Sternberg 4 -.56 .22 .32 .05 -.56 -.26 .31 -.09 -.48
Sternberg 6 -.40 .23 -.00 .24 -.59 -.08 .39 -.39 -.53
TABLE A6.3.1a - Correlation coefficients for epileptics treated by 
monotherapy with phenytoin. # denotes significance at 0.05 or less.
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TEST F2 +ve -ve time T1 T5 time recall time
F(2)/30 ★ ★ ★ ★
+ve -.82# ***★
-ve -.49# -.09
time -.36# .36# .07
W(1 )/15 -.07 .05 .03 -.21 ★ ★ ★  ★
W(5)/20 -.21 -.19 -.08 -.23 .44# ****
Time -.02 .08 -.10 .36# -.34# -.32#
Recall/15 -.12 .13 .02 .08 .28# .38# -.04
Time -.30# .37# -.05 .34# .00 -.08 .35 -.06 ★ ★  ★ ★
Recog/15 -.14 .15 .01 .09 .17 .36# .24# .43# .14
D/S/17 .13 -.14 -.01 -.05 .05 .05 -.17 -.21# -.08
Inf Proc .06 .06 -.20 .06 -.36# -.28# -.03 -.30# .03
R. T. -.05 -.03 .13 .17 .24# -.15 .14 -.06 .08
WF/25 -.04 -.07 .22 -.21 .09 .34 -.04 .01 .12
WF Time .01 -.01 -.01 .57 -.17 -.35 .44 -.47 .62#
LTM/25 -.26 .24 .11 .15 -.23 -.16 .36 -.33 .02
LTM Time .23 -.09 -.32 .70# -.32 -.32 .51# -.28 .01
Sternberg 2 .32 -.02 -.39 -.15 .39 .26 -.03 .20 .44
Sternberg 4 .45 -.07 -.50 -.36 .41 .19 -.09 .18 .22
Sternberg 6 .36 .06 -.55 -.13 .07 -.17 .29 -.09 .07
TABLE A6.3.1Ö - Correlation coefficients for epileptics treated by 
monotherapy with phenytoin. # denotes significance at 0.05 or less.
TEST Recog DS IP RT WF time LTM time S2
Recog/15 ★ ★ ★ ★
D/S/17 -.05
Inf Proc -.23 .05
R. T. -.07 .12 .07 ★ ★ ★★
WF/25 .35 .04 -.45 -.40
WF Time -.04 -.33 .39 .66# -.34 ★  ★ ★ ★
LTM/25 .25 -.04 -.04 -.57# .53# 04 ****
LTM Time -.23 -.46 .44 -.06 -.31 .54# .21# ★ ★ ★  ★
Sternberg 2 .23 -.13 .77# -.13 .71# -.30 -.11 ★ ★ ★  ★
Sternberg 4 .08 .31 .58 -.04 .56 -.07 -.19 .91# ★ ★ ★  ★
Sternberg 6 .01 .44 .18 .11 .52 .39 .25 .64# .82#
TABLE A6.3.1C - Correlation coefficients for epileptics treated by 
monotherapy with phenytoin. # denotes significance at 0.05 or less.
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TEST Dose B.L. RCF Age IQ F1 +ve -ve time
Dose
Blood L. .38# ★ ★ ★ ★  -
RCF -.23 -.08 ★ ★ ★ ★
Age .01 .13 .24 ***★
IQ -.38# .09 .20  ^ ★ ★ ★  ★
F(1)/30 .03 -.15 .11 -.44# .47# ★ ★ ★ ★
+ve .11 -.00 -.07 .53# -.41# -.73# ★ ★ ★ ★
-ve -.16 .22 -.08 .07 -.24 -.68# -.00
time .26 .34# -.17 .44# -.48# -.34# .48# -.01 ★ ★ ★ ★
F(2)/30 -.21 .01 .35# -.28 .44# .54# -.58# -.16 -.40#
+ve .22 .00 -.22 .37# -.34# -.38# .67# -.16 .41#
-ve .07 -.02 -.34# -.03 -.35# -.46# .11 .56# .14
time .23 .14 -.10 .38# -.42# -.06 .30# -.23 .74#
W(1)/15 -.09 -.12 .11 -.17 .18 .24 -.12 -.22 -.03
W(5)/20 -.29# -.08 .08 -.40# .54# .52# -.43# -.30# -.48#
Time .36# .18 -.01 .14 -.33# .23 -.07 -.26 .31#
Recall/15 .05 .16 -.06 -.17 .52# .49# -.21 -.49# -.32#
Time .22 .35# .11 .35# -.25 .13 -.05 -.14 .47#
Recog/15 -.09 -.09 -.22 -.49# .30# .48# -.19 -.44# -.39
D/S/17 -.20 -.38# .16 -.08 -.07 -.11 -.03 .19 -.33
Inf Proc .24 -.24 -.18 .23 -.67# -.36# .50# .00 .47#
R. T. .16 .18 .02 .37# -.30# -.41# .30 .29 .30
WF/25 -.08 -.09 .17 .57# .70# .31 .20 -.48 .16
WF Time -.37 -.08 .36 -.19 .40 .54# -.22 -.41 .79#
LTM/25 -.22 .26 .34 .45 .78# .51 -.29 -.31 .14
LTM Time -.14 -.18 .29 -.31 -.08 .34 -.17 -.23 .56#
Sternberg 2 -.10 -.03 .00 .55# .09 -.36 .52 -.09 .20
Sternberg 4 -.17 -.07 .05 .48# .04 -.24 .32 -.02 -.05
Sternberg 6 -.09 .05 .04 .51# -.10 -.46 .48# .09 -.11
TABLE A6.3.2a - Correlation coefficients for epileptics treated by 
monotherapy with carbamazepine. # denotes significance at 0.05 or less.
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TEST F-2 +ve -ve time T1 T5 time recall time
F(2)/30 ★ ★ ★ ★
+ve -.86# ★ ★ ★ ★
-ve -.63# .15
time -.46# .55# .06
W(1 )/15 .04 -.03 -.02 .16 ★ ★★★
W(5)/20 .40# -.29# -.33# -.33# .40# ****
Time -.16 .20 .01 .55# .08 -.07
Recall/15 .20 -.03 -.35# -.08 .23 .59# -.11 ****
Time -.05 .06 -.01 .64# .22 -.27 .56# -.08 ★ ★ ★ ★
Recog/15 .20 -.05 -.30# -.26 .10 .54# -.23 .70# -.37#
D/S/17 .00 -.04 .06 -.35# .19 .00 -.28 -.23 -.39
Inf Proc -.61# .55# .36# .59# -.36# -.41# .25 -.40# -.08
R. T. -.36 .20 .39# .22 -.03 -.19 .32# -.13 .03
WF/25 -.26 .40 -.18 .36 .18 .38 -.26 .62# -.05
WF Time .54# -.48 -.20 .67# .78# .10 .61# -.11 .69#
LTM/25 .16 -.03 -.24 .08 .25 .85# -.17 .87# -.01
LTM Time .48 -.44 -.15 .36 .34 -.33 .76# -.62# .68#
Sternberg 2 -.20 .42 -.29 -.10 -.35 -.41 -.07 -.26 .16
Sternberg 4 -.21 .32 -.13 -.29 -.62# -.26 -.16 -.22 .01
Sternberg 6 -.18 .32 -.17 -.44 -.66# -.35 -.16 -.28 -.02
TABLE A6.3.2b - Correlation coefficients for epileptics treated by 
monotherapy with carbamazepine. # denotes significance at 0.05 or less.
TEST Recog DS IP RT WF time LTM time S2 S4
Recog/15 ★ ★ ★★
D/S/17 .11 ★ ★ ★ *
Inf Proc -.35# -.06
R. T. -.35# .00 .34#
WF/25 .22 .64# -.10 .23 ★ ★ ★ ★
WF Time -.41 .24 -.46 -.15 -.04 ★ ★★ ★
LTM/25 .22 .68 -.42 .47 .70# .09 ★ ★ ★★
LTM Time -.78# -.21 -.12 -.35 -.46 .61 -.39 ★ ★★ ★
Sternberg 2 -.56# -.01 .08 .28 -.18 -.10 .06 ★ ★ ★★
Sternberg 4 -.39 .36 .24 -.23 -.42 -.10 -.01 .89# ****
Sternberg 6 -.49# .32 .19 .05 -.48 -.20 -.07 .91# .93#
Table A6.3.2c - Correlation coefficients for epileptics treated by 
monotherapy with carbamazepine. # denotes significance at 0.05 or less.
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TEST Dose B.L. RCF Age IQ F1 +ve -ve time
Dose ****
Blood L. .61#****
RCF -.37# -.07 ****
Age -.17 -.38# .01 ****
IQ -.05 -.06 .03 .05 ****
F(1 )/30 .15 .05 -.12 .14 .04 ****
+ve -.25 -.52# .15 .10 -.27 -.80#’
-ve .09 .37# .03 -.37# .29 -.63#
* ★ ★ ★
0 4  ****
time -.35 -.19 -.02 .57# -.10 .14 .01 25 * *
F(2)/30 .30 .27 -.22 -.25 .06 .24 -.19 -.15 -.40#
+ve -.37# -.38# .19 .39# -.16 -.15 .29 - . 1 1 .44#
-ve -.08 -.02 .24 .00 .08 -.23 -.02 .40# .15
time -.15 -.28 -.20 .52# .14 .28 -.17 -.25 .76#
W(1)/15 .41# .23 .12 .11 .07 -.32 .35# .08 .01
W(5)/20 .31 -.02 -.05 .04 .08 -.01 .07 -.08 .14
Time -.15 -.02 .42 .19 -.04 -.23 .05 .31 .30
Recall/15 .13 .16 -.01 .24 .36# -.10 .03 .13 .28
Time -.08 -.08 -.15 .44# .22 .29 -.28# - . 1 1 .41#
Recog/15 .03 .07 -.05 -.14 .42# -.27 .11 .31 .08
D/S/17 .03 -.28 .42# -.18 .28 -.21 .14 .18 -.40#
Inf Proc -.20 -.24 -.03 .53# -.42# .09 .19 -.42# .67#
R. T. .16 -.12 -.31 .57# .03 .08 -.07 -.04 .19
WF/25 -.58 -.46 .03 .28 .84# -.21 .21 .01 .15
WF Time .23 .32 .44 -.15 .68 .50 -.39 -.31 .82#
LTM/25 -.59 -.66 -.46 .35 .46 -.23 .29 -.10 -.61
LTM Time .63 .77 .41 -.34 -.03 -.07 -.14 .49 .63
Sternberg 2 .19 .32 .70 -.23 -.21 -.41 .22 .48 .25
Sternberg 4 .38 .44 .53 -.48 -.05 -.21 -.06 .64 .21
Sternberg 6 .15 .37 .44 -.07 -.01 -.62 .38 .66 .18
Table A6.3.3a - Correlation coefficients for epileptics treated by 
monotherapy with sodium valproate. # denotes significance at 0.05 or less.
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TEST F2 +ve -ve time T1 T5 time recall time
F(2)/30 ★ ★ ★ ★
+ve -.82# ****
-ve -.76# .26 ★ ★ ★ ★
time -.47# .50 .20 ★ ★ ★ ★
W(1 )/15 .25 -.17 -.19 -.20 ★ ★ ★ ★
W(5)/20 .36# -.37# -.19 .09 .49#
Time -.25 .17 .29 .06 .04 -.11 ★ ★ ★ ★
Recall/15 .02 -.06 .07 .25 .37 .21 -.00 *★ ★ ★
Time -.24 .15 .24 .34 -.22 -.20 .40# .23 ★ ★ ★ ★
Recog/15 -.17 .29 -.03 .11 .04 -.04 .01 .50# .18
D/S/17 .06 -.11 .04 -.34 .40# .35# -.01 -.16 -.58#
Inf Proc -.46# .47 .22 .52# -.19 -.33 .04 -.00 .15
R. T. -.26 .30 .09 .20 .00 -.17 -.05 .10 .21
WF/25 .13 -.38 .20 -.60 .11 .63 -.57 .69 .13
WF Time -.37 .41 .11 .98# -.06 .00 .50 .08 .47
LTM/25 .66# -.55 -.38 -.94# .10 .39 -.63 .15 -.32
LTM Time -.76# .35 .72# .69 .04 -.25 .38 .12 .19
Sternberg 2 -.90# .52 . .75# .11 -.22 -.44 .27 .15 .42
Sternberg 4-.88# .33 .92# .10 -.29 -.38 .01 .06 .28
Sternberg 6-.66 .17 .77# -.10 .06 -.15 .01 .38 .14
Table A6.3.3b - Correlation coeffic ients fo r epileptics treated by 
monotherapy with sodium valproate. # denotes significance at 0.05 or less.
TEST Recog DS IP RT WF time LTM time S2 S4
Recog/15 ★★ ★ ★
D/S/17 -.19
Inf Proc -.20 -.50#
R.T. .01 -.12 .45#
WF/25 .38 .31 -.28 -.23 ★ ★ ★ ★
WF Time .33 -.42 .49 -.48 -.26
LTM/25 -.31 .75# -.78# .05 .58 -.81# ★ ★ ★  ★
LTM Time .45 -.81# .93# .14 -.26 .59 -.81# ★ ★ ★ ★
Sternberg 2 .76# .62 .24 .08 .10 -.46 .73# ★ ★ ★ ★
Sternberg 4 .62 .59 .45 .11 .10 -.45 .76# .94# ★ ★ ★  ★
Sternberg 6 .63 .58 .30 .31 -.15 -.19 .60 .92# .88#
Table A6.3.3C - Correlation coefficients for epileptics treated by 
monotherapy with sodium valproate. # denotes significance at 0.05 or less.
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TEST Dose B.L. RCF
Dose
Blood L. ★  ★ ★ ★
RCF ★ ★ ★ ★
F(1 )/30 -.11 -.19 .12
+ve -.06 .04 -.03
-ve .26# .28# -.16
time .07 -.09 -.02
F(1)rate .27# -.00 .05
F(2)/30 -.13 -.04 .37#
+ve .11 -.02 -.25
-ve .06 .09 -.26#
time -.01 -.05 -.01
F(2)rate .04 .19 -.03
W(1 )/15 -.03 -.12 -.02
W(5)/20 .00 -.15 -.05
Time .18 .03 -.13
W(5)rate .28# -.02 .16
Recall/15 .00 -.27# -.07
Time .07 -.11 -.09
Recall rate .07 .22 .13
Recog/15 .26 -.11 -.20
D/S/17 .26 -.07 .12
Inf Proc -.26# -.09 -.01
R.T. .01 -.12 .11
WF/25 .36 -.08 .15
WF Time -.08 .27 .09
LTM/25 .54# -.07 -.30
LTM Time .08 .20 -.30
Sternberg 2 -.52 .36 .67
Sternberg 4 -.66 .23 .69
Sternberg 6 -.53 .21 .30
Table A6.3.4 Partial correlation coefficients for epileptics treated by 
monotherapy with phenytoin, partialling out the effects of age and IQ. # 
denotes significance at 0.05 or less.
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TEST Dose B.L. RCF
Dose
Blood L. ★ ★ ★ ★
RCF ★ ★ ★ ★
F(1 )/30 .25 -.17 .15
+ve -.03 -.04 -.16
-ve -.28 .24 -.05
time .12 .42# -.23
F(1)rate -.07 -.09 -.07
F(2)/30 -.06 .00 .39#
+ve .13 -.02 -.29
-ve -.08 .02 -.29
time .11 .16 -.13
F(2)rate .35 .12 -.19
W(1 )/15 -.03 -.12 .13
W(5)/20 -.13 -.11 .08
Time .27 .21 .03
W(5)rate .24 .16 .03
Recall/15 .30# .15 -.17
Time .17 .36# .09
Recall rate .18 .36# -.04
Recog/15 .00 -.06 -.19
D/S/17 -.26 -.36 .21
Inf Proc -.02 -.27 -.11
R.T. .07 .18 -.01
WF/25 ★ ★ ★ ★ ★ ★ ★ ★ -.87#
WF Time -.27 -.11 .37
LTM/25 .48 .46 .13
LTM Time -.21 -.14 .45
Sternberg 2 -.05 -.15 -.22
Sternberg 4 -.16 -.17 -.11
Sternberg 6 -.13 -.01 -.10
Table A6.3.5 - Partial correlation coefficients for epileptics treated by 
monotherapy with carbamazepine, partialling out the effects of age and 
IQ. # denotes significance at 0.05 or less.
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TEST Dose B.L. RCF
Dose 
Blood L. 
RCF
★  * * *
★  ★ ★ ★
★  ★ ★ ★
F(1 )/30 .18 .11 -.12
+ve -.26 -.55 .16
-ve .04 .29 .03
time -.32 .03 -.03
F(1)rate -.12 .31 .04
F(2)/30 .27 .19 -.23
+ve -.35 -.28 .21
-ve -.08 -.02 .24
time -.07 - .1 1 -.25
F(2)rate -.12 .09 -.19
W(1)/15 .44# .30 .12
W(5)/20 .33 .00 -.06
Time -.12 .06 .43
W(5)rate .11 .40 .45#
Recall/15 .20 .31 -.02
Time .00 .11 -.19
Recall rate .18 .36# -.04
Recog/15 .02 .04 -.06
D/S/17 .01 -.39 .44
Inf Proc -.18 -.09 -.04
R.T. .31 .13 -.39
Table A6.3.6 - Partial correlation coefficients for epileptics treated by 
monotherapy with sodium valproate, partialling out the effects of age and 
IQ. # denotes significance at 0.05 or less.
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TEST Dose B.L. RCF
Dose 
Blood L. 
RCF
★ ★ ★ ★
★ ★ ★ ★
F(1 )/30 -.17 -.15 .10
+ve .04 -.07 -.55
-ve .27 .24 .29
time -.09 .40 .02
F(2)/30 .00 .07 .18
+ve -.05 -.07 -.27
-ve .06 -.02 .00
time -.05 .15 -.13
W(1)/15 -.13 -.10 .31
W(5)/20 -.16 -.10 -.00
Time .01 .21 .10
Recall/15 -.26 .13 .31
Time -.12 .38 .10
Recog/15 -.14 -.09 .03
Digit span -.06 -.34 -.40
Inf Proc -.09 -.29 -.09
R.T. -.11 .18 .11
WF/25 -.06 ★ ★ ★ ★ ★ ★
WF Time .28 -.06
LTM/25 -.11 .49
LTM Time -.18 .43 ★ ★ ★
Sternberg 2 ★ ★ ★ -.25 ★ ★ ★
Sternberg 4 -.16 ★ ★ ★
Sternberg 6 *** -.12 ★ ★ ★
TABLE A6.3.7 Partial correlations between blood level of anticonvulsant 
and memory test performance partialling out the effects of age, IQ and red 
cell folate level.
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TEST Pheny Carb Sod.V.
F(1 )/30 .10 .13 -.06
+ve -.04 -.17 .21
-ve -.14 -.07 -.19
time -.03 -.20 -.24
F(2)/30 .37# .39# -.16
+ve -.26 -.29 .11
-ve -.26 -.30 .22
time -.01 -.11 -.29
W(1 )/15 -.04 .12 .33
W(5)/20 -.07 .06 .14
Time -.14 .09 .40
Recall/15 -.10 -.13 .01
Time -.11 .16 -.24
Recog/15 -.23 -.20 -.07
Digit span .11 .16 .68#
Inf Proc -.02 -.15 -.12
R.T. .09 .02 -.31
WF/25 .15 ★ ★ ★ ★
WF Time .13 .34 ★ ★ ★ ★
LTM/25 -.31 .28 ★ ★ ★ ★
LTM Time -.28 .43 ★ ★ ★ ★
Sternberg 2 .77 -.25 *★ **
Sternberg 4 .74 -.16 ★ ★ ★ ★
Sternberg 6 .33 -.12 ★ ★ ★ ★
TABLE A6.3.8 Partial correlations between red cell folate level and 
memory test performance partialling out the effects of age, IQ, dose and 
Blood Level.
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TABLE 6.3.9 SPSS generated summary of MANOVA of the results from 
Experiment 4.
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TABLE 6.3.9 SPSS generated summary of the MANCOVA of the results 
from Experiment 4.
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APPENDIX 6.4 A Pilot Experiment on the effects of Folate 
Supplements on Phenytoin Treated Epileptics
This experiment was substantially different in its overall planning from all of 
the preceding experiments thus far. The previous experiments, although 
presented in what is hopefully a logical sequence, were in fact carried out 
concurrently. This experiment was carried out in the light of the analysis of 
the preceding experiments. Unfortunately, both time and resources were 
limited at this stage of the study and the experiment suffered from a number 
of significant limitations as a consequence. In the experimenter's view this 
experiment should be regarded as a pilot study of the effect of. folate 
supplements on memory function.
Owing to limitations of both subjects and the time taken to test subjects, it 
was not possible to examine all three of the anticonvulsants as had been 
done in the study up to this point. Since only phenytoin-treated subjects 
were available in sufficient numbers, this study concentrated exclusively on 
them. However, this restriction was not inappropriate, bearing in mind, as 
folate levels were most strongly associated with impairment of memory 
function in the phenytoin group and that most evidence suggests that folate 
levels may be lowered by phenytoin, primidone or phenobarbitone 
(Chanarin, 1979; Reynolds, 1976) but are not affected by carbamazepine. 
(The position with respect to sodium valproate is not yet clear.)
METHOD
PROCEDURE
Each subject was tested individually. Each patient was tested twice with 
a six week test re-test interval. At each assessment patients were given 
the WAIS and one of four forms of the memory battery. Blood tests of serum 
anticonvulsant levels and red cell folate were taken at the end of testing 
and EEG's were given on the same day or within a few days of testing. 
Patients on phenytoin were tested and then half of the patients were 
administered 15mg per day of of folic acid in tablet form.
SUBJECTS
Twelve subjects were selected for analysis if treated by monotherapy of 
phenytoin within the therapeutic range. The analysis was the same as that 
used in Experiment 1.
RESULTS
A comparison of the mean memory performance of patients taking 
phenytoin and a folic acid supplement with patients taking phenytoin 
alone indicates that there is no significant difference in the memory
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performance of these two groups, (see Table A6.4.1).
TEST CONTROL
PRE POST
FOLIC ACID 
PRE POST SIGNIF.
Dose 367 367 348 348
Blood L. 1.28 1.27 1.23 0.66
RCF 206 229 256 338
Age 29.1 28.5
IQ 112.4 108
F(1 )/30 26.6 26.3 26.2 26.7 K
+ve 2.23 2.30 2.36 1.64 K
-ve 1.25 1.42 1.45 1.63 K
time 1.64 1.24 1.51 1.38 NS
F(2)/30 24.3 23.4 23.1 21.8 K
+ve 2.08 3.25 2.20 2.91 K
-ve 3.25 3.50 4.72 5.27 K
time 1.58 1.63 2.06 1.89 NS
W(1 )/15 5.75 6.25 6.45 6.55 NS
W(5)/20 13.2 13.4 13.5 13.7 NS
Time 1.34 1.52 0.81 0.81 NS
Recall/15 12.9 13.3 10.0 12.1 NS
Time 1.64 1.56 0.86 0.89 NS
Recog/15 14.9 15.0 14.4 14.5 NS
D/S/17 11.7 11.7 10.6 11.5 NS
Inf Proc 1.62 1.28 1.60 1.45 NS
R. T. 0.306 0.319 0.357 0.327 NS
TABLE A6.4.1 Performance scores of epileptics treated with phenytoin and 
then either remaining on phenytoin alone or supplemented with folic acid 
and then tested six weeks later. Maximum scores are displayed after test 
title where appropriate. A 'K' in the extreme right hand column indicates 
which tests were analysed using a Kruskal-Wallis Two-way ANOVA.
D I S C U S S I O N
Although not conclusive, the results presented above do not support the 
suggestion that the putative memory impairing effects of the drugs can be 
reversed by folate supplements. However, in view of the small magnitude of 
the effect of folate observed in the current experiment it is perhaps not 
surprising that investigators have produced such differing results.
The lack of significant difference between the folate supplemented groups 
and non-supplemented groups in the pilot study does not negate the 
hypothesis that folic acid supplements to phenytoin may improve memory 
performance. There were several significant weaknesses in the design, 
such as the lack of a double-blind placebo controlled procedure, lack of
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information about dietary variations, inadequate sample size and lack of 
selection of folate deficient subjects. In addition, the length of time required 
for the effects of the added folic acid to become apparent is not clear. 
Herbert (1962) reports that improvements in 'forgetfulness' were 
subjectively apparent after only 48 hours of folate supplement therapy. 
However, other workers have failed to observe such effects in folate 
deficient patients after only 48 hours, although significant changes were 
observed after two weeks (Botez et al, 1979). Lindenbaum (1975) 
suggests that folate stores may be depleted over a period of a few months 
by drugs such as phenytoin, but he gives no index of the rate at which 
folate levels in the brain may be increased.
Spaans (1970) reported no significant rise in serum folate after three 
months of folate supplements in epileptic patients, as did Mattson, 
Gallagher, Reynolds and Glass (1973) after six months of folate therapy, in 
spite of a marked rise in serum folate level. Spaans suggested the 
presence of a blood-brain barrier mechanism and this has been supported 
by the finding of Hommes et al (1973) and Mattson et al (1973). However, 
studies of animals (Levitt Nixon, Pincus and Bertino, 1971) and humans 
(Chanarin et al, 1973) suggest that there is some circulation of folate 
between the serum and the CSF. Indeed Chanarin, Perry and Reynolds 
(1974) found that doses of 3H-labelled 5-MTHF was present in 
concentrations up to 20% of total CSF folate after only four hours but that 
this had fallen considerably after 24 hours. Reynolds (1976) suggests that 
this may reflect a rapid uptake by the neurones, or a redistribution of the 
folate back to the rest of the body. It was decided in view of the above 
considerations, to keep the test-retest interval to a period of only six weeks.
C O N C L U S IO N
Bearing in mind the methodological limitations of the experiment presented 
here, the lack of significant results cannot be used to argue that folic acid 
supplements are not beneficial.
APPENDICES TO CHAPTER 6 221
APPENDIX 6.5 Results from the Subjective Memory
Questionnaire
Phenytoin Treated
Mean Ques. 1-36
Group
Variance Mean Ques. 37-43 Variance
3.94 3.29
1.11 0.82 1.00 1.00
3.06 0.71 2.14 0.90
3.56 1.11 3.57 0.98
2.39 0.93 3.14 1.07
2.64 1.02 4.00 1.00
MEAN 3.09 0.96 3.04 1.04
S 0.53 0.17 0.73 0.10
Carbamazepine
Mean Ques. 1-36
Treated Group
Variance Mean Ques. 37-43 Variance
2.97 1.12 2.71 1.11
2.89 1.14 3.00 1.53
3.29 1.30 2.71 0.76
3.76 1.07 2.29 0.76
3.44 0.81 2.43 0.53
2.81 1.14 3.29 0.76
3.31 0.82 2.57 0.79
3.00 1.32 3.86 1.46
3.17 0.95 2.43 1.13
3.22 0.64 2.86 0.69
3.03 1.21 3.43 1.13
MEAN 3.16 1.05 2.87 0.97
S 0.25 0.22 0.49 0.33
APPENDICES TO CHAPTER 6 222
S o d i u m  V a l p r o a t e
Mean Ques. 1-36
T r e a t e d  G r o u p
Variance Mean Ques. 37-43 Variance
3.00 0.48 2.57 0.53
3.22 0.96 3.00 0.00
2.86 0.99 2.43 0.53
3.22 0.80 2.57 0.79
3.67 1.35 3.00 1.41
3.14 • 1.02 2.29 0.95
4.08 1.18 1.86 0.69
2.92 0.77 3.00 1.15
MEAN 3.26 0.94 2.59 0.76
0.41 0.27 0.41 0.43
